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ABSTRACT
Tumour growth has been studied for many years in the hopes of gaining prognostic 
information, guiding cancer therapy, and better understanding the control of cellular 
proliferation within tumours. Recent methods have applied the technology of flow 
cytometry, using its ability to characterise many cells in a short space of time. This 
thesis examines the potential for two of these techniques to contribute to the study of 
tumour cell kinetics in the context of breast cancer, one of the commonest tumours, 
one of the most studied, and yet one where patient outcome has improved little in 
recent years.
The first method involves staining of tumour nuclei with fluorescent stoichiometric 
DNA dyes in order to obtain a frequency distribution of DNA contents within the 
tumour cell population. From this, the amount of nuclear DNA of the tumour cells 
relative to the norm (tumour ploidy), and the proportion of cells in the S phase of the 
cell cycle (the S phase fraction, SPF) can be estimated. These parameters have been 
described as being of prognostic significance in breast cancer. In 293 cases studied 
here, there was a non-statistically significant worse prognosis for aneuploid tumours 
relative to diploid (relative hazard in multivariate analysis 1.20, 95%Cl 0.81-1.76), 
whilst SPF shows an also non-significant trend toward poor survival associated with 
high SPF (relative hazards 1.31, 95%CI 0.87-1.98). In view of theoretical and 
logistical shortcomings of the methodology, studies of the reproducibility of the SPF 
were carried out, indicating very large variations in repeated estimates (95% Cl for 
estimates of +40% or more). This may contribute to the limited prognostic power of 
this parameter.
The second technique, which also provides information about the rate of cell cycle 
transit, involves the administration of the DNA precursor bromodeoxyuridine prior to 
tumour biopsy. Staining of nuclear suspensions for both DNA content as above, and 
for bromodeoxyuridine content, analysed by multiparameter flow cytometry, allows 
estimation of the proportion of cells in S phase (the bromodeoxyuridine labelling 
index, BLI), the length of that phase (Ts), and the potential doubling time (Tp0t) of the 
tumour. This information has been gained in 84 women, out of 89 labelled. This has 
demonstrated that the technique can be successfully applied to most breast cancers. 
Median values for the three parameters were: LI- 3.2%, Ts- 12.7hrs, Tp0l- 14.6days. 
Prognostic information is not yet available, but the relationship to other prognostic 
factors. Kinetics were closely related to histological grade, but not tumour size or 
nodal status. Although oestrogen receptor status was known for only a minority of 
tumours, within this group ER negative tumours showed significantly higher BLI. In 
terms of reproducibility, this method emerges as superior to the estimation of SPF
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(95%CI for estimations of BLI +30%). Its own limitations are considered, principally 
the inability to allow for cell loss within tumours, or to deal with variation in kinetic 
parameters in different areas of tumour.
The potential to use this technique as a means of exploring tumour biology was 
addressed in a further study of type I growth factor expression in the same group of 
breast tumours. Two members of this family of cell surface proteins were studied, the 
epidermal growth factor receptor (EGFR) and the c-erbB-2 oncoprotein. Both are 
known to be expressed in a signigicant minority of breast cancers, and in each case 
expression has been shown to be associated with poorer prognosis. This has led to the 
hypothesis that they act to give growth advantage to tumours in which they are 
overexpressed, which was tested here by looking at the relationship between 
expression and cell kinetics. In the case of erbB-2, there was a trend toward higher 
BLI in positive tumours, but this was not statistically significant (p=0.28). For the 
study of EGFR, a quantitative immunohistochemical method not previously used in 
breast cancers was used. This involves application of radio-iodinated antibody to tissue 
sections, the binding of which is demonstrated by covering the slide with 
autoradiographic emulsion. Quantification is possible by counting the number of grains 
developed in the emulsion, using an image analysis system. In all, 105 tumours were 
studied this way, as well as 9 normal breast controls. This demonstrated that 97% of 
tumours had levels of EGFR expression lower than that in normal breast. Tumours 
with preserved expression of any degree did have significantly higher BLI (rank 
correlation, p=0.019), and lower Tpot (p=0.039).
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PARTI
BACKGROUND INFORMATION
AND
HISTORICAL REVIEW
Chapter 1 2
Chapter 1:
Basic Theory of the Growth of Tumour Cell Populations
Section i: Development of models of the cell cycle
Tum ours grow  because their rate o f  cell production  exceeds the rate at w hich cells are 
lost from  them . In order to study this p rocess in greater detail, it is necessary  to 
understand the m eans by w hich individual cells divide. T hat this happened in a 
stepw ise m anner w as established by H ow ard and Pelc in the early 1950s (H ow ard  and 
Pelc 1951, 1953), by studying the incorporation o f  radioactive phosphorus into the 
nuclei o f  bean roots. They noted that after pu lse exposure to 32P, 16%  o f  m eristem atic 
cells w ere labelled. N one o f  the labelled cells w ere m itotic figures. If the exposu re  to 
32P w as prolonged, how ever, m itotic figures began to be labelled, until 50%  w ere  so 
identified after 11 hours o f  exposure. T hey  proposed from  this data that there w as a 
period o f  prem itotic D N A  synthesis, w hich they called the S phase, w hich accounted 
fo r som e 16% o f  the total in term itotic interval (ie total cell cycle tim e), and that there  
w as an 8 hour gap, w hich they referred to as G 2 , betw een the end o f  D N A  synthesis 
and the onset o f  mitosis. G iven that the interm itotic interval o f  these cells w as 30 
hours, and the process o f  m itosis occupied about 4 hours, they fu rther deduced that 
there w as a 12 hour gap, G l5 betw een the end  o f  m itosis and the beginning  o f  a new  S 
phase, by subtraction o f  the sum  o f  S, G 2  and M  from  the 30 hour total cell cycle time. 
T he m odel o f  the cell division cycle w hich they proposed w as thus a progression from  
one m itosis to the next through the phases G*, S and G 2  in that order:
S
Figure 1: Model of the G2
cell division cycle as
derived by Howard &
Pelc (1953) M
T he only subsequent addition to this m odel cam e from  the w ork o f  Lala and Patt 
(1968), w ho studied the cellular D N A  con ten t o f  populations o f  Erlich ascites tum our 
cells. T hey show ed that w hilst the num ber o f  cells w ith a D N A  content o f  G 2 cells (ie 
tw ice that o f  non-dividing cells) w as consisten t with that predicted from the H ow ard 
and Pelc model, the proportion o f  cells w ith G j content w as h igher than expected. Phis 
gave rise to the concept that there w as a com partm ent o f  cells with this D N A  con ten t 
w hich w as not contributing to cell pro liferation  within the population. T hese cam e to 
be called G 0 cells. It is fortu itous in re trospect that H ow ard and Pelc chose a cell
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population in which all cells were dividing so that there were few if any Gq cells. The 
concept that cells produced at each mitosis could either commit themselves to a further 
division (as Gj cells), or withdraw from the cell division cycle (as Gq cells) was 
entirely abstract until quite recently, when the molecular mechanisms driving cell 
division have begun to be unravelled.
Section ii: Kinetic description of the cell cvcle
Having derived a model of the process of cell division, it became possible to describe 
mathematically the interrelationships between the parameters describing it, and so 
derive the values for those which are not directly measurable. The following summary 
is based upon the work of Steel (1977), The very simplest type of cell population is 
one where every cell is dividing, doing so with the same total cell cycle time (Tc), and 
where every daughter cell in turn survives to divide. The rate of growth of cell number 
will be determined by the length of each cell cycle, with the population size doubling 
with an interval of Tc (that is, the doubling time, T^= T J . Growth will be exponential, 
and the number of cells at any given time, Nt, is related to the number at time zero, Nq, 
by the equation:
Nt = N q . 2 * ^ c (equation 1)
This is a special case of any population growing exponentially, which includes those 
where the cells do not have the same T^ where there are a proportion of non-dividing 
cells, or where cells are being lost from the cell cycle, for which the general growth 
equation is:
Nt = N0 . exp (bt) (equation 2)
where b is the growth constant (b.Nt is the rate of growth of the population at any 
given point in time). Equation 1 is given by putting:
b = In 2 / Tc (equation 3)
Tumour populations are subject to cell loss, and not all cells within them are dividing. 
Populations in which not all cells are taking part in the cell division cycle can be 
described in terms of the number of proliferating daughter cells produced by each 
mitosis, a ,  where the previous case has a  = 2, or in terms of a growth fraction 
representing the proportion of dividing cells in the population, which is equal to a-1 . 
Growth is then given by equation 2 with:
b = In a  /  Tc (equation 4)
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The doubling time in this situation is gained by putting Nt = 2Nq and t = in equation 
2, which gives:
2N 0 = N 0 . exp (Td . In a )
T1c
Or: Td = Tc (ln2 /  lna) (equation 5)
Which allows us to rewrite equation 4 as:
b = In 2 /  Td (equation 6)
Accounting for cell loss is more complex, and requires a consideration of the rate of 
growth rather than just the number of cells in the population. Cell loss can be thought 
of as the cause of any difference between the actual growth rate of a cell population and 
the rate at which it would be expected to grow on the basis of the above growth 
equations, which allow for the fact that not all cells within the population are dividing, 
but not for cells leaving the population. The rate at which a population would double in 
size under such conditions, given in equation 5, is referred to as the potential doubling 
time, Tpot, a title presumably chosen to indicate that this is represents the 'potential' for 
the population to grow, were it not subject to cell loss. T ^  can also be derived from 
the cell production rate within the population, Kp. If it is assumed that no cells are 
being lost in mitosis itself, then this is the same as the rate at which cells are entering 
mitosis (since each cell entering mitosis can then be assumed to divide into two, so 
adding one to the total cell population), which gives:
Kp = M I / T m
where MI is the mitotic index, the proportion of cells in M phase at any given point in 
time, and Tm is the length of M phase. The units of Kp are the fraction of cells coming 
into division per unit of time. If the population is growing exponentially, this implies 
that the mitotic rate is in constant proportion to the population size. If so:
Tpot = In 2 /  Kp (equation 7)
Cell loss is usually expressed as the cell loss factor, 0 ,  the ratio between the number 
of cells lost per unit time, Kl, and the cells produced per unit time, Kp, that is:
0  = Kl /  Kp
As implied in the first sentence of this section, growth is the result of cell production 
less cell loss:
cell production - cell loss = grow th
Chapter 1 5
which, in a population of N cells gives:
NKp - N 0K P = bN
Substituting for Kp from equation 7, and for b from equation 6 leads to:
0  = 1 - ( Tpot /  Td ) (equation 8)
The concept of Tp0t may seem to be rather unhelpful, but is introduced because it can 
in fact be estimated in human tumours (vide infra, bromodeoxyuridine), whereas the 
apparently more concrete parameter Td is rarely available. Where both are available 
estimates of the cell loss fraction can be made.
Section iii: Mechanisms of cell loss
It was made clear in Section ii that cell proliferation is only one side of tumour growth, 
which is also determined by the rate of cell loss from the tumour cell population. In 
fact, to presage one of the results of the current work, cell loss is far more important in 
controlling the overall rate of tumour growth than is cell proliferation. We need then to 
consider at least briefly what we mean by cell loss in this context. In terms of the 
models of population growth presented above, a lost cell is one which neither enters 
G0 or a further round of cell division. It has either left the cell population by migration, 
or it has lost viability. The latter can happen in two ways- the cell may become necrotic 
or apoptotic. Necrosis is an ancient pathological entity whereby cells are ‘killed’ by 
external forces (eg hypoxia) and digested by a combination of their own enzymes and 
macrophages. Apoptosis is a more recent concept (Kerr et al, 1994 is a good recent 
review). It refers to a process whereby the cell apparently ‘decides’ to die, that is it is 
an internally determined event, rather than one decided by external forces as necrosis is 
(Kerr et al, 1972). It occurs in normal as well as tumour tissue, including normal 
breast (Walker et al, 1989), and its rate in experimental tumours is such that at may 
represent the predominant mechanism of cell loss in this situation at least (Sarraf & 
Bowen, 1988). It certainly appears to be important in the cell death that occurs after 
irradiation (Macklis et al, 1992), chemotherapy (Searle et al, 1975), and hyperthermia 
(Dyson et al, 1986).
Recent research has explored the molecular mechanisms of apoptosis. At least one 
gene product, bcl-2 has been found to specifically protect against apoptosis in 
lymphoid cells (Hockenbery et al, 1990), but its distribution suggests that is functions 
in this way in many tissues (Hockenbery et al, 1991). It has also been shown that one 
function of the p53 tumour suppressor gene is to activate apoptosis (Shaw et al, 1992). 
Another apparent controller of apoptosis is the oncogene c-myc, the first gene to be
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implicated in inducing apoptosis (Buttyan et al, 1988). This seems at odds with its 
oncogenic abilities, but its actions are context sensitive, in that in the presence of 
growth stimuli, it acts as a proliferation transcription factor, but in the absence of such 
stimuli it acts to co-ordinate apoptosis (Wyllie 1992).
Section iv: Control of the cell cvcle
It appears that regulation is effected at a series of checkpoints within the cell cycle, 
indicated in the figure below. A specific ‘signal’ is necessary before the cell can pass 
any of these points.
START (yeast) 
R (animals)
Metaphase
completion
DNA synthesis 
initiation
G2
Mitosis
initiation
DNA synthesis 
completion
Figure 2: ‘Checkpoints’ within the Cell Cycle
Passage beyond these checkpoints depends upon phosphorylation of intranuclear 
substrates, and there exists a class of kinases specifically for this task. This was first 
discovered in fission yeast, where it was shown that mutations of a gene christened 
cdc2 caused cells to stop at two specific points in the cell cycle- at START or at the 
G2/M boundary (Lew and Reed, 1992). Cloning revealed that cdc2 encodes a 34kDa 
serine/threonine kinase, which appears to be the central regulator of cell cycle 
progression in yeast. cdc2 is highly conserved in evolution. In animals, however, a 
number of other cdc2-related proteins have been found, the family of cyclin-dependent 
kinases (CDKs). CDK1 is the member with 100% homology to the kinase domain of 
cdc2.
Self-evidently, CDK activity must be cyclical in order to selectively control progress 
through the cell cycle. This could be achieved by transcriptional control of the kinases
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themselves, but in fact their expression in non-cyclical. Instead, cyclical activity is the 
result of three regulators of CDK function: a class of cyclically expressed proteins 
which bind to the kinases and are essential for their activity, the cyclins (and thus the 
name of this class of kinases); a group of specific inhibitors of the kinases; and the 
phosphorylation state of the kinases themselves (at least some cyclins act by causing 
conformational change when they bind to kinases so as to expose phosphorylation 
sites). Passage through each checkpoint appears to require some or all of: assembly of 
a complex of CDK, cyclin and other proteins; CDK phosphorylation; and release of 
inhibition.
Current indications are that the CDKs and cyclins do not all form strict one-to-one 
pairings, but rather that some CDKs can bind more than one cyclin, and vice versa. At 
the time of writing (Nov. 1994), 12 separate proteins with the 100 amino acid cyclin 
box which contains the binding domain for the CDKs have been isolated, and assigned 
to 8 classes of cyclin, named A to H, with up to 3 subtypes of each (in the case of the 
D-cyclins). However, only cyclins A, B, D and E have been assigned fairly definite 
roles within the cell cycle so far. A similar number of potential CDKs are described, 
with 7 having at least one known cyclin partner, leading to assignation of a CDK 
number (CDK7 is unique in not having a cyclin partner. It may act upon the other 
CDKs, to activate them by phosphorylation of a critical threonine residue (Pines, 
1994)).
It was only a year ago that the first indications emerged that CDK function might also 
be subject to negative control, with the description of two small proteins which 
appeared to act as CDK inhibitors, p21 and p l6  (Serrano et al, 1993; Xiong et al, 
1993; El-diery et al, 1993; Harper et al, 1993; Gu et al, 1993; Noda et al, 1993). These 
have been followed by p i5 and p27 (Hannon and Beach, 1994; Polyak et al, 1994; 
Toyoshima and Hunter, 1994), with no doubt more to follow soon. These molecules 
appear to act in different ways, and no uniform view of their role has yet been 
developed, but in each case they bind either to CDK/cyclin complexes to inhibit their 
activity (eg p27 with the D and E cyclins) or to the CDKs alone preventing complex 
formation (eg pl5 with CDKs 4 & 6). Interestingly, p l6  (a negative regulator of D 
cyclins) appears to be negatively regulated by Rb, which is itself a major target of the 
cyclin D/CDK complexes. This provides a potential positive feedback loop at the vital 
R point in the cycle, with D/CDK activation of Rb resulting in reduced p l6  inhibition 
of the D/CDK complex. This class of inhibitors may also represent another point of 
entry for regulatory signals to the cell cycle control system, p21 having been shown to 
be transcriptionally upregulated by p53 (El-Diery et al, 1993), and pl5 similarly 
affected by TGF|3 stimulation (Hannon and Beach, 1994).
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Targets for the CDKs are not well characterised other than at the G l/S  transition, 
where CDK2 has been shown to phophorylate the retinoblastoma protein, pRb, and 
the closely related pl07 (Lees et al, 1991). The role of Rb in controlling cell 
proliferation has been well studied. It is known to be inhibitory to cell cycle 
progression in its unphosphorylated form, by binding the transcription factor E2F 
(Challappan et al, 1991). Phosphorylation by CDK2 leads to dissociation of this 
complex, with release of E2F and potentially increased transcription from the genes 
encoding thymidine kinase, myc, myb, dihydrofolate reductase-and DNA polymerase 
a ,  among others, which possess E2F binding sites in their promotors.
Section v: Cell cvcle response to external stimuli
The ways in which cell surface interactions are transmitted to the nucleus, in order to 
regulate the cell cycle, have also been elucidated to some extent in recent years. The 
restriction point in the cell cycle appears to be the major site of entry of signals from 
the cell membrane. Signalling is currently thought to channel through the mitogen- 
activated protein kinase (MAPK), which is able to cross the nuclear membrane in its 
phosphorylated form and acts upon transcription factors such as jun and fos to produce 
its downstream effects, which include induction of cyclin D (Pines, 1993), and thus 
passage through the R point. This apparently central role of MAPK may of course 
simply reflect ignorance of alternative pathways from the cytoplasm to nucleus.
The route from cell surface to MAPK is becoming clear at least in respect of the 
tyrosine kinase class of cell surface receptors, which are of particular relevance in this 
thesis. This expanding group of compounds consist of an extracellular ligand binding 
domain, a short trans-membrane domain, and an intra-cellular domain with tyrosine 
kinase activity. The paradigm of this group is the receptor for the epidermal growth 
factor (EGFR). One other member is well characterised, the product of the c-erbB-2 
oncogene (EGFR is also, rarely, known as c-erbB-1, and this type I class of tyrosine 
kinase now extends to c-erbB-3 & 4, although these are far less well studied so far). 
For all of these receptors, ligand binding results in autophosphorylation of the intra­
cellular domain. These phosphorylated tyrosine residues create epitopes recognisable 
by SH2 domains on second messenger molecules (Fantl et al, 1993). These have been 
shown to include phosphatidylinositol 3-kinase, phospholipase C-y, and the ras 
complex, ras is recruited via the GTP-ase activating protein, which in the setting of 
EGFR at least seems to join with two other factors, grb2 and sos, in activating ras. 
ras then activates the raf kinase, which in turn phosphorylates MAPK kinase, the 
controller of MAPK activity. This apparently linear sequence of events is of course 
actually taking place in the midst of many other interactions, and does not exist in the 
splendid isolation suggested by this description.
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Chapter 2: 
Overview of Methods in Tumour Cell Kinetics
Theoretical understanding of the cell division cycle provides the basis for the rational 
investigation of the rate of growth of tumour cell populations. The remainder of this 
introduction considers in detail the theoretical and practical problems associated with 
the methods developed for this purpose, and reviews the results which have been 
gained by applying them to the study of human breast cancer. Before going on to this, 
it is important to ask why it should be of benefit to bother studying tumour cell kinetics 
at all, and why breast cancer is an appropriate system to use.
Section i: Whv Study Tumour Cell Kinetics?
Abnormal growth is a defining, and fundamental, characteristic of a tumour, along 
with the ability to invade locally and metastasise to distant sites. This alone might be 
regarded as an adequate reason for wishing to understand the process. In the absence 
of the ability to intervene in the process of growth, however, the mere capacity to 
describe it is of limited value. The recent explosion in knowledge about the molecular 
mechanisms underlying cell division, and about the ways in which tumours cells 
appear to have subverted the normal controls on division, has opened up the possibility 
of intervention to obstruct the pathways used by tumours to give them growth 
advantage over other cells. If this is to be done, it is critical that methods are available 
to determine which of the many molecular abnormalities within tumours are important 
in determining their growth rate, as many of the changes seen might be non-functional. 
What are required are means for determining the rate of cell growth within tumours, to 
be compared with the abnormalities being studied. Put simply, to determine why 
tumours grow, you need the means of telling how fast they are doing so.
At a clinical level, even if intervention was not possible, the ability to describe tumour 
growth might be of some value. It is appealing to hypothesise that rapidly growing 
tumours will have a worse outlook than those which grow more slowly. That is, 
prognostic information might be gained by knowledge of tumour kinetics. 
Prognostication alone is of limited benefit to the patient, but it does make selection of 
patients for further investigation or therapy somewhat more rational- not 
inconveniencing patients with very poor outlook who are unlikely to be helped, or 
conversely not jeopardising the health of people with a very good outlook.
In the case of radiotherapy and chemotherapy, there is a stronger rationale for the use 
of information about tumour cell kinetics. These therapies are cell cycle dependent in 
the sense that they target dividing cells by interfering with the process of cell division.
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It would seem to be very helpful in planning such treatment to have information as to 
how many cells within a particular tumour are trying to divide in a given period to 
time. It is readily apparent that a tumour in which very few cells are dividing is going 
to be relatively resistant to these modalities, whilst one which provides many targets by 
having most cells in cycle is likely to be more responsive (and indeed it is an empirical 
principle that aggressive tumours of poorer intrinsic prognosis respond better to 
chemo- and radio-therapy). Information as to tumour cell kinetics may be able to help 
in two ways here- by indicating which patients might be better served by the exhibition 
of these therapies (McNally, 1989), and also in helping determine what schedules to 
use in applying them. In this way, cell kinetics might be one way of predicting drug 
resistance or resistance to radiotherapy.
A good example of the latter point is accelerated radiotherapy protocols (Fowler, 1985; 
Dische and Saunders, 1990). This form of treatment is based upon the premise that 
standard radiotherapy protocols, using daily or less frequent fractions, may fail in the 
case of tumours containing a rapidly dividing cell population because of repopulation 
of the tumour between fractions. That is, the tumour cells are capable of dividing so 
rapidly that they are able to make up the cell numbers lost or damaged in each dose of 
radiotherapy. So-called hyperfractionation involves dividing the total radiation dose 
into more fractions and giving two or even three fractions per day. The total period of 
treatment is reduced. The dose intensity is increased, and with it the incidence of side- 
effects in normal tissues, which repopulate more slowly. The use of this type of 
therapy therefore depends upon the ability to identify tumours which require this 
approach, for which the benefits may make this risk worthwhile (Tucker and Chan, 
1990). Trials are underway to see if measurement of tumour cell kinetics can indeed 
predict response to hyperfractionated radiotherapy (Begg et al, 1990; Lochrin et al, 
1992).
In summary, there are three major lines of argument to defend the study of methods to 
measure tumour cell kinetics:
- they are a tool for investigating the biology of tumour growth;
- prognostic information may be gained; and
- they may allow more rational use and scheduling of chemo- and radio-therapy. 
Section ii: Whv Breast Cancer?
The reasons for using breast cancer as the tumour type in which to explore and extend 
the application of tumour cell kinetics are also threefold. Firstly, it is now the second 
commonest non-skin malignancy afflicting females in Western society, having, in the
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last few years only, been overtaken by lung cancer. 23,000 cases are diagnosed 
annually in the United Kingdom, and 13,000 women die of this cause each year in the 
UK. These figures indicate that assuming a steady state of the disease in the 
population, 56% of all patients with the disease eventually die of it. Although like most 
tumours it increases in incidence with age (Haagensen, 1956, p.334), it is by no 
means rare in young adults, and common in middle-aged women. There is therefore a 
continuing need to improve our understanding and treatment for this condition.
This is all the more apparent when the prognosis in considered in historical context. If 
we look at the corresponding figures for incidence and mortality from Haagensen's 
book (1956, pp. 332-33), in the USA in 1950, there were 18,734 deaths from breast 
cancer, and the incidence was stated to be 62.2 per 100,000 women. Now there were 
about 75 million women in the US at that time (Encyclopaedia Brittanica, World Data 
Annual for 1992, p. 753), which translates at the given rate of incidence to 46,650 
cases per year. The number of deaths is 40% of this, rather than today’s 56%. Using 
historical data of this uncertain provenance is open to many pitfalls, but it does suggest 
that there has been little if any improvement in the outlook for patients with breast 
cancer in the last 40 years. It is also worth noting that perhaps as many as 20% of 
women with untreated breast cancer will survive for 5 years anyway (de Moulin, 
1989, table 2, p. 90). The quality of life of women with this disease may well have 
been greatly improved by current treatment, but the quantity may not have increased so 
markedly.
Finally, and perhaps because of the two points considered already, breast cancer has 
been widely studied in the past, and most cell kinetic methods have at some stage been 
applied to it. This provides a substantial body of literature to draw from in assessing 
the newer techniques which will form the experimental part o f this work.
To reduce these arguments to point form, the rationales for the choice of breast cancer 
are:
- it is a very common tumour;
- - the outlook has not improved for many years; and
- it has been well studied in the past.
Section iii: Summary of Methods Available
The techniques available for assessing some aspects of the rate of growth of tumours 
and/or their constituent cells are listed in table 1. They will be briefly introduced now, 
and then in the succeeding chapters of the introduction, those which have been applied 
to the study of human breast cancer will be considered in greater detail.
1) Direct Measurement of Tumour Volume Increase
Chapter 2 12
2) Measurements of Cell Cycle Distribution
a) Estimation of S Phase
- thymidine labelling index
- flow cytometric S phase fraction
- halodeoxyuridine labelling index
b) Estimation of M Phase
- mitotic index
c) Estimation of all In-Cycle Cells
- Ki-67
- Proliferative cell nuclear antigen (PCNA)
3) Estimation of Serum Thymidine Kinase activity
4) Measurements of the Rate of Cell Cycle Transit
a) Halogenated Pyrimidines
- in vivo halodeoxyuridine labelling
- dual labelling
b) Percent Labelled Mitoses
c) Strathmokinetics
Table 1: Classification of Methods used for Studying the Growth of Human Tumours
The most obvious means of studying tumour growth is to simply observe the rate of 
growth in size of tumours in situ. In order to do this the lesion must be accessible to 
measurement, and must go untreated for some period of time. These requirements are 
actually rather stringent, as it turns out.
A rough indication of proliferative activity can be inferred from the proportion of cells 
in different phases of the cycle. The most readily identifiable phases initially were the S 
and M phases. If a large proportion of cells are in either of these phases then it is 
assumed many of the tumour cells are 'in cycle' (ie not in Gq phase), which will result 
in an increased rate of cell production if the relative lengths of the various phases are 
not altered. M phase can be recognised histologically because of the condensation of 
chromatin at this time, and the formation of a mitotic spindle, although it must be 
appreciated that these typical appearances are not seen throughout the phase. S phase is 
recognised by methods which target the process of DNA synthesis that occurs 
exclusively at this time. This was initially done by the use of a tritiated form of the 
DNA precursor thymidine, which is incorporated during DNA synthesis or repair 
through the salvage pathway for pyrimidine bases. Its presence can then be visualised 
by detection of the emitted radiation. More recently halogenated pyrimidines, which
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can substitute for thymidine in the salvage pathway and subsequently within DNA, 
have found favour instead, as these can be detected using antibodies without the 
necessity for the use of radioactivity.
S phase cells can also be recognized by their DNA content, which is intermediate 
between that of non-dividing cells and those in the G2 or M phases (which have 
duplicated their DNA). This is achieved by staining cells with fluorescent DNA- 
binding dyes and flow cytometry, which quantifies the amount of dye bound by each 
cell nucleus. A frequency histogram of the DNA contents of . a large sample of cells is 
created, and analysed to obtain an estimate of the proportion of cells with the content 
appropriate to S phase cells. This process is explained in much greater detail in later 
parts of this thesis, as it constitutes one of the methods examined by this work.
It has only been possible to detect cells in other phases of the cell cycle more recently. 
This has come about through the development of antibodies to cell cycle specific 
antigens, that is, to proteins expressed only in cells undergoing cell division (although 
not necessarily expressed at all times throughout the cycle). The two most widely used 
antibodies are Ki-67 and PCNA. These can be used as primary antibodies for 
immunohistochemistry, and the proportion of cells expressing the antigens recognised 
counted, as a measure o f the number of 'in-cycle' cells.
Serum activity of the pyrimidine salvage pathway enzyme thymidine kinase is 
indirectly related to the amount of proliferative activity of tumours, in that the TK1 
isoform of this enzyme is present in high concentration in dividing cells, but is absent 
in GO cells (Bello, 1974). The fact that tumours represent a large mass of dividing cells 
led to the hypothesis that elevated levels of TK might be present in the serum. This 
was demonstrated to be the case in animal models (Taylor et al, 1981; Kreis et al, 
1982), and extended to human tumours by a group in Northern Ireland (O’Neill et al, 
1986, 1987), including breast cancers (McKenna et al, 1988). Although potentially, 
the level of TK could be a measure of the amount of proliferative activity occurring 
within a tumour (allowance being made for tumour mass), this does not seem to have 
been pursued, and initial responses did not confirm the Irish findings (Calvert and 
Satchithanandam, 1989).
All of these methods are static in the sense that, whilst they provide information as to 
the cell cycle distribution of cell population, they do not give any indication of the rate 
of progress of cells through the cycle. Only with this additional information can 
calculations be made to estimate such parameters as the cell production rate or potential 
doubling time. The first method developed in an attempt to gain this type of data was 
the percent labelled mitoses technique (Steel, 1977; chapter 4). To do this, S phase 
tumour cells were point labelled (this being a historical method, this was done with
Chapter 2 14
tritiated thymidine, the only label available at that time). The tumour was sampled at 
intervals thereafter, and the proportion of mitotic figures which were labelled with the 
thymidine counted. Theoretically, if the labelled S phase cohort passed through the 
cycle in concert, successive waves of labelled mitoses would be seen at an interval 
which corresponded to the total cell cycle time (figure 3). In reality the labelled cells 
progress at different rates, and so spread out in the cycle within a few rotations, a 
process referred to as damping. Mathematical models can be used to estimate the total 
cell cycle time from the damped graph. The percent labelled mitoses method was never 
widely used in human tumours in vivo, because of the need to administer a radioactive 
DNA precursor, and has never been used in human breast cancer to my knowledge; it 
is not discussed in the following chapters for this reason.
Although this problem could now be overcome by using halogenated pyrimidines, this 
does not get around the need to take many tumour samples. However, a method using 
halogenated pyrimidines as label, but requiring only a single subsequent tumour 
sample has since been developed (Begg et al, 1985). This method was developed 
using the pyrimidine bromodeoxyuridine. After point labelling, it is presumed that all S 
phase cells will have taken up the agent. A biopsy specimen is then taken some hours 
later, and stained for bromodeoxyuridine content, and for total DNA content. Flow 
cytometry allows each of these parameters to be measured in many cells. From the 
DNA content of the labelled cells, which phase they are in can be assessed, and so 
their progress in the cell cycle since they took up the bromodeoxyuridine can be 
measured. This value for 'distance' travelled can be divided by the time between 
labelling and biopsy to estimate velocity. The actual parameter obtained is the length of 
S phase in hours. A labelling index is also obtained, and the two can be combined to 
estimate the potential doubling time. This method is covered in detail in future sections 
of the manuscript.
It is also possible to obtain dynamic data from a single biopsy by using multiple labels. 
This can be done by using more than one halogenated pyrimidine, or a combination of 
one such with tritiated thymidine, since one of the labels can be incorporated in vitro. 
.So for instance, bromodeoxyuridine could be administered as just described, and the 
subsequent biopsy labelled in vitro with iododeoxyuridine. The proportion of cells 
stained with each of the labels alone, and the proportion double labelled are counted. 
The proportion of S phase cells is given by the iododeoxyuridine labelling index. 
Presuming that not enough time was allowed for cells to complete a whole cycle and 
reenter S phase, the dual labelled cells are those which have failed to complete S phase 
between the two labelling events. This allows determination of the number of S phase 
cells and the number which have left that phase in a known period of time, from which 
the length of S phase is easily calculated (Hoshino et al, 1972; Shibuya et al, 1993).
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Figure 3: Principle of Percent Labelled Mitoses (PLM) Technique, 
following the fate of an H3-thymidine labelled cohort of cells (white balls) 
alongside a plot of the proportion of labelled mitoses at each stage.
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A further method for gaining dynamic cell cycle information is the strathmokinetic 
technique (Steel, 1977, p.88 et seq). This utilitises the ability of the vinca alkaloids and 
colchicine to cause cells to arrest in metaphase, where they are easily recognisable. For 
the method, vincristine is given, samples are taken at several times thereafter, and the 
number of mitotic figures in each sample is counted. The number of mitotic figures is 
plotted against time, and the slope of this line gives the rate of accumulation of cells in 
M phase. If it is assumed that all cells survive this phase normally, then the rate of 
entry to M phase is equal to the cell production rate of the population. The problems in 
applying this to human cancer are familiar- the need to give a mitotic poison, and to 
take multiple samples, rules it out as an in vivo technique. It can be used for tissue 
samples in culture, and in the study of gastro-intestinal crypts, but like the percent 
labelled mitoses method, it has not been applied to human breast cancer.
Even dynamic cell kinetic methods still only provide information at one point in time, 
and are uninformative as to the rate of cell loss from the population (unless the action 
tumour growth fate is known, when cell loss can be inferred from the difference 
between potential and actual doubling times). Furthermore, the ability of any cell 
kinetic measurements to predict patient outcome is limited by the fact that it is 
metastatic behaviour which ultimately leads to death in nearly all cases, and so kinetics 
only provide prognostic information in as far as they are linked to the metastatic 
phenotype. These are still unresolved shortcomings of the current state of the art in 
measuring tumour cell kinetics. Following on from this overview of cell kinetic theory 
and methodology, the next section commences the more detailed review of the 
information gained in the case of breast cancer. We begin with the measurement of in 
situ, whole tumour growth rates.
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Chapter 3: 
Review of Static Methods Applied to Breast Cancer
Section i: Direct Measurement of Tumour Growth
In vivo observation appears to be the simplest and definitive measurement of tumour 
growth. Unfortunately, this type of information is rarely available. There are at least 
two reasons for this. Firstly, the calculation of growth rate relies upon at least two 
measurements being made at different time points, and if the information is to be 
related to the natural history of the tumour it follows that the lesion must be untreated 
for the interval between these measurements. Most tumours are not left untreated for a 
length of time adequate for this purpose. Nevertheless, sometimes this does happen 
because the patient is unfit for or refuses treatment. Another source of information 
comes from mammographic studies, where a tumour has been overlooked on one 
examination (but is visible and measurable in retrospect) and subsequently detected on 
another. The second reason for the rarity of direct tumour growth measurements is that 
the tumour needs to be accessible for and amenable to the process of measurement 
itself. That is, it must be well defined in its extent, superficial and non-tender if it is to 
be sized by clinical examination, or in a site favourable for radiological delineation.
Quite apart from the difficulty of finding suitable cases, the process by which tumour 
growth is calculated from clinical or radiological measurements is suboptimal. 
Obtaining a point estimate of tumour volume is problematic. True volume can of 
course only be obtained by removing the tumour. In vivo estimates are made on the 
basis of measured diameters. If a tumour were perfectly spherical, then volume could 
be accurately deduced on this basis from a single diameter, d, as V = (j i /6) . d3 . 
Tumours are not spherical, unfortunately, and the next best estimate comes by taking 3 
diameters at right angles to one another (dl, d2 and d3) and calculating V = (j i /6) . (dl 
. d2 . d3). Even then, whilst two diameters are often available the depth of a lesion 
being measured clinically is not easily obtained. Similarly, most imaging investigations 
are two dimensional, and so unless images at right angles have been taken, only two 
diameters will be gained. With only two dimensions to work from the calculation o f ' 
volume is even more approximate.
Accepting the shortcomings of individual volume measurements, accurate calculation 
of growth rates would best be achieved by multiple observations at different time 
points, when an appropriate growth curve could be fitted mathematically on the basis 
that errors will be randomly distributed. In other words, the reliability of growth 
measurement increases with the number of size determinations upon which it is based 
(Steel, 1977, p. 41). It will be readily appreciated however that in most cases only two
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or three observations are made. Furthermore, it was pointed out in the last section that 
human tumour growth is not constant, but rather slows with time as a result of 
increasing cell loss. Calculated doubling time is thus dependent upon the stage of the 
natural history at which is is being measured. Only if multiple time points are studied 
can a Gompertz curve be fitted in order to make allowance for this. There is a general 
point here, in that all observations are being made upon tumours in a very late stage of 
their natural history, and this applies to all studies of in vivo tumour growth. If it is 
assumed that a single cell weighs about 10‘9g, then it requires about 30 doublings 
before it achieves a clinically observable size of lg  (and tumours in many sites may not 
be apparent until they are substantially larger than this). Most tumours prove lethal at a 
total tumour burden of the order of 1kg, which is only 10 further generations. That is, 
only the last quarter of the lifespan of a tumour is clinically evident, in terms of 
doublings, although it must be remembered that the doubling time increases with the 
age of the tumour, so that these last 10 doublings will occupy more than one quarter of 
the lifespan of the tumour in terms of time:
Weight Cells
— —
----- 1kg -----1012
— 19 109
----- 1mg — 106
----- 1pg — 103
----- 10‘9g —  1
Doublings
40
30
20
10
Clinically
Observable
Phase
Figure 4: Relationship between tumour age (in terms of number of 
doublings) and tumour size (in terms of weight and number of cells).
The direct observation of tumour growth can be seen to be neither as simple nor as 
definitive as first imagined. Nevertheless, there is no other source of information about 
actual tumour doubling times. The published data for breast cancer is of several kinds- 
data based upon tumours missed in one mammogram and subsequently detected on 
another, data based upon the growth of recurrences in the scar from a mastectomy, 
data based upon serial observations of untreated primary tumours, and data inferred 
from the history of the illness in the patient.
Gershon-Cohen and his colleagues in Philadelphia, who were strong early proponents 
of mammography as a diagnostic tool in breast cancer, were also the first to gain
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experience of tumours visible in retrospect on previous mammograms of cancer 
sufferers (Gershon-Cohen et al, 1963). They calculated tumour volumes on two to six 
occasions, using the area (A) of the tumour on each mammogram and applying the 
formula V = 0.75 x A3//2. This assumes that the unknown diameter of the tumour is 
equal to the average of the other two. The interval between observations was from 4 to 
54 months, with the not surprising corollary that no growth was observable in one 
such case with an observation period at the lower end of this range. Tumour doubling 
times were calculated on the basis of simple exponential growth, which is reasonable 
for short observation times but not for longer ones where Gompertzian retardation 
might be significant. The doubling times which they presented were from 23 to 209 
days (mean 115 days).
A larger series of 147 cases was published by Fournier et al (1980). They had an 
observation interval of 2 months to 11 years, with an average of 27 months, during 
which time the patients had between 2 and 11 mammograms. How many of the 
observation intervals fell at the lower end of the range is not stated. Derived tumour 
doubling times were from 44 to 1869 days, with a mean of 212 days. Volumes were 
calculated from 3 diameters measured from a single view, but the equations used for 
this transformation are not stated. Doubling times were probably estimated by fitting of 
a Gompertz curve, but what was done in the half or more of cases with only 2 
mammograms is not clear. These authors made the point that the estimation of the size 
of a mammographic shadow was subjective and interpretation varied from one 
observer to another. They also discuss the assumption that the visible shadow 
corresponds to the size of the tumour, since it may be that the margin of the shadow 
consists of stromal reaction around the tumour, or conversely that the tumour margins 
extend invisibly beyond the visible abnormality. Details are provided of results 
obtained from 6 serial mammograms of one lesion over a 5 year period, which resulted 
in estimates of Td varying from 80 to 193 days, with no clear trend for doubling time 
to get shorter or longer over this interval. Rather, this would appear to indicate the 
imprecision of the method.
Spratt et al (1981) reported the doubling times of 32 tumours based on serial 
mammography. The observation intervals varied from 3 to 24 months, and doubling 
times appear to have been based on 2 measurements only, with an assumption of 
exponential growth. Volume was calculated from 2 diameters on a single view, using a 
spheroidal model of tumour shape. 9 tumours with relatively short periods of 
observation did not grow during this study. The remaining 23 tumours were reported 
as having doubling times of between 109 and 944 days, with a median of 324 days. 
Only 7 of the 23 tumours with observable growth had a doubling time of less than 200 
days, the longest reported by Gershon-Cohen et al.
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The only recent study of this type was published by Arnerlov et al (1992), who made 
measurements in 158 screen detected cancers which were retrospectively visible on a 
previous mammogram. Doubling times were calculated on the basis of a single 
diameter from two films taken 2 to 94 months apart. They state that tumours were 
presumed to be spherical in shape, but the assumed model of growth is not given. 11 
tumours demonstrated no growth during the period of observation, but insufficient 
data is presented to determine whether these were tumours with a short interval 
between the two films. In the 147 cases with measurable growth, they found a median 
doubling time of 9 months, with a range from 0.6 months to 96 months. The modal 
group was below the median, at 3-6 months. They found that tumours with above 
median growth rates were more common in stage II tumours than stage I lesions 
(because this was a study of screen detected cancers, all but one tumour was in these 
two stages, and in fact 68% were stage I). They also performed DNA flow cytometry 
upon the tumours in this series, and calculated the tumour S phase fraction (SPF) from 
the resultant histograms. This is the only attempt among all of the papers looking at 
actual doubling times to correlate this with any measurement of tumour cell growth 
rates. They found that aneuploid tumours were significantly more likely to show rapid 
growth, and that rapidly growing tumours had a significantly higher mean SPF:
Ploidy 0-3
Doubling Time (months) 
3-9 9-48 48+
Diploid 3 18 24 10
Aneuploid 17 36 39 3
Chi-square = 13.49, df = 3, p = 0.004
Doubling Time (months)
0-3 3-9 9-48 48+
Mean SPF (%) 17.8 11.5 9.0 6.2
p = 0.001 (original authors' t test)
Table 2: Data’from Arnerlov et al 1992) relating tumour ploidy and 
S phase fraction to observed doubling times
The rate of growth of mastectomy scar recurrences is calculated on the basis that they 
have presumably arisen from one or very few cells at or about the time of that 
operation, although Brown et al (1987) have provided complex statistical evidence that 
the number of initiating cells is of the order of 60,000 (this is still a very small lesion, 
with a mass of clOOpg, but represents 16 doublings of a single cell, sufficient to 
entirely invalidate this approach). If however the paucicellular origin is accepted, it
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provides Vo for use in a growth equation. In all cases calculation has been based on 
only one later observation (at the time of extirpation of the recurrence), which means 
again that only a simple exponential can be fitted, without allowance for Gompertzian 
growth. It must also be borne in mind in assessing this type of report that the growth 
of a tumour recurrence is occurring in a different milieu to that of the primary tumour, 
and represents a self-selected cellular sub-population which may have growth 
characteristics atypical of the original tumour. Phillipe and Le Gal (1968) calculated 
growth rates of 78 nodules selected as not being ulcerated or showing histological 
evidence of necrosis. They found doubling time to range from 3 to 211 days, with a 
mean of 78 days. The distribution of doubling times was bimodal, with peaks at 25 
days and at 93 days, suggesting the possibility of two different types of nodule of 
fundamentally different biology. This type of distribution is not apparent in other 
studies. The other study based on scar recurrences (Pearlman 1976) specifically refutes 
this concept, finding instead that doubling times are log normally distributed (like most 
biological characteristics). Pearlman studied 82 cases, apparently unselected. T^ was 
calculated in exactly the same way as Phillipe and Le Gal. The range of calculated 
values is not stated, but from his figure 3 appears to be from 3 to 170 days with a 
median of about 26 days.
Anecdotal evidence as to the clinical rate of growth of breast tumours was given by 
Richards (1948), who stated that the average breast cancer grows by 1cm in diameter 
every 3 months. What measurements may have led to this statement are not given or 
hinted at. More assessable data is presented by Kusama et al (1972), who documented 
the growth of 212 tumours in 199 patients with breast cancer. In 163 cases these 
observations were made upon primary lesions, and in another 49 cases upon a mixture 
of local recurrences, involved lymph nodes, pulmonary and other metastases. The 
interval over which observations were made in each case are not given, but it is stated 
that if no growth was observed over a period of one month or more, the doubling time 
was taken to be infinity. Some intervals were very short indeed, and given the 
inaccuracy of clinical measurement of these lesions, it is not surprising that growth 
could not be detected. Volume change was calculated from change in a single diameter, 
and doubling time was taken as one third of the diameter doubling time (in fact T^ = 
3/8 x diameter doubling time, so that this approximates 3/8 = 1/3). This method 
assumes that volume doubling is reflected in equal expansion in all dimensions, which 
is probably reasonable in breast and lung where there is little physical constraint on 
growth in any direction. They also note that some initial observations were made 
before referral to their centre, so that the initial and later diameters were measured by 
different people, which in this distinctly subjective field is clearly not optimal. Lesion 
by lesion growth rates are not stated, the most basic data provided being a breakdown
Chapter 3 22
of doubling times by intervals of one month, with all tumours having a doubling time 
of over 10 months being grouped together. The median Td is given as 3.5 months (105 
days) with a range of 0.2 to 18 months (6 to 540 days). They state that there is no 
significant difference in the median doubling time of primary and secondary tumours, 
although the median for primary tumours is lower. The raw data to check this are not 
presented, but from their table 1 it is possible to perform a chi-square test to examine 
the null hypothesis that there is no difference in the growth rate of primary and
secondary lesions within the total study group. Doing so gives X2 = 14.884, df = 4, p 
= 0.0049, rejecting the null hypothesis, contrary to their assertion. Examination of the 
distributions indicates that the trend is as they have indicated, in favour of faster 
growth in secondary tumours.
The final technique which has been used to assess the rate of growth of primary breast 
cancers is to note the history of the disease in the patient. Commonly, the size of the 
lesion is correlated with the length of time since any abnormality was first noted by the 
patient. Those with clinical experience in the area of breast cancer will have met many 
women with fungating tumours which they claim have only been present for a matter 
of weeks, and realize that the patient's history is a poor guide to the period that 
symptoms have been, present. Notwithstanding this argument, slower growing 
tumours as defined in this way have been reported as having a better prognosis 
(Collins et al, 1956). A similar approach was described by Charlson and Feinstein 
(1980). This was based on the interval between the first abnormality noticed by the 
patient and the time of definitive treatment, modified by the occurrence of disease 
progression during this interval. This could well be considered to represent a measure 
more of treatment delay than of tumour growth, or equally of a process whereby good 
prognosis tumours have been self selected by making no demand upon the patient's 
attention. They demonstrate that what they regard on this basis as slow growing 
tumours have a better prognosis in a sample of 685 patients with all stages of disease, 
but this was not subjected to multivariate analysis. A similar study was reported by 
Boyd et al (1981), who also found that this type of information correlated with 
prognosis in a series of 756 patients with early breast cancer, slow growing tumours 
having a better outcome. In this report, auxiometric classification was a less powerful 
predictor than nodal status, tumour size or histological grade. No multivariate analysis 
was reported. It is difficult to assess the relevance of these results to a discussion of 
tumour growth rates.
The information provided in these different ways about the growth of breast tumours 
in summarised in the following table:
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Td (days)
First Author Method Used Cases Mean Range
Gershon-C. (1963) Mammography 18 115 23 - 209
Phillipe (1968) Scar Recurrence 78 40 3-211
Kusama (1972) Direct Measurement 212 1051 6 - 5 4 0
Pearlman (1976) Scar Recurrence 82 261 3 - 1 7 0
Fournier (1980) Mammography 147 212 44 - 1869
Spratt (1981) Mammography 23 324 109 -944
Table 3: Summary of information about actual tumour doubling times from various 
means of observation of in vivo breast tumour growth. 1 = median value
From this review we can summarise that there is relatively scant information as to the 
growth of breast tumours (only 400 primary breast cancers accumulated in the course 
o f over 40 years of study). Estimates of the mean doubling time for primary tumours 
in their (late) clinically detectable phase vary from roughly 100 to 300 days. The only 
two studies o f secondary lesions, based upon scar recurrences, give doubling times 
well below this. The growth of local recurrences thus appears to be faster than that of 
primary lesions. This has to be interpreted with some caution, as it is based on 
measurements made by a different method from primary tumours. It must also be taken 
into account that recurrences are growing in a different environment from primaries. 
Putting these factors aside for a moment, this observation suggests that either tumour 
populations grow more rapidly as they evolve and acquire genetic abnormalities, that 
recurrence represents a process of clonal selection of more rapidly proliferating cells, 
or that proliferation is favoured by lower tumour size (ie is Gompertzian) given that 
secondaries are being studied at the beginning rather than the end of their growth 
curve.
Section ii: Use of the Mitotic Index
Mitotic figures are cytologically identifiable on routine histological preparations, and 
pathologists have often sought to classify tumours by the number of mitoses identified, 
as being of low or high mitotic index. There are a number of pitfalls to this approach. 
Firstly, whilst nuclei in metaphase and anaphase are easily recognizable, mitotic 
figures in prophase and telophase are not so easily discerned (Steel, p. 87). The 
proportion of cells in a given population counted as mitotic will thus depend upon the 
quality of the preparation of the specimen and the experience of the observer. This has 
important consequence for the use of this parameter as a measure of cell kinetics, as the 
mitotic index depends upon the rate at which cells enter into mitosis (which is the real 
kinetic measurement being estimated) and the length of time that they spend in it, the
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latter depending upon the period for which they are recognisable as being in mitosis. If 
this varies from one observer to another and from one preparation to another, this 
undermines the use of the mitotic index to estimate the rate of entry of cells into 
mitosis, which is based upon the presumption that the length of mitosis is essentially 
constant.
Secondly, if the process of fixation of the cells is not prompt, then entry into mitosis is 
arrested before exit from mitosis during warm ischaemia (Bullough 1950). This will 
reduce the number of cells in M phase. Such delays in fixation are not uncommon in 
the routine processing of pathological specimens. Thirdly, there is a potential 
geometric artefact in the assessment of mitotic index, because mitotic nuclei are larger 
than those in other phases of the cell cycle. The chance of such a nucleus being 
included in a given tissue section are thus higher than that of its smaller neighbours. If 
the section thickness if of the same order as the average nuclear diameter, this produces 
a significant bias in favour of mitotic nuclei in an uncorrected count. This was pointed 
out by Abercrombie (1946), who provided a correcting formula based upon the section 
thickness and the diameter of the respective types of nuclei, but this has very rarely 
been applied since. The final problem with the mitotic index is that because very few 
cells are observed at any point in time to be in mitosis, a very large number of cells 
need to be counted in order to obtain a statistically reliable estimate of the index. It has 
been shown for the counting of S phase cells that the measured index of cells in that 
phase becomes stable at about 2000 cells counted (Going, unpublished observations). 
This was done by plotting the estimated index after each 100 cells counted, and seeing 
how long it took for the initially large variations to settle down to a stable value for the 
proportion of labelled cells. Since the length of S phase is four times that of M phase, 
one would predict that 8000 cells would be required for a valid estimate of the mitotic 
index. This would represent a wearisome task indeed, especially whilst maintaining a 
rigorous system for assuring the at least semi-random choice of fields to be counted, 
so as to avoid any selection bias (there is an inate tendency to choose fields with a high 
proportion of labelled cells). Notwithstanding all of this, the mitotic index has been 
shown by many authors to be a statistically significant, independent, prognostic factor 
in breast cancer (Stenkvist et al, 1982; Baak et al, 1985; le Doussal et al, 1989; 
Joensuu et al, 1990; Clayton, 1991; Aaltomaa et al, 1992).
Section iii: Staining for Cell Cycle Specific Antigens
Only cells in the mitotic phase of the cell cycle are recognisable as such in routine 
histological sections. The problems due to the different size, and relative rarity of M 
phase cells have just been discussed. Stains which recognise cells in other phases have 
been sought for some time, and this ambition has in the last decade been realised. 
These use immunohistochemistry to identify the presence of proteins whose
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expression is cell cycle dependent. The two commonly used sets of. antibodies are not 
specific for cells in any one phase of the cell cycle, but rather the proteins recognised 
are expressed from Gj through to M phase. They provide an estimate of the growth 
fraction of the tumour, that is the proportion of cells which are actively engaged in the 
cell division cycle, as opposed to those in Gq phase. These two antibody groups are 
directed at antigens which have been named Ki-67 and PCNA.
Ki-67 was raised from mice immunized with nuclear extract from lymphoma cells 
(Gerdes et al, 1983), and found to recognize an epitope expressed from mid/late Gl5 
through S and G2 , to M phase (Gerdes et al, 1984). It proved to be difficult to clone 
the gene for the Ki-67 product in full although this has now been achieved in part 
(Gerdes et al, 1991). A major drawback with the initial antibodies to Ki-67 was that 
they only recognised the epitope in unfixed tissue sections. Newer antibodies have 
overcome this problem, and work in formalin-fixed, paraffin-embedded sections (Key 
et al, 1992).
PCNA has the same ability to recognise its epitope in fixed and embedded sections, 
and so was initially used as a Ki-67 substitute when this was the available material for 
study. The PCNA antigen is better characterised, and has been cloned in full 
(Almendral et al, 1987) and is known to be a 36kDa auxiliary protein to DNA 
polymerase 6 (Bravo et al, 1987). It is in fact the autoantibody produced by patients 
with systemic lupus erythematosis (Miyachi et al, 1978). Although cell cycle regulated, 
it has been shown the PCNA gene can become deregulated in human solid 
malignancies, specifically including breast cancer (Hall et al, 1990). This could result 
in non-cell cycle related expression under these circumstances, such that the antigen 
was no longer a marker of cell proliferation. Certainly it has been noted that there is 
marked variability of data related to the fraction of PCNA positive cells in human 
tumours (Lipponen and Eskelinen, 1992), who suggested that this might be the result 
of variable sensitivity of detection systems used by different groups, or the use of 
different scoring systems; another suggestion has been that different antibodies to 
PCNA give different results (Leonardi et al, 1992). These are arguments which apply 
equally well in comparing data from different groups using Ki-67 as well. In addition, 
whilst the use of these antibodies avoids the two problems with mitotic index referred 
to in the first paragraph of this section- the size bias, and the paucity of M phase cells, 
some of the other problems associated with that method remain. In particular, the 
selection of random fields, and counting of an adequately sized sample of nuclei are 
not always indicated in reports of tumours studied in this way.
A large number of reports show staining indices for both Ki-67 and PCNA to be 
predictive of outcome in breast cancer, and to correlate with pathological prognostic
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factors for the disease (eg in respect of Ki-67 Barnard et al, 1987; Bouzabar et al, 
1989; Wintzner et al, 1991; and Veronese et al, 1993; and for PCNA Dawson et al, 
1990; Shrestha et al, 1992; and Aaltomaa et al, 1993). It must be noted that in the case 
of PCNA not all authors have been able to achieve such results, finding no evidence of 
such correlation (Leonardi et al, 1992; Noguchi et al, 1993), or conflicting results 
(Betta et al, 1993). The majority of authors who have looked at both in the same 
tissues have concluded that the two give well correlated results. Assessing this claim 
more closely, Dervan et al (1992), for example, studied 46 tumours and normal tissues 
and achieved a Pearson correlation coefficient of 0.8. If we take the raw data from 
table 1 of their paper, and divide the tissues as above or below the median value for 
each index, then 6/46 (13%) appear in different groups with respect to the two stains 
(ie they are above median for one and below median for the other). If the distributions 
are divided into quartiles, then 13/46 (28%) are classified differently by the two 
antigens. This is not as good as the simple rank correlation value alone would lead one 
to believe. This bears out the recent statistical belief that the correlation approach is not 
an appropriate one for this type of problem (vide infra, Statistical Methods section in 
chapter 5).
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Section iv: Thvmidine Labelling Index
Identifying S phase overcomes some of these problems, as S phase is relatively 
longer, the nuclear size is the same as other phases (except M phase), and because 
methods have been developed which more clearly identify these cells. The first such 
method to be developed involves the incorporation of tritiated thymidine, which is 
taken up and incorporated into DNA by cells in S phase (although thymidine is a 
normal component of DNA, it is not a normal component of the DNA synthetic 
pathway, but the enzymes for its use are universally distributed). Due to the long half 
life of tritium and the potentially damaging effect of radiation upon DNA, it has not 
often been accepted as ethical that tritiated thymidine be given to patients in order to 
study its in vivo incorporation by tumour cells. Instead, tumour explants are incubated 
in short term tissue culture in the presence of thymidine and hyperbaric pressures of 
oxygen (which maintains the metabolic activity of the outer 500pt of the explant, 
Fabrikant et al, 1969). Uptake is detected by taking tissue sections of the explants after 
incubation and coating these with photographic emulsion (figure 5). These are exposed 
for a period of several weeks, and nuclei which have taken up the thymidine (that is, 
those which were in S phase during the incubation) are recognised by the presence of 
developed silver grains overlying them. The number of such nuclei as a proportion of 
all tumour nuclei is counted. This figure is termed the thymidine labelling index (TLI).
3H-thymidine
T=n=n=r
Autoradiography
\ 7
Figure 5: Summary of the thymidine labelling technique
Whilst this measurement overcomes some of the problems associated with mitotic 
indices, it must be remembered that in contrast to them it is based on the behaviour of 
tumour explants in short term tissue culture. The results for an individual tumour may
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not represent the kinetic behaviour of that tumour when it was in situ. It is also 
important to ensure that counting is performed in a truly random fashion, as otherwise 
there is a tendency for the observer to count on well labelled fields. This is best 
achieved by the use of a grid system, counting randomly chosen grid locations, but 
this is difficult to apply in a situation where not all of the section is suitable for 
counting because some of it will represent anoxic areas. This means that a degree of 
subjectivity is required in determining which regions have been adequately incubated, 
and this can easily introduce counting bias. :
TLI was first applied to breast cancer by Johnson and Bond (1961), and since then 
several groups have published the results of large studies of its prognostic 
significance. Meyer's group in St Louis was one of the first to embrace this technique. 
They have now studied tumours from over 500 women followed for a mean of 4.1 
years (Meyer and Province, 1988). The median value of TLI in their hands was 5.2%. 
They have divided the patients into three groups using the tertiles of the TLI 
distribution (3% and 8%). Actuarial 5 year survival rates (% of patients) in the three 
groups were:
Nodal Status
TU Negative Positive
s 3% 89 79
3-8% 64 71
>8% 66 52
Table 4: Actuarial 5 year survival rates (as % survivors) for 500 breast 
cancers studied by Meyer et al, sub-divided by nodal status and TLI
This result was independent of nodal status, grade, size and oestrogen receptor status 
in multivariate analysis. It is unfortunate that longer term survival data are not available 
from this group, and odd that in node negative patients the survival curves for mid 
level and high TLI nearly overlap, whilst in the the node positive group it is the curves 
for low and mid level groups which do so. This may indicate that the TLI is less 
discriminating than such a division suggests, and that a simple cutoff at the median 
value, as they used in an earlier report (Meyer et al, 1983) is all that is justified.
Tubiana and Koscielny (1988) have reported upon long term follow up (median 15 
years) of their 128 patients. They also divided the patients into three groups by TLI, 
and observed a large and statistically significant survival advantage to patients with 
tumours having a low TLI. Interestingly, they too demonstrated no survival difference 
between tumours of intermediate and high TLI (as in Meyer's node negative patients), 
bearing out the point that TLI appears to be relatively non-discriminating in the sense 
that it supplies only a high-low answer effectively.
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The most active proponents of the introduction of TLI into clinical decision-making 
have been Silvestrini’s group at the Italian National Cancer Institute at Milan. They 
have now analysed the prognostic value of TLI in nearly 900 patients with breast 
cancer (Silvestrini et al, 1989, 1990). The median labelling index in their hands is 
2.8%, and patients are divided into two above and below this value. Overall 5 year 
survival figures (%) for each group are:
Nodal Status 
TLI Negative Positive
s 2.8% 95 85
> 2.8% 81 73
Table 5: Overall 5 year survival rates for 900 breast cancers 
studied by Silvestrini et al, sub-divided by nodal status and TLI
These results are statistically significant, and independent of degree of nodal 
involvement, tumour size, and oestrogen receptor status. However, the survival rate 
for this group of patients is surprisingly good, with nearly three quarters of women 
still alive at five years even in the worst prognostic group (node positive, high TLI). 
This suggests that they may be a selected good prognosis group, and that these results 
are not necessarily applicable to the general run of breast cancer patients.
Thymidine labelling was also carried out on patients within the Liverpool Breast 
Cancer Series, from which series the material studied in part II of this thesis was 
derived. Long term prognostic data were recently published (Cooke, Stanton et al, 
1992). Analysis was carried out in January 1st 1990, when the minimum follow up of 
surviving patients was 93 months. The TLI was measured in 185 tumours by the 
method of Meyer (Meyer and Bauer, 1975). Fresh tumour was divided into five 2mm 
cubes, which were added to tubes containing 5 ml of RPMI and 0.2 ml of 3H- 
thymidine (25 fCi/m l; SA 44 Ci/mmol). Tubes were incubated in a shaking water bath 
for two hours at 37°C, at 3 atm produced by addition 10 mis of a 95% 02/5% C 0 2 
mixture. Tissue was then fixed in formalin and wax embedded. Five micron sections 
were mounted on histological slides and Kodak AR stripping film applied. 
Autoradiographs were exposed at 4°C for 28 days, and counterstained with 
haematoxylin and eosin.
Labelling was assessed in 2000 nuclei per tumour, four separate areas of 100 nuclei on 
each of 5 slides. Nuclei were considered to be positive if there were more than 10 
reduced silver grains over them, although negative nuclei never demonstrated more 
than 3 grains. TLI was related to other variables by the Mann-Whitney U test and the 
Kruskall-Wallace one-way analysis of variance. Univariate survival analysis was 
performed using the life-table method, expressed as the log rank probability. Patients
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alive at the close of the study, or dead of unrelated causes, were treated as censored 
observations. Multivariate survival analyses were performed with the Cox proportional 
hazards model, using both forward and backward selection of variables.
Values of TLI ranged from 0.3% to 19.1% (median 3.2%). The relationship between 
TLI and other data is indicated in the table on the next page. There is a tendency for 
higher values of TLI to be associated with indicators of poor prognosis, but this is 
statistically significant only in respect of tumour grade.
TLI (%)
Variable n :% Mean Median
Tumour Size T1 8 5 3.4 2.4
T2 119 73 4.5 3.2
T3 37 23 4.7 4.2
Nodal Status NO 57 43 4.4 2.6
N1 76 57 5.0 3.4
Hist. Grade I 37 33 3.4 3.0
II 46 4t 4.5 3.1
III 30 26 6.2 5.1
ER Status ER+ 93 58 3.9 2.7
ER- 68 42 5.5 3.3
Menopausal Pre 55 38 4.9 3.8
Post 91 62 4.1 2.1
ErbB-2 Status Neg 129 78 4.0 2.8
Pos 37 22 4.8 3.1
p = 0.529
p = 0.407
D = 0.032
p = 0.123
p = 0.168
p = 0.266
Table 6 : Distribution of prognostic variables, and comparison of TLI between groups within 
each variable. Analysis using Mann-Whitney test (2 subgroups), and Kruskall-Wallis test (3 
subgroups). The result significant at the 5% level is underlined.
Univariate survival analysis based on TLI value's above or below the median shows a 
trend to improved survival in the latter group, but this is not statistically significant 
(figure 6). Analysis dividing the patients into 4 groups based on the quartiles of the 
TLI distribution was also carried out. Although this demonstrates a difference in the 
outcome for the extreme groups, there is no statistically significant trend (table 7). 
Multivariate analysis of survival was carried out in a model containing node status, 
size, erbB-2 staining and TLI. Data were available for 164 patients. Within this group, 
nodal status is far the strongest variable, and tumour size is also independently 
prognostic. TLI does not show a statistically significant influence on survival.
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Figure 6: Life table for patients within Liverpool Breast Cancer Series in whose tumours 
TLI was measured, divided into those with TU above and below the median value of 
3.2%. Log rank probability of difference between survival in the two groups = 0.14.
The observed survival difference at 6 years in our population is 13% in favour of 
tumours with below median TLI. This accords with Silvestrini's figures of 12% for 
node negative and 14% for node positive patients. As noted above, Meyer’s group 
presented their results by dividing TLI into three groups. The survival advantage for 
those in the lowest T U  band over those in the highest is 23% for node negative and 
27% for node positive patients at five years. Our own observed difference at that stage 
between the uppermost and lowest quartiles of T U  is 27%, as shown in the table 
below:
Thymidine Labelling Index (%)
<1.4 1.4 -3.15 3.2-6.25 2:6.3
Survival (%) 73.3 61.7 65.2 46.6
Table 7: 5 yr actuarial survival for 185 patients within the Liverpool Breast Cancer 
Series, subdivided into quartiles of the thymidine labelling index of their tumours.
Although we have not reproduced the statistical significance of these studies, our data 
are very similar. Why then has the TLI not entered into routine clinical practice? 
Primarily, this is for logistical reasons, in that the autoradiographs need to be exposed 
for several weeks; taken with the very arduous task of counting at least 2000 cells for 
each tumour, the process becomes both time consuming and labour intensive. The time
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delay also means that the information obtained this way is available too late to influence 
therapy in the early postoperative period, when decisions about the use of adjuvant 
therapy need to be taken.
The question of reproducibility also becomes a very important one if these 
measurements are to become the basis of clinical decisions. This was addressed within 
the Liverpool series, as it has been by both Meyer and Silvestrini. Meyer's group 
report the labelling indices calculated by three different observers using the same. 
autoradiographs from five tumours (Meyer and McDivitt, 1986). They used the; 
coefficient of variation of each tumour (the standard deviation of the three values as a 
percentage of the mean of the three) as the measure of variability, not a very accurate 
tool because of the relative inadequacy of a standard deviation derived from such a 
small sample. The five CV's derived were 2 ,13 ,19 , 22 and 50%, for a mean value of 
21%. Since about 95% of values lie within 2 standard deviations of the mean in a 
normal distribution there is a 95% chance that a second estimate will be within ±42% 
of the first. Another approach to this problem is to normalise all estimates as a ratio to 
the mean estimate for that tumour. Since the overall mean ratio will be one, the CV 
becomes 100 times the standard deviation of the ratios, a figure based upon all 15 
estimates rather than only 3. Doing this with Meyer's data gives a slightly higher 
overall CV of 23%. It is also apparent from Meyer's data that one of the three 
observers gets values consistently below the mean and another observer gets values 
above the mean in 4 of the five cases. The variability observed may relate 
predominantly to inherently different counting by the three observers.
Silvestrini (1991) provides more substantial data that addresses this distinction 
between interobserver variation and reproducibility by the same observer on two 
occasions. The results of 240 cases counted by two observers are presented ( they are 
a little worryingly referred to as a "representative series"), showing a Spearman 
correlation coefficient of 0.96. A CV of 12% is quoted. The means of calculation of 
this figure is not given, but presumably it has been done in the same way as Meyer, 
based on the two estimates in each case. As indicated already, this is not a very 
accurate means of evaluation, but it does appear that the results for this group are better 
than those of Meyer. It is worth noting that even these apparently good results include 
such pairs of estimates upon the same slides as 3% and 6%, and 1.2% and 2.5%, 
reading off figure 1 of this paper, so that variation of a factor of 2 is present within the 
data. 50 tumours were evaluated at two institutions in this study, with a correlation 
coefficient of 0.93. The CV for this data is not given.
Within the Liverpool series, 18 autoradiograms were counted by one observer on two 
occasions, and by a second observer. The raw data is shown in the following table:
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Case SH1 SH2 RC Case SH1 . SH2 RC
1 8.20 7.00 3.50 10 8.70 3.42 4.10
2 3.50 6.30 4.50 11 11.90 7.19 8.25
3 20.70 16.70 13.40 12 0.60 1.40 1.20
4 6.80 7.05 8.30 13 4.80 7.60 5.05
5 2.80 3.00 3.70 14 3.50 4.50 3.70
6 3.70 1.90 4.17 15 8.70 9.50 8.20
7 2.40 4.85 2.95 16 3.80 6.75 6.40
8 5.60 5.60 4.70 17 5.80 9.30 6.95
9 6.90 7.75 6.90 18 7.96 9.95 8.04
Table 8: Estimates of thymidine labelling index (%) made upon the same 18 sections by 
one observer on two separate occasions (SH1 and SH2), and by a second observer (RC).
The correlation coefficient for the intra-observer variation is 0.87, and for the estimates 
of the two observers is 0.85. The ratio of each estimate to the mean of the three 
estimates for that tumour was calculated in order to compute the CV in the the same 
way as was done with Meyer's data, coincidentally giving the same value of 23%. One 
observer obtained values higher than the mean by an average of 8%, so that there was 
a systematic difference in interpretation between the observers, again as noted in 
Meyer's data. The degree of variation can be appreciated from a plot of the ratios of 
each estimate to the mean, against that mean value:
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Figure 7: Variability in the estimation of TLI. 18 slides were counted by two observers, 
one doing so twice, to give 3 estimates for each slide. The ratio between each of 
these 54 values and the mean value for that slide is plotted against that mean. The 
ratios vary from the ideal of 1.0 by up to a factor of 2.
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To summarise the results of studies of reproducibility of TLI, the use of a correlative 
approach suggests that the counting process is highly reproducible between different 
observers and different timepoints. Closer analysis reveals that the 95% ’confidence 
interval' for estimates of TLI is of the order of ±25% at best (Silvestrini) or 40% in 
other hands (Meyer, current study). This is small in comparison to the overall range of 
values of TLI which is from less than 1% to 20%. It is a level of uncertainty which is 
more important if measurements of TLI are to be used to divide patients into prognostic 
groups upon which treatment is to be based. It is salutary that the median value of TLI 
found by different groups varies from 2.8% (Silvestrini) to 5.2% (Meyer), suggesting 
that substantial interlaboratory variation in methodology exists. This would impose a 
burden of standardisation upon any laboratory that wished to provide this service.
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Section v: Flow Cytometric S Phase Fraction
Release from the time-consuming and labour intensive nature of calculating thymidine 
labelling index came with the application of flow cytometry to the study of cell 
kinetics. This technology provides a means for very rapidly studying a large number of 
cells. In essence, a flow cytometer is a machine which runs a series of small particles 
through a highly focussed laser beam, and records the amount of light of different 
wavelengths scattered or given off by each particle during its passage through the 
beam. Usually, the particles are treated in some way to make them fluorescent, and it is 
this fluorescence which is measured. The application of flow cytometry to cell kinetics 
arises from the ability to measure the DNA content of particles in this way. To do this, 
a suspension of cells or nuclei is created, and stained with a fluorescent dye specific 
for DNA which binds stoichiometrically- that is, binding is in linear proportion to the 
amount of DNA present. The amount of fluorescence given off during passage through 
the laser beam will be in linear proportion to the amount of DNA in the nucleus. If the 
suspension is run through the flow cytometer, the amount of DNA in each nucleus can 
be counted as the amount of emitted light of the particular wavelength at which the dye 
emits given off as that nucleus runs through the exciting beam. In this way, a 
frequency histogram is created which reflects the distribution of DNA contents within 
the nuclei constituting the suspension. A flow cytometer is capable of counting 10,000 
particles per minute accurately, and so a statistically valid sample is very rapidly 
achieved.
The frequency histogram built up in this way is referred to as a ploidy histogram. Its 
characteristic shape can be related to the distribution of cells through the cell cycle. 
Consider a small cell population where at a certain point in time 50 of the total of 100 
cells are in the G0 phase having differentiated after their previous cell division, 30 cells 
are in phase having committed themselves to a further cell division, 10 cells are in 
S phase synthesising DNA for their ensuing mitosis, 5 are in G2 phase after 
completing that process, and 5 are actually undergoing mitosis. Although they are 
doing different things in cell kinetic terms, the G0 and Gj cells have the same DNA 
content, that which is normal for non-dividing cells of whatever species and tissue they 
belong to (what the geneticist refers to as diploid DNA content). Those cells which 
have completed the process of DNA synthesis and have not finished the subsequent 
division (ie those in G2 and M phases) will have exactly twice this amount. The S 
phase cells will have DNA contents intermediate between these two, the amount in 
each cell depending upon how far it has progressed with synthesis at the moment of 
observation. The frequency histogram for the distribution of DNA content then looks 
like this:
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Figure 8: Theoretical frequency histogram of DNA contents in a population 
of normal cells undergoing cell division.
When this population of cells is run on a flow cytometer, small variations in the 
recorded fluorescence of cells having the same DNA content, by virtue of variation in 
binding of the dye and within the machine itself, will result in a frequency histogram 
with peaks which are not single lines. An actual ploidy histogram for such a population 
will look like the one in figure 9 (which has for clarity been drawn. This is not an 
actual flow cytometer generated histogram. Where used for illustrative purposes, such 
synthetic histograms have been used throughout, as indicated in captions. A  screen 
photograph of such a histogram is shown in fig. 10a). If a population of tumour cells 
is run through the flow cytometer after DNA staining, a histogram like this may indeed 
be obtained. In about two thirds o f cases, a histogram like that in figure 11 will be seen 
instead (also simulated ease of understanding, with photographic example in fig. 10b).
In this histogram there are two overlapping cell populations having a different Gq/G i 
DNA contents. In order to interpret this, it is necessary to realise that the population of 
cells within a tumour comprises not only the tumour cells themselves, but also a large 
number of other elements such as lymphocytes, macrophages, fibroblasts and 
endothelial cells. These non-tumour cells are non-transformed, and so will have a 
DNA content that is normal for their species and tissue type. The fact that there are two 
different populations in the above histogram indicates that some at least of the tumours 
cells do not have this same DNA content. A tumour of this type, where the cells have a 
different DNA content from normal, is referred to as DNA aneuploid. Tumours giving 
a ploidy histogram like figure 9, where only one population is seen such that tumour 
and non-tumour cells must have the same DNA content, are referred to as DNA 
diploid. This division into DNA diploid and aneuploid is the so-called tumour ploidy,
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Figure 9: Simulated flow cytometric frequency histogram of DNA 
contents of a cell population undergoing cell division.
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Figure 11: Aneuploid DNA content frequency histogram, as seen in 
some tumours. For explanation see text. Simulated histogram.
Figure 10: Screen photographs of diploid (upper) and aneuploid histograms
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and it is for this reason that the particular form of frequency histogram produced by a 
flow cytometer under these conditions is designated a ploidy histogram. The terms 
DNA diploid and DNA aneuploid are used to avoid confusion with the genetic meaning 
of diploid as the normal Gq/G^ DNA content of a cell type. In this thesis, since this 
genetic usage will not appear any further, and for the sake of brevity, the terms diploid 
and aneuploid will subsequently be used instead of DNA diploid and DNA aneuploid 
respectively.
Tumour ploidy is only one piece of information which can be gained from the ploidy 
histogram. The relative DNA content of the tumour cells with respect to normal cells 
can be more exactly expressed in terms of the DNA index. This is the ratio between the 
DNA content of the tumour Gq/G^ cells and the normal Gq/Gj cells. Thus the DNA 
index of a diploid tumour is 1.0. Most aneuploid tumours have a DNA content greater 
than normal (hyperdiploid), and so a DNA index of greater than 1, extending up to 
about 3 in highly aberrant cases. It is important in the context of this thesis to realise 
that neither the tumour ploidy nor the DNA index are cell kinetic measurements per se- 
they are items of information about the tumour biology gained incidentally in the 
course of obtaining an estimate of the S phase fraction of the tumour. Because ploidy 
and SPF are parameters derived from the same source they are almost universally 
considered together, and this convention is continued in the following experiments.
The spatial separation of cells in different phases of the cell cycle in the ploidy 
histogram allows an attempt to be made to estimate the proportion of cells within each 
of these phases. By this means alone, neither G0 and Gj cells, nor G2  and M cells can 
be distinguished from each other, since they have the same DNA content. The S phase 
cells stand isolated between the two combined peaks, and this has been extensively 
studied, usually using offline analysis software in order to fit a compartment 
simulating S phase to the histogram as in figure 12 (with real example in figure 13).
The size of this compartment is then measured, and this is taken as the flow cytometric 
S phase fraction, abbreviated henceforth as SPF. Whilst this looks straightforward in 
the example above, it will immediately be apparent that this process is not so in the 
majority of aneuploid histograms, where the S phases of the diploid and aneuploid cell 
populations overlap, and the G0/G1 and G2/M peaks intrude upon the S phases. 
Whilst the software used does allow for these problems, it must always be borne in 
mind that the process can only ever be one of approximation, however sophisticated.
A further advance was made with the publication of a protocol for the use of paraffin 
embedded tissue as the starting material for creating ploidy histograms by flow 
cytometry (Hedley et al, 1983). They recognised that the quality of the histograms
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obtained was not as high as that from fresh tissue, and that the stoichiometry of dye 
binding was dependent upon the method of fixation and embedding used, so that 
external standards could not be added as a guide to the diploid DNA peak, but the 
advantage gained by opening up the possibility of using archival material for analysis 
was considerable. This was especially so in the case of breast cancer given the very 
long lead time before the outcome of a group of patients is known. Since the advent of 
this protocol, many investigators have studied the utility of ploidy, DNA index and 
SPF in human breast cancer. The following review is not intended to be 
comprehensive, but concentrates upon larger and better conducted studies, and upon 
some methodological problems which limit their interpretation. Reviews of the area 
have been published by Friedlander, Hedley and Taylor (1984), McGuire and Dressier 
(1985), Hedley (1989), Merkel and McGuire (1990), and Frierson (1991).
Figure 12: Example of S phase compartment (dotted box) fitted by computer 
analysis to a simulated diploid histogram, as a means of estimating the 
proportion of cells in S phase. Real example in figure 13.
Ploidy analysis was possible before the advent of flow cytometry using the method of 
microscopic densitometry (static cytometry). Nuclear smears, or tissue sections stained 
by the Feulgen technique, by virtue of which the optical density of the nuclei become 
proportional to their DNA content, are scanned nucleus by nucleus in order to build up 
a frequency histogram analagous to the ploidy histogram. This can be further analysed 
to obtain an estimate of SPF, although only a minority of reports appear to have done 
this, the validity of such measurements based upon the very small sample sizes 
obtained by static cytometry being questionable. The technique was first applied to 
breast carcinomata almost 40 years ago (Atkin and Richards, 1956), and prognostic 
data were presented 20 years ago, showing better survival in diploid and near-diploid 
than other aneuploid tumours in a sample of 67 cases (Atkin, 1972). This is a very 
small study by the standards of flow cytometric ones, which reflects the comparatively
I £
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time-consuming nature of this method. Auer et al (1984) reported results based upon a 
similar analysis of 78 cases. They compared 36 tumours associated with >15 yrs 
survival and 42 tumours where the patient died in less than 2 yrs, and found aneuploid 
tumours to be more common in the latter group, and in those in the long term survival 
group who had suffered local recurrence or metastasis. By 1989, this group were able 
to present updated results based upon ploidy profiles from 464 tumours, confirming 
the prognostic power of ploidy, for node negative cases only. In contrast, Hatschek et 
al (1989) in studying 117 tumours found that ploidy did not predict prognosis, and 
although SPF did so, this was no longer the case when other clinico-pathological 
variables were allowed for by multivariate analysis.
The large number of flow cytometric studies have used different patient groups and 
end points, making direct comparison difficult. Of this plethora of papers, only seven 
reports which are based upon studies of more than 300 patients, followed for a median 
of at least 5 years, and analysed using multivariate techniques have appeared. These 
are worthy of individual consideration. Comelisse et al (1987) studied 565 patients 
with all stages of disease, for up to 10 years, and found DNA aneuploidy to be an 
independent adverse prognostic factor. In a series of 472 tumours with a minimum of 
6 years o f follow-up studied by St£l et al (1989), conversely, ploidy was not an 
independent prognostic variable. Tumours with a low SPF showed improved survival 
independent of tumour size, nodal status and ER content, although this was not broken 
down by ploidy status. They noted that the relationship between disease recurrence and 
SPF was not significant over the entire follow-up period while controlling for other 
variables, suggesting that the prognostic value of SPF was reduced by the multivariate 
analysis.
Toikkanen et al (1989) reported upon the very long term follow-up of 351 patients in 
whom both ploidy and SPF were measured. Although ploidy predicted strongly for 
survival at 25 years, this result was not borne out in multivariate analysis. SPF did 
show independent prognostic significance with low SPF predicting for survival, but 
SPF was entered as above or below a figure of 7%, chosen on the basis that this 
provided the greatest distinction between low and high figures. That this figure was 
selected from the data and then applied back to it, and not validated upon a separate 
data set weakens the findings in this study. The same criticism can be levelled at Clark 
et al (1989), who found ploidy alone to be of independent prognostic significance in a 
group of 345 patients with node-negative breast cancer, DNA diploid tumours 
showing an 11% survival advantage at 7 years in univariate analysis which remained 
significant upon multivariate analysis. They found SPF to be of no additional value in 
DNA aneuploid patients, but that it was a univariate predictor of survival in DNA 
diploid patients at cutoffs between high and low SPF of 5.0 - 9.0%, with a survival
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advantage to those falling below the cutoff. This effect remained in multivariate 
analysis using the figure of 6.7%, again not validated upon data from which it was not 
derived, and furthermore a figure which put 87% of cases into the low SPF group.
Hedley et al (1987), the originators of the technique for utilising paraffin-embedded 
material for flow cytometry, performed flow cytometry upon 490 node-positive 
tumours, with 6 or more years of follow-up. In their series, patients with DNA diploid 
tumours showed improved survival in univariate analysis, but this effect was no longer 
evident in multivariate analysis. Tumours with a low SPF showed a survival 
advantage, using a cutoff very near the median, but this was not evident in multivariate 
analysis, predominantly due to a strong association with tumour grade.
Kallioniemi et al (1988) followed 308 patients for 8 years, and found a large univariate 
survival disadvantage for aneuploid tumours (relative risk 3.0), which was not, 
however, borne out in multivariate analysis. Ploidy and SPF could be combined to 
create three prognostic groups which were independent predictors of survival, 
although once again this relied upon cutoffs determined by examination of the data. 
Finally, Fisher et al (1991) have reported upon results from the NSABP-04 trial in 398 
patients. This represented only 54% of available tumour blocks, the remainder failing 
to provide adequate histograms. In this series, ploidy did not predict 10 year survival 
in univariate analysis. SPF was divided at the median appropriate to that tumour's 
ploidy, with low SPF tumours having a survival advantage at 10 years of 14%. This 
result was remained significant in multivariate analysis, although they noted that low 
SPF tumours still had only a 53% survival at this length of follow-up.
A large study by Beerman et al (1990) reported upon the outcome in 690 patients with 
stages I-m disease, but looked only at tumour ploidy. They found that this parameter 
did predict survival in both univariate and multivariate analysis, with a median follow- 
up of 7 years. Conversely, another large series reported by Hatschek et al (1990) 
found that ploidy did not significantly predict for outcome in multivariate analysis, 
although follow-up was only 4 years in this study. Within this group, SPF was found 
to be independently prognostic. In a separate paper based upon the same series of 
patients (Hatschek et al, 1989), these workers assessed the ability of ploidy and SPF 
to predict survival after first recurrence. Ploidy did not do so, even in univariate 
analysis, but SPF again held independent significance, with a survival advantage to 
tumours with low SPF. Blanco et al (1990) looked at this same end-point in 226 
patients, and also found that ploidy did not predict for outcome. This group did not 
report upon the value of SPF.
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There are many other smaller series, often with shorter periods of follow-up, included 
in the reviews referenced above, but little if anything is to be gained by further 
consideration of these papers here. The consensus from the larger and better conducted 
studies (table 9) could reasonably be stated as: diploid tumours are often found to have 
a survival advantage over aneuploid tumours in univariate analysis, but only a minority 
of studies find this effect to be independent of existing prognostic factors; whilst most 
studies find that tumours with low SPF carry a true survival advantage over those with 
high SPF.
Author year n FU (yrs) Ploidy SPF
Cornelisse (1987) 565 3-12 yes ND
stai (1989) 472 >6 no yes
Toikkanen (1989) 351 27 no yes
Clark (1989) 345 5 yes yes1
Hedley (1989) 490 >6 no no
Kallioniemi (1988) 308 8 no yes
Fisher (1991) 398 10 no yes
Beerman (1990) 690 7 yes ND
Hatschek (1990) 430 4 no yes
Blanco (1990) 226 >4 no ND
Table 9: Summary of results from larger studies of the prognostic significance of tumour 
ploidy and S phase fraction in breast cancer, n = number of patients studied; FU = years of 
follow up (x-y: range; >x: minimum; x: median); last two columns give significance in 
multivariate analysis. ND = not done. 1 = effect restricted to diploid tumours
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Chapter 4: 
Review of Dynamic Methods Applied to Breast Cancer
The methods so far discussed give information about the distribution of cells through 
the cell cycle, but provide no indication as to the rate at which cells are progressing 
through the cycle. The technique of in vivo labelling with bromodeoxyuridine has 
made this information available for the first time. Bromodeoxyuridine (more fully 5- 
bromo-2'-deoxyuridine; henceforth abbreviated BUDR) is a thymidine analogue, 
which is stably incorporated into DNA, inter-changeably with thymidine. It has been 
used sporadically as a radiosensitizing agent for the treatment of cerebral tumours. The 
potential for using BUDR for the study of cell kinetics arose with the development of a 
monoclonal antibody which recognises it within DNA. This was achieved by Gratzner 
(1982), and created a mechanism by which cells which took up the BUDR could be 
identified, as is possible with tritiated thymidine, but without the necessity for the use 
of a radio-isotope. Because BUDR itself is non-toxic to the cells which take it up in 
low doses, it can be given to patients (doses used for cell kinetic studies are an order 
of magnitude lower than those used therapeutically without side-effects). This allows 
the labelled cells to progress through the cell cycle, and it is the study of that process 
which gives the 'dynamic' information as to the rate o f cell cycle transit. The theory 
and practice of the determination of cell cycle kinetics in this way were developed by 
Adrian Begg and his colleagues at the Mt Vernon Laboratories in London (Begg et al, 
1985).
Section i: Theoretical Basis of the use of Bromodeoxyuridine
Looking at this first in descriptive terms, if BUDR is given intravenously to a patient 
with a tumour, it should be taken up by all cells synthesising DNA at that point in time 
(its half life is so short, of the order of a few minutes, that it is effectively a point 
label). It follows from this that if a tumour biopsy were taken at that time, and stained 
so as to demonstrate not only the DNA content of each nucleus (with propidium 
iodide, just as if creating a ploidy histogram), but also the BUDR content (using an 
appropriately labelled anti-BUDR), then the BUDR labelled nuclei should occupy S 
phase. If instead the biopsy is delayed for some hours, the labelled cohort of cells will 
continue through the cell cycle, toward and into G2  and subsequently M phase, thereby 
dividing into two labelled Gq/G^ cells. Multi-parameter flow cytometry allows us to 
perform such double labelling, and identify the position of the labelled cells within the 
ploidy histogram (figure 14). We assume the position of the labelled cells in the 
histogram at the time that they took up the BUDR (distributed throughout S phase 
alone, as in fig. 14a), and can measure their position at the time of biopsy, the
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Figure 14: Principle of the Determ ination of Ts from a single sample. 
On the left of each figure, a model of the cell cycle showing as white 
balls cells which have taken up BUDR given at time zero (a), and are 
progressing through a single cycle (b,c,d). On the right, the position 
these balls is shown as a box above a ploidy histogram of the cell 
population. The mean position on the x axis of the G0/G1 peak, the 
G2/M peak, and the balls is shown in a) only as FG 1, FG2 and FL, 
respective ly.
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'distance' which they have moved can be worked out> Since the time since labelling is 
also known, it is possible by dividing distance by time to obtain an estimate of the 
velocity of this movement, in this case the length of S phase, Ts. The proportion of 
cells within the histogram which are labelled can also be calculated, which provides a 
labelling index analogous to the thymidine labelling index. The two measurements can 
be combined in an equation derived by Steel (1977, p.69):
Tpot = ^  • (Ts /  L*) (equation 9)
where lambda is a factor dependent upon the relative lengths of the phases of the cell 
cycle, discussed further below.
In mathematical terms, the rate of cell cycle transit in the form of the length of S phase 
(Ts) is derived by defining a measure of the average position of the labelled cells 
within the histogram. This was termed the relative movement by Begg et al (1985). 
Consider the ploidy histogram where the labelled cells are indicated above the ploidy 
histogram, and enclosed in the box (figure 14). The average channel number for these 
cells (that is, their average position on the x axis) is shown as FL. The relative 
movement is calculated from this value, and the average channel numbers for the 
Gq/G! and G2 /M  peaks, which we will call *G1 and FG2 respectively, as:
RM = ~ ^ gi (equation 10)
f G2 " Fgi
The numerator here represents the average distance between the labelled cells and the 
Gq/G i  peak, the denominator the distance between the means of the Gq/Gj and G2/M 
peaks (theoretically, FG2 = 2FG1, and so the denominator can be approximated by 
FG1. To use the equation in the original form is more accurate). If we ignore the cells 
which have divided, we can consider the labelled cohort to be moving as a group 
toward the G2/M  peak. Initially, given the assumption that they are evenly distributed 
through S phase, their average position will be exactly half way between the two 
peaks. Fl will therefore be half way from Gq/G^ to G2/M, and so RM will be 0.5 at 
the time of labelling under this model. This is the situation shown in figure 14a. Still 
ignoring the divided cells, at the time when the last labelled cell from S phase 
(presumptively the one which had only just entered S phase at the time of labelling) 
reaches the G2 phase, all labelled and undivided cells will be in the G2/M peak, and so 
FL will equal FG2, and RM will be 1. Note that this time corresponds to the length of S 
phase (Ts), as this last cell has traversed that phase from start to finish during the 
period of observation. As the length of time from labelling to biopsy increases from 
zero toT s, the RM thus progresses from 0.5 to 1.0. It is possible to calculate Ts from 
time and RM in this way:
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Ts = 0.5 x t (equation 11)
RM - 0.5
where t is the time between labelling and biopsy. The numerator now indicates the 
distance which the RM has to move from its initial to its final positions (between t=0 
and t=Ts), and the denominator the distance which it has actually moved.
A number of assumptions were made in deriving the above equations. It was explicitly 
stated that the labelled cells were evenly distributed through S phase at the time of 
labelling. It was on this basis that the 'starting' position of the labelled cohort was 
taken to have an RM of 0.5. In the terms of S phase analysis as discussed in the 
previous chapter, this amounts to an assumption that S phase is rectangular. It was 
noted then that although this is the simplest and most reproducible model of S phase 
for the purposes of offline analysis, a number of other models have been proposed on 
theoretical grounds. These do not assume even distribution of cells through S phase, 
the deviations being due to the process of cell loss in and subsequent to this part of the 
cell cycle (Steel, 1977, p.79). It seems likely that such loss does occur, and that as 
such the rectangular model is an oversimplification.
It is also assumed that all cells in S phase take up the bromodeoxyuridine, but it has 
been observed for both thymidine and bromodeoxyuridine that some cells in S phase 
do not incorporate these pyrimidine bases (Allison et al, 1985; Wilson et al, 1985). 
This could be the result of arrest of cells in S phase, such that they have a DNA content 
greater than the Gq/G^ content of the population but are not synthesising DNA (de 
Fazio et al, 1987) , but it also seems to be the case that some cells simply do not 
incorporate these bases despite carrying out DNA synthesis. The reason for this is not 
known. The failure of this assumption has two consequences for the process of 
calculating Tpot. The first is that it leads to underestimation of the labelling index, and 
so to overestimation of the value of Tpot, in an unpredictable way since it cannot be 
assumed that the proportion of unlabelled S phase cells is constant from one sample to 
the next. Secondly, it creates a biased sample of cells used in the determination of Ts, 
as it cannot be assumed that all of the unlabelled cells are non-contributory to tumour 
growth, nor that they are cycling at the same rate as the labelled cells which are 
amenable to analysis. As in the case of the assumption about the shape of S phase, it is 
impossible to theoretically account for this deviation within the calculation of Tpot.
The mathematics of the calculation of RM also assumes that G2/M is negligibly short. 
Consider a simplified sample in which there are 100 labelled S phase cells initially 
evenly distributed through S phase and moving toward M phase at the same rate as 
each other, but then failing to go through mitosis (that is, G2/M is infinitely long). The 
initial rate of movement of each cell is the same, and so the average velocity of
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movement is that of each cell, which we may refer to in flow cytometric terms as x 
histogram channels/unit time. Once 50 of the cells (those which constituted the second 
half of S phase initially) have reached arrest in M phase, then only 50 cells are still 
moving (with velocity x), whilst the arrested cells have velocity zero. The average 
velocity is thus only x/2. That is, the rate of change of FL (and so of RM) has halved, 
because fewer of the observed cohort of undivided labelled cells are contributing to it. 
The model thus assumes that each labelled cell divides as soon as it reaches the end of 
S phase, as at this stage it ceases to contribute to increase of FL, that is that G2 and M 
phases are vanishingly short. The longer that these two phases are, the greater will be 
the extent to which the rate of change of RM slows with time. Fortunately, G2 and M 
are indeed relatively short in the cell cycle of human tumours, but not negligibly so, 
and so the plot of RM against time is not linear as assumed, but is convex superiorly 
(figure 4 in the Begg paper). The linear relationship assumed in equation 11 is thus 
only an approximation to this curve. Begg et al did consider this problem in their 
original description, and suggested that the linear equation Ts = [0.6/(RM - 0.4)] x t 
may better fit real data, given the length of G2 and M phases in human tumours. In 
fact, observations upon cultured cell lines using the bromodeoxyuridine method to 
determine cell kinetics indicate that the uncorfected model provides adequate data. 
These unpublished experiments were performed in Liverpool by Prof Cooke's group 
prior to my own involvement with this work. Cell cultures in exponential growth were 
briefly exposed to bromodeoxyuridine and harvested at time points thereafter. Manual 
cell counts and calculation of Tpot by the Begg method were performed. In the 
situation of exponential growth, cell loss is theoretically zero, and so the actual and 
potential doubling times should be the same. Comparing the last two columns in the 
table below, it can be seen that this is in fact very nearly the case, showing that in this 
situation at least, the technique of Begg et al provides an adequate approximation to 
real values. That the Td in this experiment is consistently longer than the Tpot might 
arise from the fact that even in these ideal conditions the cell loss fraction is not in fact 
zero.
Cell line Ts(hrs) U(%) Tpot(hrs) Td(hrs)
HT29/5 12.5 44 22 24.3
HMY 9 36 20 21.9
HSN 5 37.8 11 12.6
Table 10: Observed doubling times for cell lines (T<j) compared to potential 
doubling times (Tp0t) calculated by BUDR labelling.
The calculation of Tpot from the values of LI and Ts introduces the variable lambda, a 
concept described initially by Steel (equation 9). It is needed because the calculation of
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Tpot is based upon observations made solely upon cells in the S phase of the cell cycle. 
If the distribution of cells through the cycle were even, that is, that there were equal 
numbers of cells at any given point in the cycle, observations upon any point or area of 
the cycle could be generalised to the whole. However, because each cell divides into 
two at one point, there will always be more cells in the early part of the cycle beyond 
this point, whether or not the extra cells are being lost as in a stable population size, or 
are continuing through the cycle to expand the population. Whereabouts in the cycle 
we make our observations will now make a difference to the data which we obtain 
about the number of cells in the population. Lambda is the means by which correction 
is made for the position of S phase within the cycle with respect to the division point 
(the end of M phase), and depends upon the relative lengths of the various phases of 
the cycle:
X =
pot In2 In2
exp T + TS ] 
1 pot d
- exp
T G2M 1 pot
The theoretical limits to the value of lambda are loge2 and 21oge2. Since the 
observations made upon each tumour indicate only the length of S phase, the value of 
lambda cannot be calculated individually. Fortunately, in human tumours the lengths of 
G2 and M phases are relatively short compared to those of G1 (especially) and S 
phases, and so the value of lambda lies well toward its lower asymptote (loge2, or 
0.693). The value which was assumed by Begg et al in describing the 
bromodeoxyuridine based determination of Tpot, and which we have used, is 0.8. It 
must be recognised that this is only an approximation, and is not actually a constant as 
assumed.
The desire to avoid this assumption as to the value of lambda led White et al (1990) to 
use further information as to the length of G2 and M phases contained within the two 
dimensional histogram in order to calculate Tpot without reference to any external 
constant. Whereas Begg et al exclude from consideration any cells which have divided 
since labelling, ie labelled cells in the G0/G1 peak, White et al use both the fraction of 
labelled undivided cells, f*u and the fraction of labelled divided cells, fld, to define the 
function v:
1 + f lu(t)
v = In
_ 1 - f ld (t)/2 J
They then show that for Tq2m t < Ts + Tq2/m (where t is the interval between
bromodeoxyuridine labelling and biopsy),
'pot
Tq= In (2) -2 . 
v
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The labelling times used do indeed fall within these constraints (roughly 2 to 12 
hours). Note that whilst this method avoids the assumption as to the value of lambda, 
Ts is calculated in the same way, with all of the assumptions which that involves. 
Given the values of LI, Ts and using the value of Tp0t arrived at by this method, it is 
possible to calculate the implied value of lambda, by simply rearranging equation 9:
X = L I . Tp0t 
T
If this is done using the data from patients in the current study, then lambda is 
consistently estimated at 0.7. This supports the assumption that it is a constant, albeit 
with a different value to that assumed. In this situation there would seem to be little to 
tell between the methods of Begg and of White. In this study, values of Tpot have been 
calculated by both methods, but analyses are based on those obtained using the original 
description by Begg.
Section ii: Application of the Bromodeoxyuridine Method
TheM t Vernon group applied their method in a number of different tumour types. 
Their initial report (Wilson et al, 1988 and then with several additional patients 
Riccardi et al, 1989) dealt with results obtained from 112 tumours. 50 of these were 
acute non-lymphoblastic leukaemias, and these were compared with 10 specimens of 
normal bone marrow from patients with non-haematological malignancies. The normal 
marrow specimens all showed higher labelling indices than any of the tumours, the 
values of Ts being similar in the two groups. Subgroup analysis o f the leukaemic 
patients showed that response to therapy was associated with lower labelling index. 
These data suggest that the marrow of patients with leukaemia is proliferating more 
slowly than normal, and that the more slowly the marrow proliferates, the more likely 
it is to respond to chemotherapy. This is contrary to the a priori assumption that 
response to cell cycle related treatment modalities is a characteristic of faster growing, 
'more aggressive' tumours.
In the same series, 42 gastric cancers were analysed, and compared with histologically 
normal gastric mucosa from 7 of the cases. Here, the tumours showed substantially 
higher labelling than normal (median tumour LI 10.7% cf normal 5.9%), but with a 
significantly longer median Ts (tumour 14.4hrs, normal 10.9hrs), such that median 
Tpot in the two groups was not significantly different. Advanced stage tumours had a 
higher LI than earlier tumours. The other 20 tumours reported upon by Riccardi et al 
were a variety of types of brain malignancies. It was noted solely that no differences in 
clinical behaviour were associated with kinetic data for these tumours. In their study of 
100 colon tumours (Rew et al, 1991), the median labelling index was relatively similar 
to that for gastric malignancies, at 9.0%. There was no comparison with normal tissue
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presented in this report. Kinetic parameters were found not to be correlated with 
Dukes' classification or histological tumour grade.
From 75 breast tumours (Rew et al, 1992), they could obtain no data from 6, and 
labelling index alone in a further 18. The median value for labelling index was 4.2%, 
rather lower than that for colon cancers in the previous report. Median Ts, 8.7hr, was 
shorter, but despite this the median potential doubling time was twice as long (8.2 
days). There were no statistically significant differences in kinetic parameters when 
tumours were stratified by nodal status, tumour size, histological grade, or menopausal 
status. It is worth comparing the results of in vivo labelling with bromodeoxyuridine 
in different tumours as carried out by the Mt Vernon group, on the basis that the same 
methodology can reasonably be assumed to have been used regardless of tumour type. 
The table below combines data from the four studies just discussed:
Tumour Type n LI (%) Ts (hrs) Tpot (d^s)
Leukaemia 50 6.1 12.7 8.8
Gastric 21 10.7 14.4 8.4
Colorectal 100 9.0 13.1 3.9
Breast 69 4.2 8.7 8.2
Brain 20 6.4 14.8 12.1
Table 11: Summary of results reported by Mt Vernon group, using in vivo 
bromodeoxyuridine labelling in a variety of human tumours (all values are medians).
Four other groups have used bromodeoxyuridine labelling for the study of breast 
cancers, but have used it to obtain static data only. Meyer et al (1993) labelled 450 
tumour biopsies in vitro, using a technique exactly analogous to their method for 
thymidine labelling, but simply substituting bromodeoxyuridine for the thymidine in 
the incubation mixture. Immunohistochemistry was then carried out with a primary 
antibody to bromodeoxyuridine, and the proportion of positive nuclei in a sample of 
2000 was counted. The median value of the bromodeoxyuridine labelling index was 
3.9%. This parameter was positively correlated with tumour size, nodal involvement 
and aneuploidy, and negatively correlated- with patient age and oestrogen receptor 
status. The same type of experiment was performed by Lloveras et al (1991) on 148 
breast cancers. The median labelling index for BUDR in their hands was 3.0%, and 
they found the same positive correlation with tumour size, and inverse relationship 
with oestrogen receptor status, but failed to find any relationship between labelling 
index and patient age, nodal status or histological grade. They also examined 21 
benign breast lesions, among which were 13 fibroadenomata, which had a mean 
labelling index of only 0.65% with none higher than 1.5% (for comparison the 
corresponding mean value of labelling index for the tumours was 4.6%).
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Sasaki etal also used in vitro labelling, in a group of 18 cancers, finding a markedly 
higher median index of 10.9%, based on counts of only 1000 cells (though this is less 
of a problem with such a high labelling index). In such a small series, it is possible that 
these are non-representative patients. Little information is provided that enables us to 
check this, but it may be relevant that 81% of the tumours which they studied were 
aneuploid, which is certainly higher than usual. Goodson et al (1993) labelled 109 
women with bromodeoxyuridine, and subsequently performed immunohistochemistry 
on tumour biopsies in order to calculate a labelling index in the same way as Meyer's 
group. The median labelling index was 10.3%. Since it is impossible to correct for 
division of cells which have taken up the bromodeoxyuridine into two labelled cells in 
this type of experiment, it would be appropriate to administer the bromodeoxyuridine 
immediately prior to surgery. Whether this was the case or not is not stated in this 
article. These labelling indices may for this reason have an inherent tendency to over­
estimate the proportion of S phase cells. The mean labelling index for these tumours, 
11.1%, was very close to the median figure. This is very different to the findings of 
the other workers, where the mean value is markedly higher than the median, which is 
much more what one expects for biological parameters, which so often have a long 
upward tail in their distribution. The data from Goodson et al need to be treated with 
some circumspection. This is a pity, as they made an interesting comparison between 
the labelling index in primary tumour and involved lymph nodes, a unique study in 
terms of bromodeoxyuridine labelling. They found the two to be highly positively 
correlated, that is primary tumours with high labelling index tended to have highly 
labelled secondaries. This would argue against a clonal selection model of metastasis, 
but given the doubtful nature of the basic data it is probably unwise to give much 
weight to this particular experiment.
There have been disparate reports of the application of in vivo bromodeoxyuridine 
labelling in tumour types other than breast cancer over the last 2 years. As with the two 
studies just considered, most of these have failed to make use of the capability of this 
methodology to provide dynamic data, and have calculated a tumour labelling index 
only. This is bromodeoxyuridine used simply as an alternative to tritiated thymidine, 
its only advantage being that in vivo labelling is theoretically more satisfactory than in 
vitro. All have reported their results in terms of mean values of labelling index, which 
ignores the fact that this parameter almost certainly has a non-normal distribution. They 
will not be discussed individually, but a brief summary of results is given in the 
following table:
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Author Year Tumour Type n LI Ts Tpot
Tinnemans 1993 lung vivo 27 9.9 10.0 7.8
Tachibana 1993 bladder vitro 81 10.0 - -
Popert 1993 bladder vivo 19 7.9 - -
Roncucci 1992 colorectal vivo 43 20.3 - -
Ito 1992 medullobl. vivo 26 11.7 8.0 -
Yousof 1991 colorectal vivo 7 25.8 18.7 -
Table 12: Summary of results published by various authors using bromodeoxyuridine
labelling in human tumours other than breast. Type refers to whether labelling was carried out 
in vivo or in vitro. All kinetic values are means.
This brings us up to date with the current state of play in the measurement of tumour 
cell kinetics. The relative impracticality of measuring actual doubling times, and the 
labour-intensive, time-consuming nature of thymidine labelling have precluded them 
from establishing themselves as routine techniques. The same might have happened 
with the counting of mitotic figures and of staining with Ki-67 and PCNA, but at least 
the preparation here is simple and quick. What is at risk of happening though is routine 
users taking the short cut of not counting an adequate sample of cells. This is the 
attractive element of flow cytometry- the ability to automate the counting, and 
furthermore to do it very quickly. What is lost is the ability to see what is being 
counted, and the last two sections indicate only too clearly just what assumptions are 
made in the process of interpreting flow cytometric output. Reduced to its barest 
essentials, this is what this thesis seeks to examine- do the benefits of flow cytometric 
techniques outweigh their disadvantages? This question is formalised and broken 
down to some extent in the following statement of aims, after which we turn to the 
description of the experimental work undertaken.
STATEMENT
OF
AIMS
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The preceding review indicates that all methods for the study of tumour cell kinetics 
have technical limitations. The application of flow cytometry to this area has huge 
potential advantages in terms of time saving, and the ability to measure dynamic 
kinetics. This thesis is intended to assess that potential, and the way that these data 
might best be used to further our understanding and treatment of breast cancer. The 
general aim may be stated in the following terms:'
The purpose o f the current programme of experiments is to to critically evaluate the 
potential use o f flow cytometric methods for the determination o f tumour cell kinetics, 
particularly in the study of human breast cancer.
This is effected by the study o f :
a retrospective series o f293 breast cancers in which S phase fraction is measured
a prospective series of 89 breast cancers labelled with bromodeoxyuridine
The individual experiments address a more specific group of questions:
what are the validity and reproducibility o f flow cytometric S phase fraction and 
bromodeoxyuridine-based kinetics?
what are the prognostic power of tumour ploidy and flow cytometric S phase fraction ?
what are the dynamic kinetics o f breast cancer, their relationship to traditional 
prognostic factors, and to the kinetics o f other human malignancies and normal breast 
tissue?
do in vivo labelling and flow cytometry offer any advantage over static methods of 
assessing tumour cell kinetics?
can tumour cell kinetics help assess the significance o f molecular abnormalities in 
breast cancer, specifically aberrant expression o f type I growth factor receptors?
PART II
S PHASE FRACTION 
ASA
PROGNOSTIC FACTOR
IN
HUMAN BREAST CANCER
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Introduction to the Experimental Parts of the Thesis
To address the aims of the thesis, experiments have been performed in the two major 
areas of application of flow cytometry to the field of tumour cell kinetics- the 
estimation of S phase fraction by analysis of ploidy histograms, and the calculation of 
dynamic kinetics by multiparameter flow cytometry after administration of 
bromodeoxyuridine. The following two parts of the thesis describe these 
investigations. In Part II, the results of the examination of over 300 tumours with long 
follow up, to determine ploidy and S phase fraction are described. Part III looks at the 
application of bromodeoxyuridine-based technology in an ongoing series of about 90 
cancers.
Overview of Ploidy Studies
This Part begins with a brief description of the patient base for the Liverpool Breast 
Cancer Series, and what tumour material from this cohort we were able to access for 
ploidy studies. There follows a detailed description of the process by which nuclear 
suspensions were prepared from this tissue and subsequently stained for DNA content. 
Technical details as to how these were run on a flow cytometer are then covered. This 
section continues on from the theoretical account of flow cytometry in section v of 
chapter 3. The means by which the flow cytometric output was interpreted to provide 
data as to tumour ploidy and S phase fraction are discussed, and this again follows on 
from the theory presented in chapter 3. The final section of the methodological chapter 
sets out experiments assessing the sources of variation in measurements of S phase 
fraction.
The results, and discussion of them, focus on two questions, encompassed within the 
specific aims of the thesis: firstly, what prognostic information is given by tumour 
ploidy and by flow cytometric S phase fraction; and secondly, how reproducible are 
the measurements themselves?
These experiments formed the basis for the paper: Lack of prognostic significance of 
ploidy and S phase fraction in human breast cancer. Stanton PD, Oakes SJ, Murray 
GD, Winstanley J, Cooke TG, George WD. Br J Cancer 1992; 66: 925-9.
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Chapter 5: 
Patients and Methods
Section i: Patients Studied
This study used archival, formalin-fixed, paraffin-embedded tissue from patients who 
were part of the Liverpool Breast Cancer Series. This series was established in 1979 
by Mr T G Cooke, to assess the prognostic significance of oestrogen receptor 
expression in early breast cancer. 749 patients under the care of 16 surgeons in four 
hospitals were recruited to the study. It was hoped to include all consenting patients 
with TNM stages Tq_3 Nq^ M0 breast cancer treated in the Liverpool area, and 
prospective audit of operating lists suggested that this was very nearly achieved 
throughout the period of recruitment. The absence of metastatic disease was based on 
full blood count, liver function tests, serum electrolytes, chest X-ray and skeletal 
survey with isotope bone scan in the case of equivocal X-ray results, in line with the 
limited availability of nuclear scanning at that time, especially in peripheral hospitals.
Patients were treated at the discretion of individual clinicians, with operative 
procedures ranging from simple to radical mastectomy. Some form of axillary lymph 
node sampling procedure was a requirement of the study, many patients having a full 
axillary dissection. Patients who had been given prior systemic therapy were excluded, 
as were patients given adjuvant chemotherapy (eleven patients). Subsequent treatment 
was again entirely at the discretion of the individual surgeons involved, as was follow- 
up. The patients were flagged with the regional Cancer Registry, so that the only 
deaths potentially not recorded were those of patients dying outside of Britain. 
Recurrence data from clinical follow-up are not nearly so complete as mortality data, as 
two of the four participating hospitals have since been closed, so that death is the only 
satisfactory endpoint for statistical analysis in this series.
Patient details recorded on a standard proforma at the time of entry to the study 
included age and menopausal status. Tumour size was assessed clinically, nodal 
involvement histologically by the respective hospital pathologists. Tumour grade was 
allocated by a single pathologist according to the criteria of Bloom and Richardson. 
(Estrogen receptors (ER) were assayed by the dextran coated charcoal technique at the 
Tenovus Institute in Cardiff, and the cut off between ER positive and negative tumours 
was taken as 5 fmol/mg cytosol protein. The thymidine labelling index was measured 
in 196 of the tumours as described in the previous section.
452 of the tumours were stained immunohistochemically for the erbB-2 oncoprotein 
using the 21N polyclonal antipeptide antibody developed at ICRF by Dr W Gullick.
Chapter 5 60
This work was performed by Mr J  Winstanley. Tumours were classified as positive 
for erbB-2 if any positively stained tumour cell groups were identified.
Section ii: Tissue Available
Formalin-fixed, paraffin-embedded material was sought from all cases in the series 
from the archives of the contributing hospitals' pathology departments. Due to the 
closure of two of the hospitals involved, the "blocks produced by the hospital 
pathologist at the time could not be found in many cases. In some of these cases, the 
blocks used for measuring the thymidine labelling index were available and were used 
in place of original pathology specimens to provide material for flow cytometry. One 
or more samples were available from these sources for 329 of the total of 749 patients 
within the series.
Section iii: Preparation and Staining of Nuclear Suspensions
Suspensions were made by a slight modification of the technique published by Hedley 
et al (1983), summarised in figure 15. 5Op sections were cut from each block with a 
standard microtome. Although this exceeds the calibrations on the instrument, accurate 
sections of this thickness were obtained by marking the ratchet within the instrument 
(which simply advances the block by lp  per tooth) at intervals of 25 teeth, and 
manually turning the ratchet two such markings. Two sections were cut to allow a 
repeat/duplicate section without further recourse to the block, in order to preserve the 
available material. Before taking the thick sections for flow cytometry, a standard 4p 
section was cut for H&E staining in order to verify the presence of tumour within the 
sectioned tissue. All of these sections were reviewed by the author, with the assistance 
of Dr J Going in the Department of Pathology, GRI in cases of any dubiety. Hedley's 
original description was of the use of 30p sections, but it was subsequently shown that 
increasing the thickness of the sections reduced the proportion of debris attributable to 
nuclei divided by the blade on the surfaces of the section (Stephenson et al, 1986). 
These authors demonstrated that there was no significant diminution of debris using 
sections of greater than 50p in thickness. The subsequent use of the thin and thick 
tissue sections is summarised in the following flow chart:
Chapter 5 61
50|x Section
Figure 15: Flow chart summarising 
treatment of tissue blocks.
H & E Stain
Rehydrate
Disaggregate
Flow Cytometry
Stain with 
Propridium
Paraffin Block
The thick sections were dewaxed in graded alcohols. To do this they were individually 
wrapped in 5Op, nylon mesh and placed in steel cages which were then processed in 
groups of up to 30 on a tissue processor. The stages and times in each were:
Xylene 60m ins
Xylene 30m ins
100% Ethanol 15mins
100% Ethanol 15m ins
90% Ethanol 15mins
70% Ethanol 15mins
40% Ethanol 15mins
Water 15mins
Water 15mins
The cages and mesh were then opened and the usually still intact, rehydrated tissue 
section transferred with metal forceps to a 5ml plastic test tube.
The sections were then disaggregated by the addition of 1ml of 0.5% pepsin in water at 
pH 1.5, with incubation at 37°C for 30min. The tubes were centrifuged at 2000g for 5 
minutes at 4°C, and the supernatant aspirated manually using a glass Pasteur pipette, 
lm l of phosphate buffered saline ph7.4 (PBS) was added to the tubes as a wash 
solution, and the centrifugation and aspiration repeated. Each sample was then passed 
through a 25g hypodermic needle by aspiration with a lml syringe three times, to 
achieve additional, mechanical disaggregation, and the suspension passed through a 
50p, nylon mesh into a fresh tube. These were again centrifuged and the supernatant 
aspirated and replaced with a staining solution of 30pg/ml propridium iodide in PBS 
for 30 minutes at room temperature. After a final spin and resuspension in PBS 
samples were ready for flow cytometry.
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Section iv: Flow Cvtometrv
All samples w ere  run on the Coulter Epics Profile II benchtop flow cy tom eter  in the 
University Departm ent o f  Surgery at the Glasgow Royal Infirmary. This m achine has a 
single, air-cooled, 15mW argon laser emitting at 488 nm. collimated into a beam o f  
elliptical cross section. T he sample o f  between 25 and 200pl is injected at a rate o f  10 
to lOOpl/second into an outer fluid stream. The combination o f  sam ple flow rate and 
sheath  pressure maintains the sample as a very narrow fluid stream such that the 
contained nuclei progress single file through the beam:
S am ple
Sheath Fluid
Laser Beam
Injection 
Needle
Figure 1 6 : Fluid dynamics of Coulter flow  
cytometer. Cells are presented to laser beam 
in an orderly array by injection into the middle 
of a stream of sheath fluid, the pressure of 
which constrains the sample fluid to maintain 
a cylindrical form.
This occurs not in open  air as in many cytometers but in a quartz block. L ight scattered 
or emitted by each nucleus is collected directly in front o f  the beam, and at 90° to its 
direction w here  the fluorescence pick up lens recollimates the scattered and emitted 
light. T he  side o f  the quartz block opposite the fluorescence pick up lens is mirrored to 
direct light scattered away from the sensors back toward them. Within the sensor 
system  are four photomultiplier tubes to which the collimated light is d istributed by a 
system  o f  filters (figure 17). T he sensitivity o f these detectors can be adjusted by 
controlling the voltage supplied to them. The signals from each detec tor are 
individually amplified using either a linear or log amplification, and displayed and 
stored by the cy tom eter until the end o f  the run. In this machine most param eters  can 
be changed in real time as the run progresses.
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Figure 17: Detection system of the Coulter Epics Profile II flow cytometer. Light scattered 
from the sample is collected by the fluorescence pick up lens (FPL), and directed by 
numbered filters to the 4 sensors (FL1,2&3 for various wavelengths of emitted light, and SS 
for side scatter of laser light). Scattered laser light is also detected by the forward light scatter 
(FLS) sensor.
In the current study, a lOOjil sample from each nuclear suspension produced as in the 
previous section was run at a rate of between 100 and 200 nuclei per second passing 
through the beam, to a total of 10,000 nuclei. If a suspension proved to be too 
concentrated for this to be achieved even at the minimum rate of sample flow of 
10pl/second, it was diluted with further PBS and rerun. If the suspension was too 
dilute to achieve an adequate flow rate, it was centrifuged and resuspended in a smaller 
volume of PBS. The sample sheath pressure was set throughout at 7.5psi.
Parameters collected for each nucleus were: forward light scatter (FLS), peak red 
fluorescence (FL2P) and total red fluorescence (FL2). The filter set up used to achieve 
this was a 488nm dichroic mirror to split off the scattered laser light (filter a in figure 
17) followed by a 457-502nm laser blocking filter (filter b), a 550nm dichroic mirror 
(filter c, no filter was used in the d position), and 635nm band pass filter in front of the 
FL2 detector (filter e). In fact filter c is not necessary for this work, but was present as 
the machine was simultaneously being used for two colour fluorescence work 
requiring discrimination between green and red fluorescence, which this filter is 
designed to separate.
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The photomultiplier tube voltage was set such that the cell populations lay centrally 
within the histogram, leaving an adequate number of channels on either side to be used 
for the estimation of background counts when this was subsequently done in the 
process of estimating S phase fraction (vide infra, section 7). Usually it was possible 
to include both diploid and aneuploid populations in the case of aneuploid populations, 
but with some tumours of very high DNA index (the G2 /M DNA content of which 
might be 6 times diploid Gq/Gi content) this was not possible, in which case priority 
was given to the aneuploid population, upon which S phase fraction estimation was to 
be performed.
Three histograms were created from these parameters:
a) peak red fluorescence versus total red fluorescence. This histogram is used solely to 
select the desired population for analysis in the ploidy histogram (histogram c in this 
list), and to gate out debris and clumped nuclei in doing so. In order to understand the 
means by which it does so it is necessary to consider the time course of a Gq phase 
nucleus passing through the laser beam. The contained propridium iodide will emit 
fluorescence whilst any part of the nucleus is in the beam. Thus a fluorescent signal (in 
FL2 in this case) will be detected as soon as the 'leading edge' of the nucleus enters the 
beam (figure 18(a)). When the entire nucleus is in the beam momentarily later, a larger 
signal will be detected as more propridium iodide is now being exposed (figure 18(b)). 
As the nucleus leaves the beam, the detected fluorescence will fall back off (figure 
18(c)). The consequent shape of the signal emanating from the photomultiplier is 
shown in the figure.
It is the area under this curve which is used as the indicator of total propidium content 
for the purpose o f building a ploidy histogram. The figure compares the sequence of 
events as two objects pass through the beam- firstly the nucleus just considered, and 
secondly one which consists of two nuclei of exactly half that content clumped together 
(viewed by the cytometer as a single object). Both have the same propridium content 
but note that the peak height of the signal given off by the clump is lower than that of 
the G2  nucleus, so long as the clump is longer than the height of the beam as illustrated 
and passes through the beam in a lengthwise orientation (which it will tend to be 
constrained to do by the fluid dynamics of the flow cell).
In a histogram of the peak signal against the total signal, the two objects will be 
separate, although they would not be in a ploidy histogram based on the total signal 
alone. The presence of doublets in such a histogram would artificially inflate the 
population of G2 /M cells. On the two parameter histogram however, an area of interest 
can be drawn around those objects having a peak signal 'appropriate' to their total 
signal, and the ploidy histogram drawn from these objects only, a process referred to 
as doublet discrimination.
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Figure 18: Principle of doublet discrimination, exemplified by the time 
course of the fluorescence signal recorded as a single object (a-c) 
and two clumped objects of the same total size (d-f) pass through the 
laser beam.
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b) Forward light scatter versus number of counts. The amount of laser light scattered 
in the forward direction by each object is related to its size. This histogram is 
theoretically a frequency histogram of the distribution of nuclear sizes within the 
sample. At least one previous group have reported that this parameter is of some 
prognostic significance separate from that of ploidy and SPF (St3l et al, 1989). They 
used fresh tumour material with added trout and chicken red blood cells, against which 
nuclear size could be standardised. Our own experience was that FLS was highly 
variable between samples, and in the absence of any means of standardisation because 
of the use of paraffin embedded material, it proved to be impracticable to obtain reliable 
measurement of size in this way.
c) Total red fluorescence versus number of counts, which is the ploidy histogram. It 
was produced only from counts which fell within an area of interest drawn on 
histogram a, a process referred to as gating. The area of interest is drawn with a touch 
sensitive pad attached to the cytometer, and is done in real time while run is in progress 
(it can be altered subsequently if necessary). It is drawn so as to exclude doublets in 
the manner discussed above.
Section v: Data Storage
Data from each sample was stored in two ways. The ploidy histogram produced during 
the run was stored as such onto the hard disc within the machine at the end of the run, 
and at the end of each session these histograms were downloaded to floppy discs. 
These discs were then used to transfer the histograms to the separate personal 
computer on which offline analysis was performed in order to calculate SPF.
The cytometer’s data list, containing the raw data from each photomultiplier tube, was 
also copied onto floppy discs at the end of each run. It is bulky in storage terms (each 
data list amounts to some 100 kilobytes of disc space), but allows most run parameters 
to be altered and the histograms to be recreated in the light of the modifications, which 
cannot be done with the histogram data alone. The list mode data was not used in this 
study, but was transferred to storage tape in case future reanalysis is indicated.
Section vi: Allocation of Tumour Ploidv
Ploidy histograms were classified simply as diploid or aneuploid, using the population 
of non-tumour cells within the sample as a standard. If the tumour cells have the same 
DNA content as the non-tumour cells, then only a single population will be seen in the 
histogram (diploid), if not then two or more populations will be seen (aneuploid). 
Matters are not always as clear cut as this would suggest. For instance, does a 
histogram with very broad peaks represent poor quality, or is it so because there are
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two populations very close to one another such that they are not resolved into separate 
peaks? How large does a putative aneuploid peak have to be before it is accepted as 
such? Is a substantial peak in the G2/M position for the diploid population an indication 
that there are many cells in those phases of the cycle, or does it suggest that there is an 
overlying aneuploid population with exactly twice the diploid DNA content? There is 
an element of subjectivity to the allocation of ploidy for some histograms, since 
different observers will interpret answer the above questions differently in specific 
instances. This has been demonstrated by Kallioniemi et al (1990) as a cause of 
interlaboratory variation.
Two means have been used to limit this problem in the current investigation. Firstly, 
all histograms were reviewed and discussed jointly by a panel of at least three people 
experienced in this area, and the interpretation of each histogram determined by 
consensus. In cases of uncertainty, a further section was processed and run, and the 
two histograms considered together. Secondly, objective (although arbitrary) criteria 
were used to answer two of the queries in the paragraph above:
a) Histograms were only considered interpretable if the coefficient of variation (CV) of 
the putative diploid Gq/Gx peak was less than or equal to 10%. This provides a means 
of excluding histograms of poor quality, and those with near-diploid populations 
which cannot be resolved from the diploid peaks (which would wrongly be classified 
as diploid). This concept of the CV of a peak requires explanation. All of the Gq/G^ 
cells o f a given cell population have exactly the same DNA content, certainly in the 
case of normal cell populations. They should therefore all demonstrate exactly the same 
amount of fluorescence in the flow cytogram, and be counted in a single channel. In 
reality there are minor variations in the staining of each nucleus, and in the signal 
detected by the cytometer even given exactly the same emitted fluorescence, as 
explained above. As a result, the cells are not counted in one channel, but rather in 
several. The more the variation due to technical factors, the wider the peak. Such 
variation is greater for peaks with a high mean amount of fluorescence, as a 1% 'error' 
for a cell of theoretical fluorescence of 50 units will only be half of that resulting from 
the same error for a cell with 100 units of fluorescence. The CV is the ratio between 
the standard deviation and mean channel of a peak. It expresses the peak width in 
relationship to its position in the histogram, and so takes account of this 'magnifying' 
effect o f a stronger mean signal.
b) A putative aneuploid peak overlying the diploid G2/M peak (a so-called tetraploid 
peak) was only considered to exist if the proportion of total histogram events contained 
within that peak exceeded 15%. In respect of such peaks, the acceptable range for the 
DNA index (DI, see Ch.3, Sect. v) was taken to be 1.85-2.10. Obviously, the DI of
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the G2/M population should theoretically be 2.0, but varies from this is a result of non­
stoichiometry in dye binding, and non-linearity of the machine response to increasing 
signal strength. The range stated was based upon that observed in diploid histograms. 
The reason for having such a criterion was that if the mean channel of a putative G2/M 
peak fell outside of this range, it was presumed that the peak must actually represent a 
small G2/M peak merged with a larger aneuploid Gq/Gj^ peak of DI outside of the 
range. In this circumstance, the presence of the aneuploid population would be 
accepted without the need to fulfill the 15% criterion.
Section vii: Estimation of S Phase Fraction (SPR
SPF was calculated using the Cytologies software package provided by Coulter 
Electronics, run on an IBM compatible, 386-based PC. All histograms were assessed 
by the author. With this software, the histograms are read off the floppy discs on 
which they were stored by the cytometer at the end of each session. The area of the 
histogram containing the population of interest is then indicated by the placement of 
cursors in channels either side of that population. Only counts within these cursors 
were then further considered by the software.
An option is then provided for the subtraction of background counts due to debris and 
machine 'chatter'. Within the Cytologies package, this is done using an exponential 
model (that is, with an assumption that the number of background counts falls off 
exponentially from left to right in the histogram). This model was found by Feichter et 
al (1988) to provide the best of correlation of SPF with TLI. In this study, background 
subtraction was always attempted, although in a minority of cases, it was not felt that 
an adequate estimate of background counts was produced by the software, and so the 
uncorrected histogram was used for the estimation of SPF. The estimate of 
background counts is produced by the placement of cursors around channels on either 
side of the population of interest, felt to represent background counts only, that is, to 
the left and right of all populations within the histogram. The fact that this will need to 
be done has to be borne in mind when the samples are run on the cytometer, so that the 
PMT voltage is set such that adequate areas are deliberately left at the margins of the 
cell populations. The number of counts in the indicated channels is then used by the 
software to calculate the putative background counts in the channels in between, that is 
in the area of interest. This curve is drawn onto the screen superimposed onto the 
histogram (figure 19), and an option is provided to accept or reject the estimate. If 
rejected, an option is provided to try again using different channels to indicate the 
background counts, and the method is very sensitive to changes of even a single 
channel on some occasions. Whether an estimate is accepted is purely a matter of 
subjective assessment on the part of the operator. In the current study, the major 
criterion was whether the background curve paralleled the top of the S phase
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component of the histogram- that is, converted this compartment into a rectangle, this 
being the presumed shape of S phase for this investigation.
Figure 19: Exponential model of background counts used by the Cytologies analysis 
software. The counts regarded as due to debris are included in the shaded box.
The programme next detects what it regards as the Gq/Gj peak, and places cursors to 
mark it. The operator is given the chance to move these cursors, and this option was 
always exercised. The reason for doing so is that the software looks for the top of the 
peak, its sharpest and most symmetrical part. It then assumes that the peak is Gaussian 
in shape and extends this top down in both directions to form the full peak, rather than 
following the actual shape of the peak. Any surplus of counts when this theoretical 
peak is subtracted from the actual peak are counted as events outside of Gq/G^. On the 
right hand side, these are regarded as S phase cells. Now the presence of S phase cells 
with DNA contents down as low as the mean channel of the G0/G1 peak is undeniable, 
and these will produce a non-Gaussian distortion of this side of the peak, but the fact 
that such variation is often seen to just the same extent on the left side of the peak 
indicates that this is not the predominant source of this phenomenon. As such, 
allowing the software to make this interpretation will inflate the apparent S phase 
fraction, and this is borne out by the fact that the compartment as fitted with the 
Gaussian assumption visibly exceeds the interpeak size of the S phase fraction. 
Subjectively more satisfactory estimates are obtained by moving the cursors indicating 
the top to the Gq/G j^ peak to encompass the entire peak. This process of identification 
and modification is then repeated for the G2/M peak. An option is now provided to 
exclude any extraneous peaks overlapping the S phase. In the most common aneuploid 
tumour, with a DNA index of between 1.5 and 1.8, the G2/M peak of the diploid cells
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will do just  this. If any such peak requires identification, this is done in just the sam e 
w ay  as the G q /G j and G 2 /M  peaks.
T h e  so ftw are  now  subtracts from each channel in the area o f  interest the calculated 
background  counts  and the counts attributed to any peak, and takes the remaining 
counts  be tw een  the G q/ G j and G 2/M  peaks to be due to cells in S phase (figure 20). In 
an aneuploid  histogram, S phase is divided into two separate com partm ents  either side 
o f  the in tervening  diploid G 2/M  peak: It this peak is too close to either o f  the aneuploid 
population  peaks, there m ay be no net counts in the channels in betw een, and so the 
com pute r  will fit no S phase to this area. This is one reason w hy histogram s with 
low er C V s (narrow er peaks) are more readily analysable.
Figure 20: Estimation of SPF (dotted region) as the net counts remaining after 
subtraction of the background counts (shaded area), extending from the middle of 
the G0/G1 peak to the middle of the G2/M peak.
Four m odels  are provided within the software for converting the net S phase counts in 
each channel into an estimate o f  the S phase fraction. That used here and in nearly all 
o ther  series is a rectangular model, owing originally to Baisch et al (1982). To use this 
model, the com pu ter  simply sums the net S phase counts and divides by the num ber o f  
channels  betw een  the mean channels o f  the G q/G j and G 2/M  peaks to g ive the average 
num ber o f  S phase counts per channel. The S phase fraction is then represented as a 
box s tre tch ing  between the means o f  the G q/ G j and G 2/M  peaks, with a height equal to 
the m ean S phase counts per channel. In numerical terms, the S PF  is the sum  o f  the net 
counts , expressed  as a percentage o f  the total counts (less background) in that 
population . T h e  fitted com partm ent is displayed on screen, and its suitability assessed, 
w hich  is a purely subjective assessment on the part o f  the operator as to w he ther it fits
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over the S phase component of the histogram in the way illustrated in figure 20.
The other three models provided by the software were used only in the reproducibility 
studies in this experiment. All four are illustrated on a blown-up histogram in figure 
21. The trapezoid model fits a compartment analogous to the rectangular, but instead of 
a horizontal line on top of the compartment (created by averaging the counts in each 
channel), uses a straight line of any slope (calculated by least squares regression of the 
counts). The rectangular model is a special case of the trapezoid with the slope of the 
line restrained to be zero. The quadratic model fits the counts with a second order 
quadratic, such that the top can now have a varying slope. The three models so far 
discussed fit a single compartment extending from the middle of the Gq/G j peak to the 
middle of the G2/M peak. The fourth m odel, the multiple broadened rectangles, takes 
a different approach, by dividing S phase into up to 9 compartments (the number is 
user selectible). Gaussian curves are then fitted to each compartment and the areas 
under these summed. Unfortunately the Cytologies package implements this model 
poorly, as it often fits negative compartments, which is of course a theoretical 
nonsense.
Section viii: Statistical Methods
The distribution of values of SPF was not statistically normal, and so non-parametric 
methods have been used. For description, medians and either full or interquartile 
ranges are given, whilst for comparison of the SPFs of sub-groups the Mann-Whitney 
(where there are only two groups) or Kruskall-Wallis (for three or more groups) have 
been applied. In analysing ploidy differences between sub-groups, the chi-square test 
was used. The only parametric statistic employed was the two sample t test, for 
comparing the, normal, age distributions of patients with aneuploid and diploid 
tumours. Differences between groups were regarded as statistically significant if the 
null hypothesis had a probability <5%.
Survival analyses were carried out to relate survival to ploidy, SPF, lymph node status 
(positive or negative), tumour size (Tl, T2, T3), oestrogen receptor status (positive or 
negative), and c-erbB-2 staining (positive or negative). Patients known to be alive at 
Jan 1st, 1990 or who were known to have died from causes unrelated to cancer, were 
treated as censored observations. Univariate analysis was performed using Kaplan- 
Meier estimates and log rank tests. In light of the differences between SPF as 
calculated in DNA diploid and DNA aneuploid tumours, the effect of this variable was 
analysed separately for the two ploidy groups. A combined analysis using a common 
median was also done, on the grounds that this was the method used in other reports. 
Multivariate analyses used the Cox proportional hazards regression model, using both 
forward and backward selection of variables. The tests sought interactions within a
Chapter 5
Figure 21: Models of S phase available in the Cytologies analysis 
package, a) rectangular; b) trapezoidal; c) quadratic; d) multiple 
broadened rectangules. In a) - c) the estimated S phase fraction is 
shown by the dotted region (background counts are ignored). In d) 
the SPF is the combined area under the Guassian curves.
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model containing the effects of six prognostic variables - ER status, node status, size, 
c-erbB-2 status, ploidy and SPF. SPF was analysed as a binary variable, above or 
below the median appropriate to the ploidy of that particular tumour.
Inter- and intra-observer variation, and the comparison of different models of S phase 
were carried out by the method of Bland and Altmann (1986), who pointed out that the 
correlative approach used up to that time to compare two means of measuring the same 
thing was not ideal, in that this statistical process is designed to test the hypothesis that 
two samples are not independent. If the samples represent two measurements of the 
same thing, then perforce they are not independent, and the existence of a correlation is 
almost preordained. Bland and Altmann suggested that it was more appropriate to 
describe the differences between estimates of the same thing, rather than the 
similarities. The method which they developed was to take the difference between each 
pair of observations upon the same patient or specimen. Statistical description of the 
distribution of these differences then provides two items of information:
a) the mean of the differences indicates whether there is any tendency for one set of 
observations to consistently exceed the other, and if so by how much. This follows 
from the fact that however widely the pairs of observations may vary in individual 
cases, if neither has an intrinsic tendency to give a higher answer than the other, then 
observation A will be higher than observation B just as often as the contrary holds, and 
by the same average amount. The difference of the mean from the null expectation that 
it will be zero can be tested with a one sample t test, but this can be approximated by 
considering the 95% confidence intervals for the mean as lying 2 standard errors on 
either side. If zero does not lie between these intervals, then a significant difference 
exists, and the limits of the probable size of this are indicated.
b) Even if the mean difference is zero, the differences between the two observations or 
measurements in individual cases may be large. The magnitude of the individual 
differences is indicated by the standard deviation of the distribution. Since the 
distribution of differences will tend toward a normal distribution (Bland, 1987, 
p. 172), it is reasonable to state that 95% of differences will be less than 2 standard 
deviations from the mean.
This method of analysis can be displayed graphically by plotting the difference 
between each pair of observations against the mean of the two. In the medical sphere, 
the differences often tend to be proportional- that is, the difference increases as the 
value of the measurement gets larger. In such cases it may be more appropriate to 
describe the ratio between each pair, rather than the absolute difference, a suggestion 
made by Murray and Miller (1990). This will then be independent of the value of the 
measurement, for if this criterion is not met it would really be necessary to give a mean
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difference (or ratio) and standard deviation (SD) for each value or range of values of 
the original measurement, rather than one overall mean and SD. The modification of 
Murray and Miller is more often used for the analyses in this study because ratios did 
indeed demonstrate greater independence.
In light of the novelty of this method of analysis, it is worth examining an example in 
more detail, for which we will use some of the data from part III. In chapter 9, section 
xi (b), the following results are given for calculating a labelling index by two methods 
in the same 19 tumours. In each case the difference between the two values is also
given: 
Method 1: 0.4 2.9 9.5 0.6 5.0 1.3 2.2 1.9 1.8 0.6
Method 2: 1.1 3.2 8.9 0.5 3.2 1.2 1.6 1.2 0.8 4.1
Difference: -0.7 -0.3 0.6 0.1 1.8 0.1 0.6 0.7 1.0 -3.5
Method 1: 7.1 2.2 8.2 8.3 8.3 9.9 3.7 8.0 1.2
Method 2: 5.1 1.9 7.9 4.8 5.1 7.9 3.6 6.4 0.8
Difference: 2.0 0.3 0.3 3.5 3.2 2.0 0.1 1.6 0.4
The respective median labelling indices are 2.9% and 3.2%, not significantly different 
on a Mann-Whitney test (W=391.5, p=0.55). The pairs of values are plotted against 
each other in fig 22(a) below, showing clear correlation. The Spearman coefficient, 
p=0.86, p<0.0005. This would lead conventional analysis of these results to conclude 
that the two methods gave similar results. All it actually shows is what it says- that 
there is a correlation between the values obtained by the two methods. This is hardly 
surprising, and tells us nothing about the results in individual cases.
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Figure 22: Two ways of comparing results from two methods for measurement, 
a) correlative approach b) Bland-Altmann approach. See text for details.
We see pairs like 0.6% vs 4.1%, and 8.3% vs 5.1%. If we take the difference between 
the pairs in each case, and plot these against the mean value for each pair (because this
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is the best guess as to the 'real' value), we get the graph in fig 22(b). Now ideally the 
differences will all be on the zero line (both methods the same), but we can see firstly 
that most points are above this line, and that some are quite distant from it. This 
indicates that method 1 tends to give higher values than method 2, and that large 
differences occur in some cases.
We can summarise this using descriptive statistics for the distribution of differences. 
The mean difference is +0.73%, with a standard error of 0.35%, and a standard 
deviation of 1.52%. This confirms that method 1 gives larger estimates, since the mean 
is above zero. Since this mean (0.73) is more than two standard errors (0.35) from 
zero, this trend is probably statistically significant at the 5% level, which can be 
confirmed by performing a t-test of p=0 for the 19 differences, which gives t=2.08, 
with p=0.05. With a standard deviation of 1.52%, the 95% confidence interval for the 
difference is 3.04% (2x1.52) either side of the mean difference. That is, in 95% of 
cases we would expect the difference between the two to be no more than 
0.73±3.04%, or from -2.31 - 3.77%. That sort of difference is large in relationship to 
the labelling indices themselves (up to 10%, but with a median of around 3%). It can 
be seen from fig 22(b), that the differences get larger as the mean value increases, and 
for this reason in the Chapter 9, when these data are analysed, this is done in terms of 
the ratio of the two estimates, rather than the difference between them as here.
Section ix: Reproducibility Studies
Because of the subjectivity in the measurement of S phase fraction in terms of defining 
peaks and background subtraction (section 7), experiments were carried out to assess 
the inter- and intra-observer variation for this measurement. These were not carried out 
upon histograms from tumours in the Liverpool Breast Cancer Series. They were 
however performed upon breast cancers, from a series of lumpectomy specimens 
collected by Mr C S McArdle at the Glasgow Royal Infirmary between 1983 and 1986, 
for the purpose o f looking at predictors of local recurrence after breast conserving 
cancer excision. Blocks were obtained for all 119 of these tumours, which were 
processed for flow cytometry in exactly the same way as described in section 3. The 
ploidy histograms were then analysed to obtain estimates of SPF as explained in 
section 7. This was done by the author on two separate occasions two months apart, 
using each time all four models available within the Cytologies software and not just 
the rectangular method used for the prognostic analyses above. Independent 
measurements of SPF using the same histograms were also performed at two times, 
using the rectangular method, by another worker within the laboratory (Ms S J Oakes). 
A total of ten estimates of SPF for each of the 119 histograms was therefore made (or 
at least attempted). These data sets have been analysed using the Bland-Altmann 
method to assess the reproducibility of this endeavour.
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Chapter 6: 
Results
Section i: Patient Characteristics
Paraffin blocks were found for 329 tumours from the original series total of 749 
patients, for the reasons given in section ii of the previous chapter. Histological review 
indicated that 36 of these blocks examined showed no remaining tumour. The study 
population for the current series consisted of the 293 remaining specimens. The 
distribution of prognostic factors is available for the 224 from whose tumours SPF 
coud be gained (vide infra, Section iv), and is indicated below:
Variable Groups n %
Nodal Status NO 130 59
N1 91 41
Tumour Size T1 19 9
T2 152 71
T3 43 20
Grade 1 41 34
2 39 33
3 39 33
ER Status Pos 128 59
Neg 88 41
c-erbB-2  Status Pos 52 24
Neg 163 76
Menopausal Pre 49 24
Status Post 159 76
Table 13: Distribution of prognostic factors among the 224 patients from whom 
both SPF and ploidy were available
Section ii: Basic Ploidv Data
Histograms meeting the criteria enunciated in the methods section were obtained in 281 
cases (96% of those with tumour-containing blocks). Appendix I gives the following 
raw data for each of these tumours- CV of the Go/Gi peak, ploidy, DNA index, SPF, 
and (in Appendix la, in respect of patients for whom SPF is available) the menopausal 
status of the patient, tumour size, nodal status, histological grade, oestrogen receptor 
and c-erBB-2 status. 179 (64%) of histograms were classified as DNA aneuploid, and 
102 were DNA diploid. The median CV for the Go/Gi peak was 5.6% (interquartile 
range 4.6 - 7.0%). The distribution of DNA indices is shown:
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Figure 23: Distribution of DNA indices for 281 tumours in which interpretable 
histograms were obtained, excluding the 18 polyploid tumours.
The relationships between ploidy and other prognostic factors recorded for each patient 
are analysed in table 14. There is no statistically significant difference in the 
distribution of subgroups for any factor when cases are divided by ploidy. There is a 
trend for erbB-2 positive tumours to be aneuploid, but in the case of tumour size, 
nodal status, menopausal status and expression of oestrogen receptors there is really no 
suggestion of a relationship with ploidy in this group of patients. Mean age of patients 
with diploid tumours was 58.4 years, and for patients with aneuploid tumours was 
58.1 years, there also being no statistically significant difference between these two 
(t=0.15, df=191, p=0.88).
Menopausal Status Tumour Size
Pre Post T1 T2 T3
Diploid 43 42 42 41 37
Aneuploid 57 58 58 59 63
Nodal Status Histological Grade
N1 N2 G1 G2 G3
Diploid 42 41 39 49 38
Aneuploid 58 59 61 51 62
(Estrogen Receptor Status ErbB-2 Expression
ER+ ER- erbB2- erbB2+
Diploid 44 36 45 33
Aneuploid 56 64 55 67
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Factor X2 df P
Menopausal Status 0.028 1 0.867
Tumour Size 0.268 2 0.875
Nodal Status 0.017 1 0.896
(Estrogen Receptor Status 1.178 1 0.278
erbB2 expression 2.607 1 0.106
Histological Grade 1.072 2 0.585
Table 14: Relationship between tumour ploidy and various prognostic factors. In the upper 
part of the table, tumours are subdivided by each factor, and the percentage of diploid and 
aneuploid tumours in each subgroup is given (ie all figures are column percentages). The 
chi-square statistics for each comparison (using the raw data rather than percentages given in 
the lower part of the table). Raw data in Appendices I and la.
Section iii: Prognostic Power of Tumour Ploidv
Univariate analysis of survival stratified by ploidy is shown in figure 24. There is a 
survival advantage in favour of DNA diploid tumours of 4% at five years and of 3% at 
10 years, but this result is not statistically significant. Expressed in terms of a hazards 
ratio, the relative hazard for patients with DNA aneuploid tumours is 1.20 with 95% 
confidence limits of 0.81 -1.76.
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Figure 24: Life table for 281 patients subdivided by the ploidy of their tumours. Probability 
of difference between the groups (log rank X^) = 0.23.
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Section iv: Basic Data on S Phase Fractions
Estimates of SPF were obtained in 224 cases (80% of those from which ploidy was
interpretable). The median value of SPF was 7.25% overall, 4.5% in DNA diploid
tumours and 10.9% in DNA aneuploids. The distribution of values of SPF is shown: 
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Figure 25: Frequency distribution of SPF in the 224 cases in which it was available.
Values along the x axis are midpoints, that is 3 represents values 2.50 - 3.49.
No attempt has been made to compare the distributions of values for DNA diploid and 
DNA aneuploid tumours statistically, because of the different nature of the 
measurement in the two types of histogram (see discussion). The relationship between 
SPF and other prognostic factors has also been analysed separately in the two ploidy 
groups, as otherwise the comparisons would be based on a combination of ploidy and 
SPF. This is because a subgroup with a higher proportion of aneuploid tumours would 
tend to have a higher mean SPF for this reason, so that a difference in SPF between 
groups could be due to a ploidy imbalance alone. The relationships between SPF and 
other prognostic factors, looked at in this way, are shown in table 15. Analyses were 
performed using the Mann-Whitney test where 2 groups are being compared and the 
Kruskall-Wallace test when 3 groups are involved (tumour size, histological grade). 
Results significant at the 5% level are underlined. Node positive, high grade, and 
oestrogen receptor negative tumours had significantly higher values for SPF. In the 
case of nodal status and ER status, this was only the case for aneuploid tumours, but 
with a trend in the same direction for diploid tumours. This may simply reflect the fact 
that there are twice as many aneuploid as diploid tumours. The only other positive 
finding is that pre-menopausal women had tumours with higher SPF than 
postmenopausal women.
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Factor Ploidy Subgroup Median SPF P
Nodal Status diploid NO 4.05
N1 4.50 0.674
aneuploid NO 9.90
N1 12.55 0.003
Hist. Grade diploid G1 3.10
G2 4.40
G3 4.80 0.035
aneuploid G1 10.50
G2 12.85
G3 11.95 0.039
Menopausal diploid pre 5.60
Status post 4.15 0.05
aneuploid pre 11.7
post 10.5 0.397
erbB-2 diploid neg 4.1
expression pos 4.1 0.968
aneuploid neg 10.3
pos 11.3 0.15
Tumour Size diploid T1 4.35
T2 4.10
T3 5.15 0.381
aneuploid T1 9.4
T2 11.3
T3 11.9 0.199
CEstrogen diploid pos 4.3
Receptor Status neg 4.65 0.532
aneuploid pos 9.55
neg 12.2 0.019
Table 15: Relationship between prognostic factors and S phase fraction. Analyses using 
Mann-Whitney and Kruskall-Wallace tests. Significant results underlined.
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It should be stressed that these results are not independent; for instance there may be 
more node positive tumours among the premenopausal women. This type of analysis 
does not address the question as to which of the prognostic factors if any is 
functionally associated with SPF, and which are associated secondarily.
The relationship between tumour size and SPF is potentially interesting. A large 
tumour may have become so either because it has grown faster, or because it is further 
along in its natural history; in this case, if Gompertzian conditions apply, it may 
actually be growing more slowly than an earlier tumour. Although there is no 
statistically significant difference in this series, the trend in both diploid and aneuploid 
tumours is for an increase in SPF with tumour size. This supports the former 
hypothesis, that large tumours are so because they are intrinsically faster growing. 
This assumes that tumours do not grow in an ’inverse Gompertzian' fashion and speed 
up as they enlarge, but there is no evidence that this is the case.
Section v: Prognostic Power of S Phase Fraction
Life tables for survival for these populations split at the respective medians, and at the 
overall median, are shown in figure 26. None of these analyses show a statistically 
significant survival effect of SPF. Analysis was also performed within each ploidy 
group using quartiles of SPF, to assess whether there was an effect restricted to 
extreme values, but this provides no evidence that this was the case (table 16). The 
relative hazard for all tumours with above median SPF, regardless of ploidy, is 1.31 
with 95% confidence intervals 0.87 -1.98.
Ploidy Survival Q1 Q2 Q3 Q4
Diploid 5yr 67 78 58 75
10 yr 54 65 53 55
Aneuploid 5 yr 71 69 60 58
10 yr 59 57 49 45
Table 16: Percentage survival at 5 and 10 years in subgroups defined by 
tumour ploidy, and quartiles of SPF within each ploidy group.
Section vi: Multivariate Analysis
Multivariate analysis using the Cox proportional hazards model was carried out in the 
201 cases where all prognostic variables were available for the tumour (table 17). This 
represents 72% of tumours for which ploidy was measured, and 89% of those for 
which SPF was available. In a stepwise procedure with all terms starting out of the 
model, only nodal status is found to be independently prognostic. The same result is
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Figure 26: Life tables for tumours divided by SPF above or below 
median value, a) all tumours (median 7.25%, p=0.11) b) aneuploid 
tumours (median 10.9%, p=0.33) c) diploid tumours (median 4.5%, 
p=0.33)
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obtained with a model where all terms start in. The relative hazard for aneuploid 
tumours was 1.17, and for high SPF 1.28, but both have very wide confidence 
intervals, are not statistically signicantly different from 1.0.
Because this excludes almost a third of cases for which ploidy was available, the 
prognostic effect of the two study variables was also analysed using all data available 
for each patient (table 18). The results were very similar to the preceding analysis; no 
independent prognostic effect for ploidy or SPF was observed.
Variable Coeff. SE ecoeff. eco.-2SE eco.+2SE
Nodes 0.6457 0.2199 1.9073 1.2286 2.9609
ER -0.0766 0.2281 0.9263 0.5870 1.4617
erbB-2 0.0445 0.2570 1.0455 0.6253 1.7480
T1 -0.7860 0.5010 0.4557 0.1673 1.2411
T2 -0.4902 0.2528 0.6125 0.3694 1.0155
Ploidy 0.1568 0.2264 1.1697 0.7438 1.8397
SPF 0.2495 0.2225 1.2834 0.8224 2.0027
Table 17: Multivariate analysis 201 cases in which all variables available. The column ecoeff- 
gives the relative hazard for that variable, and the following two columns are the lower and 
upper limits of the 95% confidence intervals for the hazard. Nodal status is the only significant 
predictor of survival in this model, as it is the only variable for which a hazard of 1.0 is not 
included within the confidence intervals.
Variable n Coeff. SE ecoeff. e co.-2SE gCO.+2SE
Nodes 728 0.7699 0.1139 2.1595 1.720 2.712
ER 714 0.2289 0.1149 1.2572 0.999 1.582
erbB-2 449 -0.3407 0.1677 0.7112 0.508 0.995
T1 v T2 574 0.3471 0.2086 1.4150 0.932 2.147
T1 v T3 220 0.7778 0.2271 2.1768 1.382 3.428
Ploidy 273 0.1792 0.1926 1.1963 0.814 1.758
SPF 220 0.2698 0.2063 1.3097 0.867 1.979
Table 18: Multivariate analysis using all data available for each patient. Columns correspond to 
those in table 17 (ie relative hazard and confidence intervals in the last three columns).
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Section vii: Reproducibility Studies
Two or more estimates of SPF could be made from histograms obtained from 91 of the 
119 blocks (76%) analysed in this experiment. This is very similar to the rate of 
interpretability seen in the main series. 7 of the blocks were found upon histological 
review not to contain tumour, but these have been retained within the current analyses, 
as the question here is not one necessarily specific to tumour histograms. In respect of 
these 91 cases, Appendix II gives for each histogram the half peak coefficient of 
variation (CV), ploidy, and each SPF estimate made. The median CV for these 
histograms was 4.5%. 45% of histograms were aneuploid (49% of tumour 
histograms). More than half of all estimates made with the multiple broadened 
rectangles model (model 4) were negative, presumably becuase of poor implementation 
o f the model by the software. Since this is theoretically ludicrous, results given by this 
model were not further considered in analysis.
a)Comparison o f different models o fS  phase
Let us start by comparing the results given by each to the three remaining models 
(rectangular, trapezoid, quadratic) on the same histograms. In my first analysis of the 
series, an estimate for the SPF was gained with the rectangular and trapezoid models in 
87 cases each, and for the quadratic model in 80 cases. Results are shown for analysis 
by the Bland-Altmann technique. For each histogram, the estimate of SPF obtained by 
one method had been divided by the estimate obtained by another. The distribution of 
these ratios is summarised in the table below, to provide the information discussed in 
section 8 of the Methods chapter.
Comparison n Mean Ratio SE Mean SD Ratios
Rectangular/Trapezoid 87 1.114 0.021 0.193
Rectangular/Quadratic 80 0.917 0.053 0.472
Trapezoid/Quadratic 80 0.846 0.047 0.424
Table 19: Comparison of estimates of SPF made by analysing the same histograms using 
different models. In each row, the answer obtained using the first named model has 
been divided by the answer obtained using the second named model. The summary 
statistics describe the distribution of these ratios. Raw data in Appendix II.
This reveals that the quadratic model gave the highest answer on average, followed by 
the rectangular model and the trapezoid in that order. The low standard deviation of the 
rectangular vs trapezoid comparison indicates that in this case the rectangular model 
tends to relatively consistently give an estimate higher than the trapezoid by the mean 
ratio (ie, by 11%); that is, these two models give consistently similar results with one a 
little higher than the other. The two comparisons involving the quadratic model both
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have much higher standard deviations, which shows that although it gives on average a 
higher estimate of SPF than either of the other two models, it is sometimes much 
higher, and sometimes a lot lower. This method is less consistent judged against the 
other two. It is also possible for fewer of the histograms (80 cf 87 for the other two).
Let us now turn to the reproducibility of each of the models, when I repeated the 
analyses upon the same histograms two months later. Here, the estimate of SPF 
obtained at the first sitting has been divided by the estimate using the same model from 
the second sitting to give the ratios summarised in the table:
Model n Mean Ratio SE Mean SD Ratios
Rectangular 80 1.025 0.024 0.219
Trapezoid 78 1.052 0.026 0.227
Quadratic 69 1.201 0.111 0.919
Table 20: Comparison of estimates of SPF made on two occasions by analysing the 
same histograms with the same model. In each row, the answer obtained the first time 
has been divided by the answer obtained the second time. The summary statistics 
describe the distribution of these ratios. Raw data in Appendix II.
There is little to tell between the rectangular and trapezoid models in these terms. 
Estimates were gained in 2 more cases with the former, and the mean ratio is nearer to 
zero, which shows it to be slightly more consistent between the two sittings, 
reinforced by the fractionally lower value for the standard deviation. The huge value 
for SD for the quadratic model indicates that there were some very large differences 
between the estimates made at the two time points. This makes this model much less 
suitable than the other two for routine use. The rectangular was used in the prognostic 
series because of its small advantage in reproducibility over the trapezoid, as well as its 
widespread adoption in previous studies. Ideally it would be desirable to use all 
models in the multivariate analysis of results, as the best model is that which gives the 
most prognostic information, regardless of its reproducibility.
b) Inter-Observer Variation
In light of the above results, inter-observer variation was assessed using only the 
chosen, rectangular, model. In the table below, my estimate of SPF for each histogram 
has been divided by that of the second observer (Ms Oakes), in each case using the 
values obtained at our respective first sittings. The second line of the table looks at the 
results of dividing the average of my two estimates upon each histogram by the 
average of her two estimates, to see if this improved agreement.
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Comparison n Mean Ratio SE Mean SD Ratios
PS1/S01
PSave/SOave
66
64
0.842
0.843
0.028
0.027
0.229
0.214
Table 21: Comparison of SPF estimates by two observers analysing the same histograms 
using rectangular model. In each row, the answer I obtained has been divided by the 
answer obtained by the other observer. The summary statistics describe the distribution 
of these ratios. The first row compares single estimates, the second compares the 
averages of two estimates by each observer. Raw data in Appendix II.
It can be seen that the mean ratio in each case is significantly below one, indicating that 
I tend to get a lower estimate of SPF by 16%, which gives an indication of the degree 
of subjective influence which the operator can have with this software. Putting the 
value of SD into context, this shows that in 95% of cases, the ratio of my estimate to 
the second observer's lay between 0.38 and 1.30. That is, if my value for a given 
histogram was 10%, then we could statistically guess hers to be from 3.8% to 13% 
with 95% certainty. This is not terribly encouraging, and is not much altered by using 
the average of two estimates by each observer. In light of this it is instructive in this 
one case to illustrate the simple plot of our estimates against one another (fig. 27). The 
seductive appearance of this graph (the value of r is 0.945) belies the poor 
reproducibility just demonstrated, and this was the rationale for the development of the 
Bland-Altmann approach.
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Figure 27: Results of analysis of the same histograms by two observers using 
the rectangular model of S phase, plotting the two estimates against each 
other. Line of best fit is y = 1.058 + 1.024x.
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c) Intra-Observer Variation
Finally, we compare the results at the two sittings by the two observers, using the 
chosen model. My results are of course, presented already in table 20, as the results 
for the rectangular model. Once again, the earlier estimate is divided by the subsequent 
one:
Observer n Mean Ratio SE Mean SD Ratios
The Author 80 1.025 0.024 0.219
Ms Sarah Oakes 66 1.026 0.026 0.212
Table 22: Comparison of estimates of SPF made on two occasions analysing the same 
histograms with the rectangular model, by each of two observers. In each row, the 
answer obtained the first time by that observer has been divided by the answer obtained 
the second time. The summary statistics describe the distribution of these ratios. Raw 
data in Appendix II.
The results are similar. Neither of us tends to get higher or lower results at the second 
sitting, and the standard deviations are very close. This measure of agreement is very 
similar to that seen when comparing the two of us (previous table), suggesting that the 
range of variation for a second estimate is about the same whether the analysis is 
repeated by the same observer or another (but I get a higher answer on average).
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Chapter 7: 
Discussion and Conclusions
These results provide evidence of only a very limited prognostic effect for tumour 
ploidy. There was an observed survival difference by univariate analysis of 3% at 10 
years of follow up, in favour of patients whose tumours were classified as diploid. 
This was not statistically significant, nor did it become so with multivariate analysis. 
This is in keeping with the previous studies presented in chapter 3, where there was an 
overall a trend toward better survival for patients with diploid tumours, which was 
statistically significant in only a minority of those reports. There are a number of 
technical reasons which may well act to limit the usefulness of ploidy data.
It must firstly be recognised that all tumours are aneuploid in the sense that cytogenetic 
analysis shows that they have both quantitative (Remvikos et al 1988) and qualitative 
(eg point mutations) chromosomal abnormalities. Flow cytometry is a less sensitive 
tool for measuring DNA content, and so there is a 'threshold' below which a tumour is 
not recognised as different from normal, because the difference in DNA content is not 
large enough to be recognised by the technique. This threshold is arbitrary, depending 
upon the quality of the nuclear suspension gained from a particular tumour, of the 
process of staining and running that suspension on the flow cytometer, and the 
characteristics of the cytometer itself. We can compare this series with others in this 
respect by looking at the overall proportion of tumours classified as diploid, since if 
the distribution of ploidies is the same in different series, then the higher the technical 
threshold, the higher will be the proportion of diploid tumours. The figure of 36% 
diploid tumours for the current population is comparable with the other series 
discussed (eg 36% Kallioniemi et al, 1988; 37% St&l et al, 1989; 43% Fisher et al, 
1991).
Another index of quality is the coefficient of variation (CV) for the ploidy histograms. 
The intrinsic CV of the Coulter Epics Profile II flow cytometer is of the order of 1.5% 
using calibration beads. The best histograms using paraffin embedded material achieve 
CVs within 1% of this figure. At the upper end, once peaks become too broad they run 
together and it becomes impossible to accurately interpret the histogram in terms of the 
ploidy of the sample. The arbitrary level taken as the upper level of acceptability was 
taken as 10% in this study, and only 3% of the original 293 histograms fell beyond 
this level. The median CV for the study population of 281 cases was 5.6%.
The ploidy of a tumour sample can only be established by comparison with cells with a 
known DNA content. When using fresh tissue, standards such as trout or chicken red 
blood cells are often added to nuclear suspensions. These have a DNA content of 80%
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and 33% of normal human DNA content, respectively, and so allow identification of 
the diploid Gq/Gj peak. Unfortunately the staining characteristics of formalin fixed, 
paraffin embedded tissue are not uniform, and appear to depend upon the original 
fixing and embedding conditions (Hedley et al, 1985). The stoichiometry of DNA 
staining is maintained, but the amount of dye bound by a given quantity of DNA is 
variable under these circumstances. As such, external standards which have not been 
fixed and embedded with the tissue are unhelpful for the type of sample used in this 
study. The assessment of ploidy in this situation relies instead upon the presence of a 
population of normal cells within the sample. These are present in all tumours, in the 
form of lymphocytes, fibroblasts, endothelial cells, fat cells, and in some cases non- 
tumour breast epithelium. These cells provide an internal standard against which to 
measure the DNA content of the tumour cells. If only one cell population in apparent in 
the histogram, then it is presumed that the two different populations must be overlying 
one another, that is that the tumour cells have the same DNA content as the non-tumour 
cells, indicating that the tumour is diploid. Where two or more populations are 
apparent, they are presumed to arise because the tumour cells have a different DNA 
content from the non-tumour cells, so that the tumour is aneuploid. In this situation it 
is not possible to definitively identify which of the populations represents the tumour 
cells, and which the non-tumour cells. Cytogenetic experience indicates that the 
majority of aneuploid tumours have a DNA content greater than that of normal cells, 
and so in this situation the peaks with higher DNA content are presumed to represent 
the tumour population. External standards overcome this problem when using fresh 
tissue as the starting material for flow cytometry, as the position of the diploid peaks 
can be inferred.
Some authors have sub-classified aneuploid tumours into up to five groups (figure 28):
a) hypodiploid;
b) those with DNA content between once and twice normal (the majority);
c) those with twice normal DNA content, where the Gq/Gj peak overlies the normal
population G2 /M peak, referred to as tetraploid;
d) those with more than one aneuploid population, referred to as polyploid or
multiploid; and
e) those with greater than twice diploid DNA content.
It has been proposed that tetraploid tumours may have a better, and polyploids a 
worse, prognosis than other aneuploid tumours. The incidence of polyploid tumours in 
the current series is so low (18/281, or 6%) that it is impossible to make any separate 
comment about them. The definition of a tetraploid tumour is problematic, because it 
overlies the diploid G2 /M peak, which itself may account for 10% of the events within 
the that population. If the population of tumour cells is small compared to that of non-
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Figure 28: Types of aneuploid histogram. The identifying letters 
correspond to the text descriptions.
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Figure 28a: Screen photographs of different types of aneuploid histograms, corresponding 
to those in figure 28. Above, classic hyperdiploid; below, tetraploid.
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Figure 28b: Screen photographs of different types of aneuploid histograms, corresponding 
to those in figure 28. Above, multiploid; below, hypertetraploid.
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tumour cells- the aneuploid population rarely accounts for more than 50% of total 
events in the histogram, and often substantially less, then the aneuploid Gq/G} peak 
may be no larger than this. Its corresponding G2/M peak will be even smaller, and 
more difficult to identify. In this situation, it is only possible to use an objective cutoff, 
and that which has been employed in this series is that any G2/M peak which accounts 
for more 15% of total events within the histogram indicates the presence of a tetraploid 
population at this position. Others have applied a cutoff of 10% of total events, and 
this will result in the classification of a higher proportion of histograms as tetraploid. 
Note that such histograms would be classified in the current series as diploid. There is 
a further problem as to just what range of DNA indices are to be regarded as tetraploid. 
Theoretically, the tetraploid tumour has a DNA index of 2.0. However, the vagaries of 
the preparation and running of the samples, referred to already, result in some variation 
from this figure for the index of G2/M peaks to their own Gq/Gj peaks. From the 
experience of analysing many histograms where the Gq/Gj and G2/M peaks of 
individual populations were clearly distinguished, the range of ratios was found to be 
from 1.85 - 2.10. This was taken as the range in which aneuploid peaks would be 
taken as tetraploid. Other reports do not so clearly indicate the criteria applied in the 
definition of tetraploid tumours. All o f the above would seem to render impracticable 
the reliable subclassification of aneuploid histograms, and no separate analysis of 
subtypes has been carried out.
The final technical problem in the analysis of ploidy is that of tumour heterogeneity. 
The assignment of tumour ploidy by the analysis of flow histograms assumes that the 
DNA content of tumour cells throughout the tumour is consistent, in that a single small 
sample is used in order to categorise the entire lesion. In fact, as with most tumour 
characteristics, this parameter does indeed vary from place to place within at least some 
tumours. Two papers in the literature report the analysis of more than one sample from 
the breast tumours. Fuhr et al (1991) analysed multiple samples from different areas of 
fresh breast cancer biopsies. They found that 14 of 74 aneuploid tumours (19%) 
produced at least one sample which was diploid. Curiously, the overall rate of 
aneuploidy in this report was only 52% (cf 64% for the current series), when one 
would have expected multiple sampling to have 'exposed' more aneuploid tumours. 
Kallioniemi (1988) looked at 1394 biopsies from a number of tumour types (breast 
cancer accounted for 37%). Two samples were processed, from fresh and paraffin- 
embedded material respectively. 10% of breast tumours were aneuploid in one sample 
and diploid in another, and in a further 10% of tumours the DNA index was different 
between samples, but both were still classified as aneuploid. It is possible that some or 
all of the variation in this study arose from a difference between the types of starting 
material (fresh vs paraffin-embedded), but the findings do concord with Fuhr's, and 
with those from other tumour types (Hiddeman et al, 1986; Ljungberg et al, 1985; 
Quirke et al, 1985; Vindel0v et al, 1980)
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Not only will variation between distant areas within the tumour be missed by the single 
sample approach, but variation within the small segment used for analysis may also be 
obscured. A small proportion of aneuploid tumours show more than one non-diploid 
population, and as noted in the previous paragraph, these are referred to as polyploid 
or multiploid. Here the presence of variation in DNA content within the sample is 
recognised, but if one population of tumour cells were aneuploid and another diploid 
then this variation within the sample would not be seen. It is also possible that very 
small aneuploid populations can be missed because they are obscured by background 
counts within the histogram. Thus variation in tumour DNA content both within and 
outside of the studied sample can be missed in flow cytometric analysis of tumour 
ploidy. This leaves the whole approach open to the criticism that the allocation of 
ploidy is arbitrary. In answer to this it must be realised that the majority of tumours are 
not heterogeneous in their ploidy, as indicated by the work of Fuhr and of Kallioniemi. 
In those which are heterogeneous, an alternative approach is that given a certain 
distribution of ploidies within a total tumour cell population, the probability of 
obtaining a sample of a given ploidy is related to the proportion of that population 
having that ploidy. That is, if in a given tumour 75% of tumours cells are aneuploid 
and 25% diploid, then these are the odds of obtaining a sample giving those two 
answers as to the tumour ploidy. The most likely ploidy to be assigned is that of the 
majority population, and this is one reasonable answer to the philosophical problem as 
to the ’appropriate' ploidy of a heterogeneous tumour. Other answers to this query are 
that the presence of any aneuploid population is adverse, or that the presence of 
variability itself is prognostically bad. If either of these hypotheses were true, then the 
flow cytometric approach applied to a single sample will not allocate the appropriate 
ploidy in some heterogeneous cases. Neither this study nor any other provide any 
information upon which to base an answer to this, and so the problem of heterogeneity 
must remain an open question in relationship to this type of investigation.
All o f the foregoing indicates that the assignation of tumour ploidy is not as 
straightforward as it first appears, and that in terms of prognostic information there are 
a number of circumstances in which a tumour could be assigned to the 'wrong' group 
on the basis of the type of data derived in this study. This may explain the apparent 
lack of prognostic information given by tumour ploidy in this analysis.
In respect of SPF, our results are compatible with the trend toward improved survival 
in the low SPF tumours found by most previous studies, with an observed survival 
advantage to this group of 5% at 10 years in DNA diploid tumours, and of 11% at that 
stage in DNA aneuploid tumours. That these results are not statistically significant may 
represent a type II statistical error. The extent of this potential error can be assessed 
from the broad confidence intervals for the relative hazards calculated for ploidy and
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SPF. The relatively low observed level of risk in high SPF tumours may also reflect 
our decision to divide SPF at the median rather than at a level chosen from the data as 
in other studies, a process which is open to criticism as stated previously.
The method of calculation of SPF is fundamentally different in diploid and aneuploid 
tumours, such that SPFs from tumours of different ploidy cannot really be compared. 
In a diploid tumour, the single population present in the ploidy histogram is a mixture 
of tumour and non-tumour cells, as already discussed. When the SPF of this 
population is measured, it reflects the SPF of both of these components. If we assume 
that the SPF of the non-tumour cells is lower than that of the tumour cells, then their 
admixture will lead to a falsely low estimate of the SPF of the tumour cells by this 
method, due to the dilutional effect of the non-tumour cells. In an aneuploid histogram, 
the tumour cell population is separate, and is analysed on its own. That is, the SPF of 
an aneuploid tumour is that of the tumour cells themselves, whereas the SPF of a 
diploid tumour is that of all the cells in the tumour. In some cases this difference could 
be overcome by measuring the SPF of both diploid and aneuploid components of an 
aneuploid histogram, and taking an appropriate weighted average of the two, in order 
to give an answer which approximates to that which would have been obtained if the 
tumour cell population had been diploid rather than aneuploid. However, in most 
aneuploid histograms the two populations overlap to a degree that precludes SPF 
calculation upon both, and furthermore, since it is the aneuploid histogram which gives 
us the purer measurement, it seems intrinsically undesirable to adulterate that answer 
for the sake of comparability alone. The dilutional effect of non-tumour cells upon the 
calculated SPF in diploid tumours creates an inbuilt tendency for diploid tumours to 
have a lower SPF than aneuploid tumours, if we accept that the non-tumour cells 
themselves have a lower rate of proliferation than the tumour cells (which is indeed the 
case in those histograms where both components can be separately analysed). This is 
the reason that the two tumour types cannot directly be compared. Few previous 
studies have attended to this problem, and most have analysed SPF of all tumours 
together. If this is done, the figure becomes not solely one of SPF, but a compound 
measure of ploidy and SPF. Whilst this may be a valuable variable, it must be 
recognised that it does not fairly assess the prognostic value of SPF itself. In this 
study, therefore, results are presented both separately for diploid and aneuploid 
tumours, as well as combined together.
The use of offline analysis packages for the calculation of SPF from ploidy histograms 
has technical limitations which result from the necessity of fitting a real histogram to a 
mathematical model. The source of the width of peaks within the histogram has already 
been considered- all nuclei of a given peak have exactly the same DNA content, but 
variability in dye binding and measurement of emitted fluorescence result in small
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apparent deviations from this figure. These variations should be random, and so the 
shape of the peak should be Gaussian, which is the universal assumption made within 
software analysis packages. On this basis, when the software searches for a peak it 
looks for its top, and then rather than following its actual outline down to the baseline, 
it extends the top down as a Gaussian curve. The assumption is then made that any 
deviation of the actual shape from the Gaussian is the result of other elements within 
the histogram, ie S phase cells. This is not necessarily so, as is apparent from the fact 
that the deviations occur on both sides of the peaks. This problem can be overcome by 
overriding the computer definition of the peak, and instead defining its full extent 
manually, which involves indicating between which channels the peak shall be taken to 
lie. Whilst this avoids the previous source of inaccuracy, it introduces an element of 
subjectivity which undermines the rationale for computer analysis that it is algorithmic 
and thus objective and repeatable. There is a further manner in which subjectivity 
enters into the analysis, which is in the subtraction of background counts from the 
histogram. These arise from any contamination of the nuclear sample, or from the 
presence of nuclear fragments. Such fragments are numerous in specimens prepared 
by the disaggregation of fixed tissue sections, where they arise by division of nuclei 
situated on the margins of the section. Since nuclei in the body of the section should 
not suffer in this way, the proportion of divided nuclei will diminish as the thickness 
of the section increases, and this is one of the ways in which the current protocol 
varies from Hedley's original, in that he used 30p sections whereas we and most 
others now use 50p thickness.
The process of background subtraction involves the identification of areas either side 
of the cell population itself, wherein all counts represent background. The pattern of 
background counts within the cell population channels is then inferred by mathematical 
extension of these areas, and these counts are then subtracted from each channel to 
leave the estimated 'true' count for that channel. The type of mathematical model used 
varies from programme to programme. The Cytologies software used here assumes an 
exponential falloff of background counts within the histogram from left to right. This 
is the simplest model, assuming that the smaller the nuclear fragment (which is what 
these spurious counts are assumed to represent), the more likely it is to occur. More 
sophisticated background subtraction algorithms, which allow for the presence of 
sliced nuclei and clumps, and take account of the frequency distribution of nuclear 
sizes within the histogram, are not implemented by this software. The estimate of 
background is very sensitive to the areas used for definition, with variations of only a 
single channel markedly affecting the outcome. It is up to the operator to assess the 
accuracy of fit of the background counts, and further subjectivity is thus introduced.
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Once the peaks and background counts have been defined, the computer measures the 
number of counts in the remaining S phase compartment, and expresses this as a 
proportion of total counts within the cell population under study. The problem of 
which mathematical model of the shape of S phase to use was referred to in the 
methods section of this chapter. These models are based upon different assumptions as 
to the distribution of cells throughout the cell cycle. The previous literature has 
established the rectangular model of Baisch as the norm, and and we have also found 
this this to be the most consistent model.
Overlap between the tumour and non-tumour cell populations in an aneuploid 
histogram may further complicate S phase analysis, and is a major problem in the 
analysis of this, the most common pattern of histogram. An illustrative example is 
shown in figure 29. Given the most frequent DNA index of 1.5 - 1.7, the G2/M peak 
of the non-tumour cells lies over the S phase of the tumour cell population. The 
software allows for the identification and subtraction of confounding peaks, although 
this involves yet further operator intervention with its reduction in objectivity, but the 
rectangular model requires the identification of a flat segment of S phase between each 
pair of peaks (if there is a confounding peak, S phase is divided into two components 
by the software). If the peaks are too close, then no flat segment of S phase can be 
distinguished between them, and so one of the components of S phase is simply not 
estimated. In this type of histogram the size of S phase will be underestimated with 
respect to other aneuploid tumours. Whatever model is being used, the complexity 
created by the overlap of two separate S phases, along with the intrusion of peaks into 
each, makes this a more demanding exercise for the fitting program.
In view of these technical and theoretical problems, the findings with regard to 
reproducibility are not surprising. The good correlation of repeated estimations does 
suggest that in general, taking a group of tumours, most will be assigned to the same 
part of the range of SPF each time. We can explore this using my own two series of 
estimations using the rectangular method upon 119 histograms. Values were assigned 
both times for 80 tumours. If tumours were assigned simply into those above or below 
the median value, then 5 out of the 80 (6%) would have changed group depending 
upon which series of estimates was used. If tumours were divided into three groups 
based on the tertiles of the two series, then 13 tumours (16%) would have changed 
group. That this attempt starts to break down with even such a blunt classification as 
low, medium or high SPF is a consequence of the finding that the actual value of SPF 
is subject to large variation in individual tumours, such that the 95% confidence 
interval for a single estimate is of the order of ±40%. How we assess the usefulness of 
SPF as a prognostic indicator, or as a parameter of tumour biology, depends upon the 
situation. If we are considering a series of tumours, as here, then it is a tool capable of 
dividing them into broad categories of proliferation. But in the context of trying to
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Figure 29: Printout of actual analysis of an aneuploid histogram by the Multicycle package. 
Both G0/G1 peaks are stippled (the aneuploid peak is the right hand one . Note that the y 
axis scale has been expanded so that the top of these peaks is lost, in order to 
t demonstrate the S phase); the aneuploid G2/M peak has vertical bars; the diploid G2/M
4 peak is in the middle of the aneuploid S phase, which has oblique bars; background
counts are shown with horizontal shading. This well demonstrates the complexity of the 
modelling used to separate out the aneuploid S phase.
Chapter 7 99
apply this to the individual case, the degree of uncertainty about a single measurement 
makes this an unsatisfactory method.
The artificial constraints imposed by the use of analysis software have led one group to 
eschew their use entirely (O'Reilly et al, 1990). These workers use a very simple 
manual method of calculation, drawing a rectangular S phase component between the 
means of the Gq/Gj and G2 /M peaks at what they assess to be the height of the 
compartment. The number of counts within S phase is then readily calculated as the 
height of the box multiplied by the number o f  channels between the two peak means. 
Although this seems very subjective, it has been clearly demonstrated above that the 
supposedly objective method of algorithmic analysis is anything but, and is 
furthermore hampered by its inability to assess the histogram in other than 
mathematical terms. In support of this, the method is very reproducible in their hands.
The S phase fraction may be expected to show the same heterogeneity as tumour 
ploidy. There has been no published experimental work on this topic, but given the 
known information about the heterogeneity of tumour ploidy presented above, the 
assumption seems reasonable, and poses a corresponding problem- what is the 'true' 
value of SPF. The possible answers are the same, and there is likewise no way of 
resolving the matter. All of the foregoing make it no great surprise that tumour ploidy 
and SPF have provided only limited prognostic information despite the fact that they 
represent fundamental aspects of tumour biology.
PART III
in vivo ADMINISTRATION
OF
BROMODEOXYURIDINE
IN
HUMAN BREAST CANCER
1 0 1
Overview of Bromodeoxyuridine Studies
This second experimental part of the thesis takes cognizance of the largely negative 
results from the last part, and asks: can we improve upon this with the use of in vivo 
labelling with bromodeoxyuridine? This has been addressed by studying an ongoing 
series of patients, 91 at the time of production of this manuscript. The layout of this 
Part is similar to the previous one. I begin by describing the patients we have recruited, 
the means by which they were labelled, and the specimens obtained from their 
tumours. Once again the most detailed sections deal with the protocols for preparation 
of samples for flow cytometry, and the way in which the cytometer was set up and 
used to analyze them. Histogram interpretation is also examined in depth, following on 
from the theoretical discussion of this subject in section i of chapter 4.
The results chapter is somewhat different in style from the corresponding chapter in 
Part II, reflecting the more developmental nature of the bromodeoxyuridine-based 
technique. More basic questions about the parameters measured are examined first: are 
the dynamic data independent of the static component; is the length of time between 
patient labelling and biopsy critical; can the flow cytometric counts be validated by 
reference to tissue sections; and what is the relationship between the kinetics of breast 
cancer and those of normal breast and of other tumours? Since follow-up is still too 
short for prognostic information to have emerged, this question is approached instead 
by looking at the relationships between the kinetic data and existing pathological 
factors known to predict outcome. As in the previous part, there is an examination of 
the reproducibility of the methodology. We then look beyond the simple area of 
prognosis, to examine the biological significance of kinetic measurements by their 
correlation with tumour ploidy and with expression of oestrogen receptors, c-erbB-2, 
and EGFR. In the case of the last, a relatively novel, quantitative immunohistochemical 
method has been used. In view of the need to describe this in greater detail, a separate 
chapter is devoted to this comparison.
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Chapter 8: 
Patients and Methods
Section i: Patients Studied
Patients were selected from among those being treated on the academic surgical unit of 
the Glasgow Royal Infirmary (GRI) and under the care of Mr D Smith at the Victoria 
Infirmary (VI). All stages of disease were considered, including patients with known 
distant metastatic disease at the time of surgery. Only postmenopausal patients and 
those who had previously had a hysterectomy were entered, in view of the unknown 
embryotoxicity of bromodeoxyuridine. Other selection criteria were that a firm 
cytological or histological diagnosis was available preoperatively (so that 
bromodeoxyuridine was not administered to women who turned out not to have breast 
cancer), and that the tumour was clinically of such a size that adequate tissue seemed 
likely to be available for analysis once diagnostic needs had been met (about 2cm 
diameter). Because o f these constraints, the labelled population is not representative of 
the total population of breast cancers treated in the two units.
Patients who fulfilled these criteria were asked to give written informed consent to 
taking part in this study. Only about 5% of interviewed patients refused consent. 
Approval for the project was given by the Ethical Committees of the Eastern (covering 
GRI) and Southern Units (VI) of the Greater Glasgow Health Board. The way in 
which the patient was treated formed no part of this study, and was entirely at the 
discretion of the surgeons involved. Patients having breast conservation or mastectomy 
were included, as were those having adjuvant radiotherapy or chemotherapy.
Section ii: Bromodeoxyuridine Labelling
Bromodeoxyuridine from two sources was used in the course of this study. Initially, a 
commercial product provided in 200 mg ampoules by Takeda Chemical Company was 
purchased. When this ceased to be made, pharmaceutical grade bromodeoxy-uridine 
was packaged by the CRC Drug Formulation Unit at the University of Strathclyde 
specifically for CRC funded research. The ampoule size for this product was 250mg. 
Bromodeoxyuridine was administered in one of two ways, depending upon the time of 
day at which the patient was scheduled to have their operation. Where possible, the co­
operation of clinicians was gained such that operations were performed in the middle 
of the day. If this was the case, bromodeoxyuridine was given as an IV bolus in the 
morning. This was made up by the addition of 10ml of normal saline to the ampoule. 
Either the entire solution (Takeda product) or 8ml of it (Strathclyde product) were 
drawn up and administered, noting the time at which this was done.
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In the case of patients being operated on early in the morning, an alternative method of 
administration was used. Once again 200 mg of bromodeoxyuridine was drawn up, 
but diluted to 25ml with saline in a 50ml syringe. This was done the evening before 
operation, and the syringe labelled and stored in the ward refrigerator. An IV line was 
established before the patient retired for the night. The order for the administration of 
the bromodeoxyuridine was placed on the IV fluid chart, and at the indicated time the 
syringe was sidelined through the infusion by agency of a Vickers infusion pump at 
maximum rate (lOOml/hr). This resulted in administration of the bromodeoxyuridine as 
an infusion over 15 minutes. This was timed to be done roughly 4 hours before the 
anticipated time of biopsy.
Section iii: Specimen Collection
In nearly all cases I attended the operations upon these patients when performed in the 
Royal Infirmary, in which case I received the operative specimen directly, and 
transected the tumour. A 5mm thick section off the face of the tumour was removed 
and placed into 70% ethanol as fixative. If the tumour was large enough, a further 
specimen was taken and placed into liquid nitrogen. For cases at the Victoria 
Infirmary, one pathologist (Dr Morag McCallum) agreed to receive all labelled 
specimens, and removed a sample into 70% ethanol from them. All alcohol fixed 
biopsies were stored at 4°C pending subsequent analysis.
Section iv: Patients and Tumour Data Noted
The following details were noted on a proforma at the time of bromodeoxyuridine 
labelling - unit record number 
-age
- menopausal status
Subsequent course was followed by casenote review at intervals, noting the following:
- pathology department number
- type of operation, mastectomy or breast conserving
- macroscopic tumour size (maximal diameter) as recorded by the reporting
pathologist. For the purposes of analysis, this was coded in accord with the 
TNM classification as T l-  tumour less than or equal to 20mm in diameter, T2- 
tumour greater than 20mm but no more than 50mm in diameter, T3- tumour 
greater than 50mm in diameter. There were no T4 tumours in this study.
- involvement of ipsilateral axillary lymph nodes (number of involved/number of
uninvolved nodes) as determined histologically by the reporting pathologist. For 
the purposes of analysis, this was coded as NO- no nodes involved, N l- one or 
more involved nodes, NX- no nodes available to pathologist.
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- oestrogen receptor status (fmol/mg protein, dextran coated charcoal technique),
where tumour was sent for this assay by the pathologist. For the purposes of 
analysis this was treated as a binary variable with a cut off of 5 fmol/mg protein.
- adjuvant therapy given, if any
- clinical course, including results of investigations
Section v: Specimen Preparation
This was done by using an adaptation of the Hedley method for ploidy studies upon 
paraffin embedded tissues described in the previous chapter. This adaptation was 
developed in the laboratories of the Departments of Surgery at the Royal Liverpool 
Hospital and then the Glasgow Royal Infirmary by Ms G Forster.
After at least 24 hours fixation in 70% ethanol at 4°C, segments from the tumour 
biopsies were paraffin embedded, and a 50p. section taken and dewaxed in the same 
way as for the ploidy studies in the previous chapter. A  consecutive 5p, section was 
taken for H&E histology to confirm the presence of tumour in the section being used 
for cell kinetic studies. All histological material was reviewed with Dr J Going, Senior 
Lecturer in the Department of Pathology at the Royal Infirmary.
The subsequent treatment of the specimens is as follows:
- place dewaxed sections in 5ml plastic test tubes
- disaggregate the sections by addition of 1ml of 0.5% pepsin in water brought to
pH 1.5 with 2M HC1. Incubate the tubes in a water bath at 37°C for 30min.
- centrifuge for 5min at 2000rpm (all subsequent spins were the same)
- using a glass Pasteur pipette, pipette off and discard supernatant
- wash off remaining pepsin by adding 1ml PBS, pH 7.4 (made up from Sigma
tablets)
- centrifuge and remove supernatant
- resuspend with 1ml PBS
- aspirate and expel sample 3 times using a 1ml syringe and a 26g hypodermic
needle. This provides mechanical disaggregation.
- push into a fresh tube through a 50p, nylon mesh, thereby removing any large
aggregates remaining in the suspension. The surviving sample consists of 
mostly intact nuclei, as well as small membrane and cytoplasmic fragments.
- centrifuge and remove supernatant
- add 1ml of 2M HC1 whilst rotamixing, and leave for 30min at room temperature.
This partially denatures the nuclear DNA in order to expose the contained 
bromodeoxyuridine to the monoclonal antibody used to detect it.
- centrifuge and remove supernatant
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- neutralise remaining acid with 1ml of 0.1 M Borax at pH 8.5 for 5min at room
temperature
- centrifuge and remove supernatant
- wash by addition of 1ml of PBS
- centrifuge and remove supernatant
- wash again, with 1ml of PBS with 0.5% bovine serum albumin (Sigma, to block
non-specific antibody binding) and 0.05% Tween 20 (Sigma, a detergent to 
permeabilise the nuclear membrane). This solution will be referred to as PBT.
- centrifuge and remove supernatant
- add lOOp.1 of a 1/30 dilution in PBT of anti-BUDR antibody (Dako, mouse
monoclonal IgGl). Rotamix gently and incubate at room temperature for lhr.
- add 1ml PBS
- centrifuge and remove supernatant
- add 1ml PBS, centrifuge and remove supernatant; repeat
- detect anti-BUDR by addition of 100pl of rabbit anti-mouse IgG conjugated with
FITC (Dako), diluted 1/40 with PBT, and incubate for 30min at room temp.
- add 1ml PBS
- centrifuge and remove supernatant
- add 1ml PBT
- centrifuge and remove supernatant
- add 1ml PBS
- stain total DNA by adding lOjxl of lOmg/ml prqpridium iodide (PI, Sigma), giving
a final concentration of lOOpg/ml PI.
- incubate for 30min at room temperature
- centrifuge and remove supernatant
- add 1ml of PBS. The sample is now ready for flow cytometry 
This is summarised in the flow chart below:
50^
Section
-Section
Figure 30: Flow chart summarising 
treatment of tissue blocks.
H & E Stain
Rehydrate
Disaggregate
Denature DNA
Flow Cytometry
Stain with 
Propridium
Stain with anti-BUDR Ab
Paraffin Block
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The procedure was often carried out over 2 days, the samples being stored over-night 
after the pepsin was washed off. The first day consisted of dewaxing and 
disaggregation of the specimens, and the second of their staining. The final samples 
were also often stored at 4°C overnight before being run on the cytometer. It was in 
fact observed that after they were run the samples could be stored at 4°C for at least a 
week and rerun with the same results.
Section vi: Flow Cvtometrv
The cytometer was set up as for the ploidy studies. The filter set up was described in 
the last chapter, where it was noted that filter d (in figure 14) was not necessary for 
that study. In the current investigation, this dichroic mirror separates the green 
(fluorescein isothiocyanate, that is BUDR) fluorescence, which being of shorter 
wavelength is reflected by the mirror, from the red (propridium iodide, that is total 
DNA content) fluorescence, which passes the mirror. Green fluorescence is then 
collected in FL3, through a 525nm band pass filter (filter f  in figure 14), and red 
fluorescence in FL2 through a 635nm band pass filter. The propridium iodide signal is 
much the stronger, but the strongly positive FITC positive cells do make a small 
contribution to the measured signal in FL2. Because of the strength of the PI signal, 
even the lower limit of its emission spectrum provides enough emitted light to add 
noticeably to the signal in FL3. This has the effect of adding apparent strength to the 
BUDR signal as the PI signal increases- that is, nuclei with high DNA content show a 
spuriously higher BUDR content, and so may be counted as positive when they are 
not. This is dealt with by the cytometer by what is termed colour compensation, 
whereby a percentage of the signal from one channel is subtracted from that registered 
in another. The machine allows each of the six potential crossovers between the 3 
fluorescence channels to be dealt with. In this case, the crossover from red to green 
channels can be negated by subtraction of 2-5% of the FL2 (red) signal from the FL3 
(green) signal. The amount of FL3 - FL2 colour compensation was individually set for 
each sample. FL2 - FL3 compensation of 1 or 2% was normally adequate to prevent 
strongly FTTC positive cells from showing a spuriously high DNA content.
The amount of compensation required on any given day was largely determined by the 
sensitivity of the photomultiplier tubes (PMTs), which is determined by the voltages 
supplied to them. These voltages were set to be appropriate for the first run of the day. 
The voltage for FL3 was rarely altered for the rest of that day's specimens. That for 
FL2 was often altered in order to position the ploidy histogram optimally. The ploidy 
histogram was positioned so that the population of interest (that is, that upon which 
calculation was to be carried out, the one containing the tumour cells) was as far to the 
right in the histogram as possible. This was done so that it occupied the maximum 
number of channels, thereby increasing the statistical accuracy of the positional
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measurement which underlies the estimation of relative movement. In some cases a 
change in the PMT voltage for FL2 carried out to achieve this was large enough to 
significantly alter the crosstalk into FL3, such that a change in colour compensation 
was required. The FL3 PMT voltage was set at the highest level at which the bulk of 
negative nuclei continued to register as having a zero fluorescence, unless this resulted 
in positive nuclei giving a reading at the very top of the scale, in which case a lower 
voltage was used to ensure that no positive nuclei were lost off the top of the 
histogram. Even so, there is a very large difference in the signal from positive and 
negative nuclei such that to encompass them both on the same axes, log amplification 
of the FL3 output was used. This provides progressively less amplification the 
stronger is the original signal, so that a single histogram axis can encompass a range of 
values covering about 3 orders of magnitude. Using the linear amplification used for 
instance for red fluorescence, only 1 order of magnitude is covered.
Events were collected at 200 counts per second if possible, by manipulation of the 
sample flow rate. If the final nuclear suspension was too concentrated for this to be 
achieved at minimum flow rate (10pl/sec), then the sample was diluted with further 
PBS. If the suspension was too dilute, then it was centrifuged and resuspended in a 
lower volume. The minimum volume used was 0.5ml, but even in this volume some 
samples gave lower counting rates than the desired 200/sec at the maximal flow rate of 
200pl/sec. Such samples were counted at the maximal achievable rate.
At least 50,000 nuclei were counted if possible, although this total was not achieved in 
dilute samples. In concentrated samples, counting was allowed to continue until 
terminated by the cytometer, which has an inbuilt limit to the number of counts 
accumulated in any one channel of any histogram. The bulk of events were recorded in 
the zero channel of the green (BUDR) fluorescence, and so the machine automatically 
cut out in most cases at about 70,000 events. Such a sample size is obviously well 
above what is required to give a reliable estimate of the ploidy, S phase fraction or 
proportion of BUDR labelled cells in the suspension. The process which may require 
this number of nuclei counted is the measurement of the relative movement of the 
BUDR labelled cells, since here the sample size is that of the labelled undivided cells. 
If we consider a sample of 50,000 nuclei with a labelling index of 1%, then only 500 
nuclei will be BUDR labelled. If one third of the labelled cells have moved into Gq/G^ 
between labelling and biopsy, then the eventual sample for the estimation of RM is 
333. In order to gain a statistically adequate sample, a lower limit of 100 BUDR 
labelled, undivided cells was set, and if at all possible, 200 such events were 
accumulated by running a second, double specimen (ie two sections were 
disaggregated and stained together).
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The following histograms were created at the time, in order to allow calculation of 
labelling index and relative movement from the machine printout without offline 
analysis:
a) Peak vs Total Red Fluorescence
As with the ploidy study, this histogram was used to select the desired cell 
population(s) for further analysis, and to carry out doublet discrimination and exclude 
some debris at the lower end the histogram.
b) Red vs Green Fluorescence
This is the main analysis histogram for the determination of cell kinetics. DNA content 
(red fluorescence) is represented on the x axis and BUDR content (green fluorescence) 
on the y axis
c) Red Fluorescence vs Number of Counts
This is a ploidy histogram, as used in the investigation described in the previous 
chapter. It is used firstly to clearly demonstrate the tumour ploidy (although with 
experience it is nearly always possible to do this from either of the above histograms), 
secondly to set more accurately the areas of interest in histogram b by defining the 
extent of the various peaks, and thirdly for offline analysis of S phase fraction as 
described in Part n .
d) Green Fluorescence vs Number of Counts
This histogram portrays the range of values of BUDR content, which is essentially 
bimodal, with negative cells set to be very close to zero, and positive nuclei in the 
upper half of the histogram even with log amplification which is applied to this signal. 
This demonstrates that this separation has been achieved, and as with histogram c 
allows accurate determination of the optimal position for setting boundaries between 
different areas of interest in histogram b.
Section vii: Data Storage
Both histogram and list mode data were stored on floppy disc for offline analysis. Due 
to a bug in the system software of the cytometer, only about 25% of the full data list 
was transferred to disc in each case.
Section viii: Determination of Cell Kinetic Parameters
In order to determine the bromodeoxyuridine labelling index and the relative movement 
of the labelled cells, three sub-populations of cells within the total tumour cell 
population must be identified and characterised- firstly the cells which are not labelled 
with bromodeoxyuridine, secondly those which are labelled and have not divided since
Chapter 8 109
labelling (that is, those which are still in S, G2 or M phase), and thirdly those cells 
which are labelled with bromodeoxyuridine and have divided since prior to biopsy 
(those now in Gq or Gx phase). With the system software of the cytometer, this is 
done by drawing rectangular areas of interest (boxes) onto the two parameter plot of 
red versus green fluorescence (histogram b in section vi). These areas are used to 
encompass the three groups of cells described above, as shown in figure 31. The 
software indicates the number o f events in each box and the mean position of those 
events on each of the axes.
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Figure 31: Example of two-parameter histogram, showing analysis boxes. Box 1 
includes cells not labelled with BUDR, with concentrations of cells representing 
G0/G1 (left) and G2/M (right) peaks. Box 2 encompasses labelled cells which have 
divided, and Box 3 labelled undivided cells. An actual example is shown in figure 32.
To work out the kinetic parameters by the method of Begg et al (1985), let us call the 
number of events in boxes 1-3 in the figure N l, N2 and N3 respectively. Because each 
of the cells in box 2 has divided into two since taking up the bromodeoxy-uridine, to 
calculate the number of cells which were in S phase at the time of labelling we must 
count each of these cells as only one half. Thus the labelling index is the number of 
labelled undivided cells (box 3) plus half of the labelled divided cells (box 2), divided 
by the total number of cells, or:
LI = [N3 + (N 2/2)] /  [N l + (N 2/2) + N3]
The mean position on the x axis of the events contained in box 3 will be seen to be the 
quantity referred to in the derivation of equation 10 (Chapter 4) as FL. The values Fqi 
and Fq 2  from that equation can be gained from histogram c, by putting cursors across
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Figure 32: Screen photograph of two parameter histogram for analysis of dynamic cell kinetics 
as simplified in figure 31 for illustrative purposes. Ploidy histogram for this tumour above.
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the respective peaks and thereby obtaining the mean channel number for the peak in 
each case (in transferring this result to a calculation made in histogram b, it is 
necessary to divide the obtained values by 4, as histogram c has 256 channels whereas 
histogram b has only 64 on the x axis). All of the terms required for the calculation of 
RM are now available, and so given the time between labelling and biopsy it is 
possible to obtain the estimated value of Ts from equation 11 (Chapter 4). Tpot can 
then be arrived at given the values of LI and Ts, making the assumption as to the value 
of lambda already discussed.
To estimate Tpot by the method of White et al requires the fractions of labelled divided 
and labelled undivided cells (f^ and f*u in equation 12), which are given by N2 and 
N3 as proportions of the total number of cells respectively. Ts is calculated in the same 
way as for Begg's method, n from equation 12 and Tpot from these two (equation 9).
The degree to which these calculations reflect the theory outlined in the introduction 
depends upon the accurate delineation of subpopulations by the boxes drawn onto the 
histogram. To place these requires answering two questions- firstly in which channels 
do the Gq/G! and G2 /M peaks start and finish, and secondly where is the cut off 
between unlabelled and labelled cells? Question 1 is answered by referring to the 
ploidy histogram (histogram c), on which areas of interest are defined by cursors. 
These take the form of horizontal bars with upright cross bars at either end, placed 
over the relevant peaks with the cross bars in the channels felt to represent the limits of 
the each peak (figure 33). The numbers of these channels are then given by the system 
software of the cytometer, and these can be transferred to histogram b by dividing by 
four as previously mentioned. The left hand edge of boxes 1 & 2 is the lower channel 
of the Gq/Gx peak, the junction between boxes 2 & 3 is the upper channel of that peak, 
and the right hand edge of boxes 1 & 3 is the upper channel of the G2 /M peak.
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Figure 33: Method for delineating peaks in one-parameter histograms, showing 
placement of cursors from lower to upper channels of each peak.
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The second question is answered by referring to histogram d, identifying there the 
nadir between the unlabelled cells (which take the form of a descending exponential 
curve from the left hand margin) and the labelled cells (which should constitute a 
distinct peak to the right of this, figure 34). The channel number is identified by 
placing a cursor, and can be transferred without correction to the y axis of histogram b. 
This defines the upper limit of box 1 and the lower limit of boxes 2 & 3.
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Figure 34: Example of a single parameter histogram of BUDR 
content, indicating the position of labelled and unlabelled cells.
The above calculations are demonstrated upon a diploid histogram. The situation in 
analysing an aneuploid histogram is complicated by overlap between the diploid and 
aneuploid populations. The usual situation is that the diploid G2 /M peak lies in the first 
half of the S phase of the aneuploid population. The number of diploid cells in late S 
phase and the G2 /M peak is usually small compared to the total aneuploid population, 
and as such should have little effect upon the calculated labelling index even if they 
were ignored. This is not necessarily the case with the estimation of relative 
movement, as the number of cells upon which this is based can be quite small as 
already discussed. Even a small number of labelled diploid G2 /M cells lying in the 
lower reaches of the aneuploid S phase may markedly drag down the mean channel 
number of the cells in box 3, the more especially because they most often lie well 
toward the left hand size of the box.
In some histograms, the cohort of labelled diploid G2/M cells is quite distinct from the 
labelled aneuploid cells (the divided cells to its left in the histogram, the undivided cells 
to its right). This occurs where the time between labelling and biopsy is long enough 
that the labelled cells have had sufficient time to move out of the early part of S phase, 
but not so long that the divided cells have yet entered a new S phase. The situation is 
not so unlikely as it may sound, and if so it is possible to exclude the labelled diploid
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G 2/M  cells by leaving box 3 's h o r t ' on its left hand side, so that there is a gap  betw een  
the two, the diploid cells lying in this gap (figure 35). N ote that there rem ain labelled 
diploid S phase cells adm ixed w ith the aneuploid G q/G 1 peak, and no attem pt has been 
m ade to exclude the unlabelled diploid cells w hich overlap, in both cases because the 
cells involved are not distinct from the aneuploid com ponent. T he process ju s t 
described is thus only a partial correction  for this problem , but does probably  deal w ith  
the area w here  the overlap  causes greatest error. It is not possible w here  the labelled 
diploid cells are not distinct in the histogram , in w hich case any attem pt to exc lude 
them  w ould  inevitably also leave out the labelled aneuploid cells in low er S phase and 
bias the estim ate o f  relative m ovem ent to the right.
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Figure 35: Example of two-parameter histogram in an aneuploid tumour, 
showing placement of analysis boxes so as to exclude labelled diploid G2/M 
cells. The ploidy histogram for this tumour is overlaid at the top to aid in 
interpretation. Peaks identified in both components are a) diploid G0/G1, b) 
aneuploid G0/G1, c) diploid G2/M, d) aneuploid G2/M.
It is im plied in the above discussion that in an aneuploid tum our the population  o f  
tum our cells can be distinguished from the population o f  norm al cells to at least som e 
degree. T his is obviously  im possible in a diploid tum our, w here the tw o popu lations 
overlie  each other. T he im plications for cell kinetie m easurem ents w ere  discussed in
a b c d
DNA Content
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Figure 35a: Screen photograph of a two parameter histogram for analysis of dynamic cell 
kinetics in an aneuploid tumour, using the method demonstrated in figure 35 for excluding 
labelled cells in the diploid G2/M population. Ploidy histogram for this tumour above.
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the previous chapter. An attempt has been made in this study to level this playing field 
by defining the total labelling index (TLI). The TLI is an attempt to make LI 
measurements comparable for aneuploid and diploid tumours by 'handicapping' 
aneuploid tumours. To make the measurement, aH labelled cells in the histogram are 
taken as a proportion of ah cells (labelled or unlabelled). Thus aneuploid tumours are 
'watered down' in the same way as diploid ones are normally. No correction is made 
for the fact that cells in Gj must have arisen by division since the time of taking up 
bromodeoxyuridine, and their numbers thus halved, as is done in calculating the 
normal LI. Thus the TLI for a diploid tumour (Gj population not halved) will be 
slightly higher than normal LI (G! population halved). Given that the LI of the normal 
cells is presumptively lower than that of the tumour cells, the TLI of an aneuploid 
tumour should be substantially lower than the normal LI.
Section ix: Other Data
a) Immunohistochemical Counts o f Labelling
50 of the tumours within the series were counted manually on histological sections 
after immunohistochemical staining for bromodeoxyuridine by Dr James Going, 
Senior Lecturer and Honorary Consultant, Department of Pathology, Glasgow Royal 
Infirmary, in order to determine the labelling index in the tumour. Whilst time 
consuming and unable to provide information as to the rate of cell cycle transit, such 
immunohistological study has the advantage that tumour cells can be identified by their 
cytological and histological characteristics. By contrast, with flow cytometry even in 
an aneuploid tumour it is rarely possible to analyse the tumour cells in total isolation 
from overlapping normal cells, and in a diploid tumour the two become 
indistinguishable. The two methods are important adjuncts to one another in 
determining cell cycle kinetics with bromodeoxyuridine, and the immunohistological 
labelling indices provide a valuable quality control for the flow cytometry.
3-4mm specimens for immunohistochemistry were fixed overnight in 10% neutral 
buffered formalin, and processed for paraffin histology. 4p sections were immuno- 
stained for bromodeoxyuridine by an ABC method. The primary anti-bromodeoxy- 
uridine antibody (Becton-Dickinson) was diluted 1:20 and applied after acid hydrolysis 
with 0.7M HC1 for 1 hour at room temperature, followed by trypsin digestion for 1 
hour.
Counting was performed on random fields selected with an 'England' field-finding 
stage graticule. The only field exclusion criterion was the absence of viable tumour 
cells. Labelled and total tumour cell counts were recorded for every field, with the help 
of a lOxlO-square eyepiece graticule. Successive fields were used until a minimum of 
2000 cells had been counted.
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b) Expression of c-erbB-2
4p sections from the alcohol-fixed, paraffin-embedded blocks used for kinetic studies 
were stained immunohistochemically by Ms S Oakes to determine expression of c- 
erbB-2. The 21N anti-peptide polyclonal antibody developed and supplied by Dr W 
Gullick at the Imperial Cancer Research Fund laboratories was used at a concentration 
of 2pg/ml as the primary antibody. Endogenous peroxidase was blocked by prior 
incubation with hydrogen peroxide/tris buffered saline, and non-specific binding 
reduced by use of normal swine and human serum. Antibody binding was 
demonstrated by incubation with biotinylated secondary antibody (swine anti-rabbit), 
followed by streptavidin-horseradish peroxidase developed with diaminobenzidine. 
Control sections for every tumour were run with non-immune rabbit serum as primary 
antibody, and previously established positive and negative controls were included with 
each batch.
Stained sections were assessed by two observers (Ms Oakes and Dr Going), and 
regarded as positive for expression of c-erbB-2 if any groups of membrane stained 
tumour cells were present. Cytoplasmic staining alone was classified as negative. In 
any cases of dubiety, repeat sections were stained and scored.
Section x: Statistical Methods
As with SPF in the previous section, the distributions of the kinetics parameters were 
not normal, and so non-parametric statistics have been used throughout this section. 
Distributions are described by median and range (or interquartile range), and inter­
group comparisons are made with the Mann-Whitney or Kruskall-Wallis methods as 
appropriate. Labelling index and length of S phase were correlated using the Spearman 
rank method. Ploidy variations between groups were analysed using the chi-square 
statistic, and comparisons of like with supposed like were performed with the Bland- 
Altmann approach, generally using ratios. For a detailed description of this technique, 
see the methods section of the previous chapter.
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Chapter 9:
Results
Section i: Patient Characteristics
88 patients with 91 tumours were given bromodeoxyuridine between October 1989 
and October 1992, 80 at the Royal Infirmary and 11 at the Victoria Infirmary. 
Specimens for determination of kinetic parameters were obtained in all but two of these 
tumours. In a further two cases, no invasive tumour was present in the specimen, as 
determined by examination of H&E sections. In three other tumours, no cell kinetic 
data could be gained by analysis of the specimen, as explained in the next section. The 
age, menopausal status, pathological tumour and nodal stage, and oestrogen receptor 
status of the remaining 81 patients and 84 tumours, who constitute the study 
population for this investigation, are given in Appendix HI.
Summaries of each of these prognostic variables are given in table 23. The high 
median age of the patients is a result of the deliberate selection of postmenopausal 
women for this study. (Estrogen receptor status is unfortunately available for only a 
minority of cases, due to a change in the arrangements for carrying out this assay 
within the hospitals involved over the period of the study.
Variable n Subgroups
Nodal Status 52 NO 31
N1 21
Tumour Size 57 T1 22
T2 25
T3 10
Hist. Grade 68 Gl 13
Gil 23
Gill 32
ER Status 28 pos 16
neg 12
Age 77 mean 62 years
range 36-90 years
Table 23: Summary of prognostic factors. Column 2 gives the total number of patients 
for which information about the variable is available. Raw data in Appendix III
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Section ii: Basic Cell Kinetic Data
O f the 87 tum ours from  w hich specim ens for flow cytom etry  w ere obtained, 3 
repeatedly failed to give adequate num bers o f  cells from  disaggregation  for h istogram s 
to be built. N o kinetic data could be ascertained from  these specim ens. T he o ther 84 
sam ples could at least be used for the calculation o f the labelling index, w hich requires 
only the separation o f  nuclei positive for BU D R  from  the rem ainder. If T s (and so 
T pot) are to be determ ined, then the population o f  labelled undivided cells m ust be large 
enough and clearly enough defined to be reliably distinguished in the histogram . T his 
involves an ob jective criterion (num ber o f  such cells), but also a subjective assessm ent 
o f  the quality o f  the 2 param eter histogram . T he distribution o f  the num ber o f  labelled 
undivided cells in each case is show n in figure 36, w ith 2 cases falling below  the 
cu to ff  at 100 cells. T he m edian num ber o f  labelled undivided cells counted  w as 501.
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Figure 36: Frequency distribution of the number of labelled undivided cells in 
the 84 cases interpretable for labelling index. Column labels are midpoints, 
that is, 50 means 1-100 cells. Raw data in Appendix III.
A  further 15 cases w ere regarded as being unsuitable for in terpretation o f  T s, e ither 
because the population o f  labelled undivided cells w as indistinct, or because the 
tum our w as polyploid in w hich case m ultiple such populations are present and 
overlapped. From the original 91 cases given BU D R, this leaves 67 in w hich full 
kinetic data w ere determ ined. A  breakdow n o f  the reasons for loss o f  the o thers is 
given:
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N o specim en obtained 2
N o tum our in specim en obtained 2
Inadequate yield o f  nuclei from  sam ple 3
Inadequate labelled undivided cells 2
Labelled undivided cell p o p n not distinct 15
T he follow ing param eters for each histogram  are given in appendix III- the num ber o f 
labelled undivided nuclei counted, the half peak coefficient o f  variation (C V ) o f  the 
diploid G q/G j peak, and the D N A  index o f  the tum our. A  frequency histogram  o f  the 
D N A  indices is show n in figure 37, and a breakdow n o f  the ploidy d istribu tion  is 
g iven in table 24. T he frequency distribution o f  CVs is show n in figure 38. T he 
m edian C V  w as 5.0%  (in terquartile  range 3 .0% -7.0% ).
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Figure 37: Frequency distribution of DNA indices for all cases which gave at least 
some kinetic data, excluding the one polyploid tumour (83 cases). Column labels 
are midpoints, that is 2 means 1.95-2.04. Raw data in Appendix III.
Ploidy No. %
Diploid 36 43
Aneuploid 48 57
DNA index 1.1-1.85 35 42
Tetraploid 7 8
Hypertetraploid 5 6
Polyploid 1 1
Table 24: Summary of ploidies of the 84 tumours which gave kinetic data.
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Figure 38: Frequency distribution of half-peak coefficients of variation of the diploid 
G0/G1 peaks in each histogram. Column labels are midpoints, that is 4 means 3.5-4.4. 
Raw data in Appendix III.
To sum m arise, LI could be calculated  in 84 cases, and all three kinetic param eters in 
67. A ppend ix  V  gives these data case by case. Frequency distributions o f  each are 
represen ted  in figure 39, and sum m ary statistics in table 25. It can be seen that there is 
g rea ter varia tion  o f  labelling  index than the length o f  S phase, the LI vary ing  by a 
facto r o f  o v er 30, w hilst T s ranges only over a factor o f  6 w ith a narrow  interquartile 
range betw een  10 and 16 hours. T hese tw o com bine to give values o f  T pot vary ing  
from  3 days to over 60  days.
BLI
3.5 7.0 10.5 14.0 (%)
Ts
7.0 14.0 21.0 28.0 (hrs)
H + ++ Tpot
40 80 120 160 (days)
Figure 39: Distribution of kinetic parameters in all cases. Raw data in Appendix IV.
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Parameter n Median IQ Range Range
BLI (%)
Ts (hrs) 
Tpot (days)
84
67
67
3.2
12.7
14.6
1.2 - 6.4 
10.3- 16.5
8.0 - 37.5
0 .4 -12 .9  
4.8 - 32 
3 .7 -1 5 3
Table 25: Summary of kinetic parameters in all cases in which they were measurable. 
IQ Range = interquartile range. Raw data in Appendix IV.
Section iii: Independence of Labelling Index and Length of S Phase
If the dynamic information provided by in vivo labelling with bromodeoxyuridine is 
to provide any advantage over existing static methods, the speed of cell cycle transit 
must be independent of labelling index so that it provides additional information. It is 
possible, for instance, that the tumours with high labelling indices are also those in 
which the rate of cell cycle transit is high, in which case little is being gained by 
measuring the latter. In figure 40, the labelling index for each individual tumour is 
plotted against the length of S phase for that tumour, for each of the 67 cases where 
both parameters were calculated. It is apparent from inspection of this graph that there 
is no strong trend for one to vary with the other, the points lying in a nearly horizontal 
band across the chart. This is borne out by statistical analysis, with Spearman rank 
correlation coefficient r = -.010 (p = 0.93). The length of S phase for a particular 
tumour is therefore independent of the labelling index of that tumour within this series, 
and represents a novel item of information about the lesion. This does not presuppose 
any significance for this additional data.
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Figure 40: Plot of bromodeoxyuridine labelling index against length of S phase 
in tumours for which both are available (n=67). Raw data in Appendix IV.
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Section iv: Relationship of Length of S Phase to Labelling Time
The mathematical model used for the calculation of Ts from data derived from the 
bivariate histogram assumes that labelled cells are initially evenly distributed through S 
phase, and progress at uniform rate toward tetraploid DNA content. If these conditions 
are not met then the relative movement will not vary linearly with time, and the estimate 
of S phase made from the histogram will partly depend upon the labelling time.
In order to obtain an accurate estimate of RM it might also be necessary for the labelled 
cells to have progressed some distance through S phase. This is a result of the fact that 
the DNA content of each cell is reduced to a channel number within the histogram. 
Each channel covers a range of values of DNA content, and this range is larger in the 
64 channel two parameter histogram than the 256 or 1024 channel one parameter 
ploidy histogram used for calculating SPE This uncertainty about the position of each 
point in the histogram is fixed, and so it is proportionally greater at low DNA contents, 
or small differences between two points of interest. As an extreme example, it the 
labelling time were very short indeed, each labelled cell might have moved less than 
one channel within the histogram. Some would have crossed a channel boundary even 
in making this small movement, but many will not have, and so will appear not to have 
moved in the histogram at all. If the labelling time were longer, such that the average 
movement was of six channels this error of one channel is proportionally less (only 
16% rather than 100%). So the calculation of relative movement becomes statistically 
more accurate the longer the labelling time. This is counterbalanced at long labelling 
times by the loss to the calculation of cells which have divided, but this is another 
reason why Ts may be dependent upon the labelling time used.
To examine the effect of these points upon the estimation of Ts, figure 41 shows this 
parameter broken down by labelling time. It can be seen that as anticipated from the 
second argument above, Ts does have a different distribution at very low labelling 
times. Encouragingly, for labelling times above 4 hours (80% of all tumours), Ts is 
independent of labelling time, suggesting that the mathematical model for calculation is 
appropriate within the current setting.
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Figure 41: Variation of Ts with time between bromodeoxyuridine labelling and tumour 
biopsy. For each interval indicated on the x axis, the distribution of values of Ts for the 
tumours which had this labelling time is given. The line inside each box indicates the 
median value, the box itself encloses the central two quartiles of the distribution, and 
the whiskered lines show the full range. + indicates outlying values.
Section v: Flow versus Immunohistochemical Labelling Indices
The labelling index as determined from the bivariate histogram could be compared to 
that calculated by counting at least 2000 cells on a suitably stained tissue section (the 
immunohistochemical labelling index, ILI; see methods, section ix) in 50 cases. As 
discussed in the previous chapter, the calculation of bromodeoxyuridine labelling index 
(BLI) is ploidy dependent, being inherently higher in aneuploid tumours. An attempt 
has been made to overcome this bias by calculation of the total labelling index (TLI), 
which includes all cell populations within the tumour, and makes no correction for 
cells which have divided since taking up the label. Since the immunohistochemical 
counts cannot make allowance for cells which have divided, the TLI might theoretically 
accord better with the ILI, in diploid cases at least. Counting on the sections does only 
include tumour cells, and so in an aneuploid tumour the BLI, which also only includes 
tumour cells, would theoretically be expected to be the more appropriate figure for 
comparison.
Appendix IV includes the tumour ploidy, the bromodeoxyuridine and total labelling 
indices, and the immunohistochemical counts for each case. The first two are plotted 
against each other below.
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Figure 42: Plot of bromodeoxyuridine labelling index (BLI) against 
immunohistochemical labelling index (ILI) in 50 cases for which both are available.
Line of best fit is y = 0.799 + 0.896x (r = 0.777). Raw data in Appendix IV.
In table 26 the degree of agreement between the flow and histochemical methods is 
presented as analysed by the Bland-Altmann technique. Cases are considered all 
together, and also broken down by ploidy, with mean differences more than two 
standard errors different from zero underlined. In all cases the ILI is slightly higher 
than the flow cytometric indices, giving a negative result for the difference as 
calculated. As predicted theoretically, agreement is better with the BLI for aneuploid 
tumours, and with the TLI for diploid tumours. For these two comparisons, there is no 
significant difference between the flow derived and immunohistochemical labelling 
index overall. The degree of divergence in individual cases can be judged from the 
standard deviations for the differences, given in the final column of the table. The SDs 
of just over two percent indicates that 95% of differences were less than about 4.6%. 
This is a substantial figure in relationship to even the highest labelling indices of the 
order of 10%, indicating that the good overall agreement does not preclude relatively 
large differences in individual cases.
Comparison n Mean Diff SE Mean SD Diffs
BLI - ILI (all) 50 -0.389 0.325 2.30
TLI - ILI (all) 50 -1.279 0.388 2.74
BLI - ILI (dip) 22 -0.597 0.505 2.31
TU - ILI (dip) 22 -0.285 0.503 2.31
BLI - IU (an) 28 -0.354 0.429 2.27
TLI - ILI (an) 28 -2.034 0.546 2.89
Table 26: Comparison of labelling indices calculated by flow cytometry (BLI & TLI) 
and immunohistochemistry (ILI), for all 50 cases counted immunohistochemically, 
and separately by ploidy groups. Bland-Altmann analysis using differences. Mean 
differences significantly different from zero are underlined. Raw data in Appx. IV
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One further point to be made from these results follows from the observation that the 
TLI in aneuploid cases is lower than the other two labelling indices. This indicates that 
the labelling index in the non-tumour component is indeed lower than that in the 
tumour itself, as assumed in talking of the 'dilutional' effect of this component. This is 
in keeping with the following result.
Section vi: Comparison of Kinetics in Tumour and Normal Breast
In patients being treated by mastectomy, an attempt was made to obtain a specimen of 
breast tissue from a site distant from the tumour. In many cases, histological 
examination showed this to consist of fatty stromal elements only. In eight cases 
specimens of normal breast parenchyma were obtained, and these were processed for 
multivariate flow cytometry in the same way as tumour samples. The values of BLI, Ts 
and Tp0t for each of the 8 cases are listed in table 27. One of these samples came from 
one of the two patients in whom there was no tumour in the 'tumour' sample taken for 
analysis of cell kinetics. The distributions of the kinetic parameters in all 8 specimens 
have been compared to the values for all 84 tumours; in the 7 cases where there was a 
corresponding tumour sample, the normals have been compared with the tumours from 
the same patients. The results of this analysis are summarised in table 28.
Tumour BU Ts "*"pot
1 1.2 14.3 33.8
2 0.6 10.4 46.9
3 0.2 11.8 168.0
4 0.3 11.9 104.7
5 0.5 27.7 163.4
6 0.3 17.7 163.0
7 0.2 16.6 308.1
8 0.9 13.7 43.1
median 0.4 15.5 128.9
Table 27: Kinetic parameters in 8 specimens of normal breast
The bromodeoxyuridine labelling indices of the normal samples were significantly 
lower than those of all tumours, and also lower than those of the 7 tumours from the 
same patients. Length of S phase was no different with either type of comparison. As 
might be expected from these results, the potential doubling time was significantly 
longer in the normal tissues than the tumours. All normal specimens were diploid. Of 
the 7 corresponding tumours, 6 were aneuploid. Not for the first time, we run into the 
problem that ploidy biases the kinetic values obtained, so that direct comparisons such 
as the foregoing are are potentially misleading. Comparison of the bromodeoxyuridine
Chapter 9 126
labelling index in the normals with the total labelling index for the tumours should 
address this problem, and it is for this reason that the results of this analysis are also 
presented in the table. The normal samples have also been compared to all diploid 
tumours as a further check. It can be seen that the finding of lower labelling in the 
normal tissues is unchanged by removing the ploidy bias in these ways.
Comparison n
norm
n
turn
median
normal
median
tumour
95%CI
(t-n)
P
BLI, all normal 
vs all tumours 8 84 0.4 3.2 0.9 - 4.9 <0.0001
Ts, all normal 
vs all tumours 8 84 15.5 12.0 0.8 - -5.0 0.14
Tpot, all normal
vs all tumours 8 84 129 12.5 -3 5 --153 0.0001
BLI, normal vs
corr. tumours 7 7 0.3 4.8 0.2 - 6.2 0.011
Ts, normal vs
corr. tumours 7 7 14.3 12.7 4.7 - -7.6 0.90
Tpot, normal vs
corr. tumours 7 7 163 7.6 -25--161 0.015
BLI, normal vs 
diploid tumours 8 36 0.4 1.25 0.4 - 2.1 0.0009
BLI normal vs
TU all tumours 8 84 0.4 2.65 0.85 - 3.48 0.0001
BLI normal vs
TU corr tumours 7 7 0.3 2.89 0 .18 -4 .4 0.015
Table 28: Comparison of kinetic parameters in tumour and normal breast. The first column 
indicates the parameter(s) being compared and the cases being used for the comparison. 
Column 6 gives the 95% confidence intervals for the difference between the two groups 
(tumour - normal). Significant differences are underlined in the last column.
Section vii: Comparison of Labelling Index and S Phase Fraction
The ploidy histograms obtained in the course of running these specimens were 
analysed offline to calculate the value of SPF, as used in the section II save only that 
here this was done using updated software (Multicycle, Phoenix Systems). 
Theoretically this is the same measurement as the bromodeoxyuridine labelling index, 
since the label is supposedly taken up by all S phase cells, and only by S phase cells. 
The corresponding values of BLI and SPF have been compared for each tumour.
Calculation of SPF using the objective criteria employed in Part II was possible in 74 
of the 84 cases (88%) for which BLI is available. The higher success rate in obtaining 
values for SPF compared with the series reported in Part II is probably the result of 
two factors, firstly the greater number of nuclei counted for each histogram (about
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50,000 here, but only 10,000 in the earlier series), and secondly because the newer 
software is more capable than the Cytologies programme used in Part II. The data on 
SPF for each tumour are included in Appendix IV. The 74 pairs of values of BLI and 
SPF are plotted in fig. 43, and the distribution of values of SPF is shown in fig. 44.
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Figure 43: Plot of bromodeoxyuridine labelling index against S phase fraction for each 
of the 74 tumours in which both could be measured. Raw data in Appendix IV.
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Figure 44: Frequency distribution of values of S phase fraction in the 74 
tumours in which it could be measured. Column labels are midpoints, that is 3 
means 2.5-3.49. Raw data in Appendix IV.
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Spearman rank correlation of the two distributions gives r = 0.667, p < 0.0005. Since 
the two are supposedly measurements of the same thing, this finding is not surprising, 
and in order to assess the association between the two, Bland-Altmann analysis has 
again been used. Examination of the data showed that disagreement increased with 
increasing mean value, and so the analysis was performed using the ratio between the 
two figures in each case:
Mean Ratio SE Mean SD Ratios
4.11 0.374: 3.2
Table 29: Summary of the distribution of the ratios SPF /  BLI in the 74 cases in
which both could be measured. Raw data in Appendix IV.
It can be seen that the value of SPF tends to be higher than that of BLI for the same 
tumour (there are only three examples where this is not the case), on average by a 
factor of 4. Given the standard error of this figure, this is highly significantly different 
from the ideal ratio of 1. The fact that the standard deviation is so high in relationship 
to the mean indicates that very large variations are observed, and indeed the highest 
ratio between the two is 16.4 (SPF = 14.8%, BLI = 0.9%). Although there is close 
rank correlation between these two measurements of the proportion of S phase cells in 
the tumour population, SPF almost uniformly gives a higher estimate, by a very 
variable factor. If we accept that the two are theoretically measurements of the same 
biological parameter by different means, they cannot both be right. Is the SPF tending 
to overestimate the true proportion, the BLI to underestimate, or both? Although the 
updated computer software is a great improvement upon the original, most of the 
caveats about the use of such packages discussed in Part II remain. It has also already 
been stated that not all cells synthesising DNA take up thymidine or its analogues, so 
that there is some rationale for suggesting that BLI might underestimate the true S 
phase percentage. The answer to the query above is probably both. Even so, the good 
correlation between S phase fraction and bromodeoxyuridine labelling index is 
encouraging in the sense that if we are not too concerned with the actual value for the 
number of cells in S phase at a point in time, but rather with the relative values for 
different samples, then the two techniques provide comparable answers. In terms of 
determining prognosis, or guiding therapy, or exploring tumour biology, it is just this 
type of relative information that is needed. In this sense, the two methods do tend to 
bear each other out.
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Section viii: Relationship of Kinetics to Pathological Prognostic Factors
Follow-up of these patients is still too short to assess the prognostic significance of the 
kinetic parameters themselves. Some indication can be gained by studying the degree 
of correlation between these variables and other tumour characteristics known to 
predict outcome. These interrelationships are summarised in table 30.
None of the three kinetic parameters are significantly associated with nodal status, the 
single strongest predictive factor for outcome, or with size of the primary tumour. 
Histological grade is very strongly related to labelling index, grade 3 tumours having a 
median labelling index 5 times higher than that of grade 1 tumours. This result is not 
altered by the use of total labelling index or immunohistochemical labelling index as the 
basis of comparison, indicating that if is not the result of ploidy bias. Grade is not 
related to length of S phase, but the effect upon labelling index is carried through into 
potential doubling time, which is significantly shorter in high grade tumours.
Factor
n
(LI) LI
Median Values of:
Ts oCL
1
-
n
Crs &T,
Nodal Status NO 31 3.2 12.1 16.15 24
N1 21 4.8 13.7 14.2 17
P 0.83 0.12 0.60
Tumour Size T1 22 4.05 11.3 13.45 16
T2 25 2.0 13.6 25.1 21
T3 10 4.2 11.7 10.5 9
P 0.58 0.41 0.18
Tumour Grade 1 13 1.0 13.5 37.5 13
2 23 2.4 13.6 17.7 19
3 32 5.1 11.9 8.6 23
P <.001 0.60 <.001
CEstrogen ER- 12 4.0 14.35 11.35 10
Receptor ER+ 16 1.2 12.85 36.5 14
Status P 0.026 0.77 0.14
Table 30: Relationship between kinetic parameters and prognostic factors. The second and 
last columns give the numbers of patients in that subgroup for whom LI and Ts, respectively, 
are available. Probability values are based on Mann-Whitney (nodal and ER status) or 
Kruskall-Wallis analysis (size and grade). Results significant at the 5% level are underlined. 
Raw data in Appendices III & IV.
The prognostic factor most strongly associated with labelling index independent of 
ploidy, the histological grade, is also the factor which predicts ploidy to some degree 
in cross tabulation. In this analysis the proportions of aneuploid and diploid tumours in
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subgroups defined by each prognostic factor were compared by the chi-square method 
(table 31). High histological grade is associated very strongly with an increasing 
proportion of aneuploid tumours, with only 2 of 13 grade 1 tumours being aneuploid 
compared with 22 out of 32 grade 3 lesions.
Nodal Status Tumour Size
NO N1 TO T1 T2
Diploid 42 40 38 48 30
Aneuploid 58 60 62 52 70
ER Status Hist. Grade
Neg Pos GO G1 G2
Diploid 27 50 85 45 31
Aneuploid 73 50 15 55 69
Factor x 2 df P
Nodal Status 0.019 1 0.90
Tumour Size 1.079 2 0.58
Hist. Grade 10.60 2 0.005
ER Status 1.395 1 0.24
Table 31: Relationship between tumour poidy and prognostic factors in the BUDR labelled 
tumours. The upper part of the table gives the proportion of aneuploid and diploid tumours in 
each subgroup (that is, all figures are column percentages). The tables for each factor have 
then been analysed by the chi-square method, using the actual numbers in each cell rather 
than the percentages, and the results are shown in the lower part of the table. The only result 
significant at the 5% level is underlined. Raw data in Appendix III.
Section ix: Relationship of Kinetics to Ploidv
The fact that kinetic parameters are measured upon different populations within the 
histogram in aneuploid and diploid tumours has already been explained. This creates 
an inherent tendency for aneuploid tumours to appear to have higher labelling indices, 
and this is indeed reflected in the current sample. When the values of BLI are simply 
broken down by ploidy status of the tumour as in figure 45, the median labelling index 
for the aneuploid tumours, 5.2%, is significantly higher than that for diploid tumours,
1.25% (Mann-Whitney, W = 905.5, p < 0.00005).
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Figure 45: Box and whisker plot of values of bromodeoxyuridine labelling index broken 
down by tumour ploidy. The line within each box indicates the median, the boxes enclose 
the central two quartiles of the distribution, and the whiskers span the full range of values 
save for outlying values indicated with a + symbol. Raw data in Appendix IV.
Although the same problem exists for the calculation of Ts, it is not so clear a priori 
that the rate of DNA synthesis in tumours will be any different to that in normal tissue. 
Values of Ts broken down by ploidy are shown in figure 46; there is no significant 
difference between the two groups (aneuploid median 13.6hrs, diploid median
11.7hrs; Mann-Whitney, W = 1024.5, p = 0.14). There are two possible explanations 
for this. The simpler is that there is no difference in the length of S phase between 
either diploid and aneuploid tumours, or between tumour and non-tumour cells. It is 
also possible that there is a difference between aneuploid and diploid tumours, which 
is being counterbalanced by difference in the opposite direction between tumour and 
non-tumor cells. If, for instance, diploid tumour cells have a shorter Ts than aneuploid 
tumours cells, but the non-tumour cells with which they are mixed in the histogram 
have a longer Ts than either, then the mixture of diploid and non-tumour cells seen in a 
diploid histogram may give the same net value of Ts as the pure tumour cell population 
of an aneuploid population. This is an inherently less likely explanation on Occamite 
grounds, but but it does demonstrate that a difference in the rate of DNA synthesis 
between diploid and aneuploid tumours cannot be excluded on the basis of this result 
alone.
Diploid
+ Aneuploid
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Figure 46: Box and whisker plot of values of length of S phase broken down by 
tumour ploidy. Symbols as in figure 38. Raw data in Appendix IV.
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The same arguments can be made in respect of labelling index, but in this case it is 
possible to eliminate the bias in favour of aneuploid tumours and establish whether the 
observed difference in labelling index is real. This has been looked at in two ways- by 
the use of a corrected labelling index (the TLI); and by the use of immuno­
histochemical counting (the ILI), which ignores non-tumour cells. Figure 47 illustrates 
the relationships between these indices and tumour ploidy:
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Figure 47: Box and whisker plot of values of TLI (above) and ILI (below) broken 
down by tumour ploidy. Symbols as in figure 38. Raw data in Appendix IV.
In each case, the statistically higher labelling index in aneuploid tumours persists 
(Mann-Whitney, p = 0.001 for TLI, p = 0.01 for ILI). Within this series then, 
aneuploid tumours have a higher labelling index than diploid lesions. Given the 
absence of any difference in length of S phase between the two ploidy groups, this 
would be expected to lead to lower values for Tp0t in the aneuploid tumours, and this 
is indeed the case (diploid median Tpot = 33.35 days, aneuploid median Tpot = 8.9 
days, Mann-Whitney W = 1475, p = 0.0001).
Section x: Relationship of Kinetics to c-erbB-2 Expression
Expression of the growth factor receptor oncoprotein c-erbB-2 has been associated 
with a poor prognosis in breast cancer (Winstanley et al 1992, Slamon et al 1987, 
Clark and McGuire 1989). It is not unreasonable to hypothesise that this might be 
because overexpression of such molecules conferred a growth advantage upon such
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cells. If so it might be possible to observe that rates of cell growth were more rapid in 
tumours exhibiting overexpression than in those not doing so, and this has certainly 
been the finding of some groups using SPF or TLI as measures of cellular proliferation 
(Anbazhagan et al 1991, Barnes et al 1991, Kallioniemi et al 1991, Tommasi et al 
1991). This question has been approached here by immunohistochemical staining for 
the presence of the c-erbB-2 protein, as described in the methods section.
74 of the tumours for which kinetic data were available were assessed for this marker. 
29 of these (39%) were found to be positive. The result for each tumour is given in 
Appendix IVa. Figure 48 shows each of the three kinetic parameters broken down by 
the c-erbB-2 status of the tumour, and table 32 gives the results of statistical 
comparison of the two groups in each case.
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Figure 48: Box and whisker plot of values of kinetic parameters broken down by expression 
of the c-erbB-2 oncoprotein. The line within each box indicates the median, the boxes 
enclose the central two quartiles of the distribution, and the whiskers span the full range of 
values save for outlying values indicated with a + . Raw data in Appendices IV&IVa.
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number median
Parameter neg pos neg pos 95% Cl p
BLI(%) 45 29 2.8 4.0 -2 .4 -0 .40  0.28
Ts(hrs) 38 20 13.6 13.55 -3.4- 1.7 0.48
Tpot(days) 38 20 19.6 13.65 -6.8- 12.9 0.77
Table 32: Comparison of kinetic parameters in tumours which do or do not express c-erbB-2. 
The first two columns give the numbers of negative and positive tumours for which that 
parameter is available. Mann-Whitney test, including the 95% confidence interval for the 
difference in medians. Raw data in Appendix IVa.
Within this series, there is no difference between the cell kinetics of tumours which do 
or do not express c-erbB-2. It has been noted by previous authors that expression of 
c-erbB-2 is more common in aneuploid tumours, and a ploidy imbalance between any 
two groups of interest will bias their comparison because of the difference in the 
method of calculating labelling index in aneuploid and diploid tumours. It is therefore 
important to look at the relationship between the ploidy-independent labelling indices 
TLI and ILI in the two c-erbB-2 groups, and this is done in figure 49. In table 33 
tumour ploidy and staining for c-erbB-2 are cross tabulated. Chi-square analysis 
using this data shows that in keeping with previous reports, aneuploid tumours are 
more likely to express c-erbB-2, but allowing for this does not reveal any hidden 
relationship with labelling indices (Mann-Whitney, p = 0.63 for TLI, p = 0.19 for 
ILI).
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Figure 49: Box and whisker plot of values of total and immunohistochemical labelling indices 
broken down by expression of c-erbB-2. The line within each box indicates the median, 
the boxes enclose the central quartiles of the distribution, and the whiskers span the full 
range of values (outlying values indicated with a + ). Raw data in Appendices IV&IVa.
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c-erbB-2 
Negative Positive
Diploid 24 (75%) 8 (25%)
Aneuploid 21 (50%) 21 (50%)
Table 33: Comparison of ploidy in erbB-2 positive and negative tumours.
2
Figures in brackets are row percentages. X = 4.76, 1 df, p = 0.03. Raw data in 
Appendices IV&IVa.
Section xi: Reproducibility Studies
The validity of the parameters measured by this methodology has been tested in a 
number of ways. Since there is no gold standard against which to check the absolute 
values obtained, testing has concentrated on establishing the limits of consistency and 
reproducibility of the method. This has been done by:
- running duplicate sections of the same tumour at different times;
- comparing the results obtained by disaggregation of dewaxed tissue sections, as
used in this study, with the method of Begg et al involving disaggregation of 
non-embedded tumour; and
- multiple analysis of derived histograms at different time-points and by different
individuals to establish the inter- and intra-observer reproducibility of the 
subjective process of histogram interpretation.
This work has been carried out in association with other workers within the laboratory 
performing similar investigations in cancers of the cervix and head and neck. Some of 
the results use data from these series rather than this one.
a) Results from Serial Sections
This was done by Ms G Forster using material derived from head and neck cancers, 
processed in exactly the same way as in the current series. A new 50p section from 12 
previously studied tumours was processed and the kinetic values obtained were 
compared to those gained from the original section. Analysis was by the Bland- 
Altmann method, using the ratio between pairs of results (that is, the distribution of the 
quotient 'first observation / second observation'). This form of analysis is used 
throughout this section. The data and results are given in the table:
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Labelling Index (%) Length of S Phase (hrs)
Patient Sectionl Section2 Sectionl Section2
1 8.0 8.6 16.9 14.8
2 7.1 8.0 13.2 12.8
3 14.6 13.2 18.6 16.1
4 9.3 9.1 10.5 10.3
5 10.0 10.2 17.6 16.3
6 9.4 9.9 14.9 14.8
7 11.2 8.5 22.6 20.4
8 1.4 1.6 16.4 14.9
9 9.3 8.7 20.3 17.1
10 15.8 13.3 28.8 29.7
11 14.4 12.3 19.3 21.5
12 1.8 1.6 15.0 16.6
Mean Ratio SE Mean SD Ratios
LI 1.05 0.038 0.13
Ts 1.05 .0.027 0.09
Table 34: Comparison of results obtained from two sections of the same tumour, run 
separately. Raw data above. For the lower table, the first result has been divided by the 
second for each tumour, and the columns describe the distribution of these ratios.
The mean value of the quotient did not vary significantly from unity in respect of either 
kinetic parameter, indicating no overall tendency for the second series of sections to 
provide either higher or lower answers than the first series. The size of the standard 
deviations means that 95% of the second estimates for each parameter were within 
25% of the original estimate for that parameter upon that tumour. For biological data 
with this degree of variability from tumour to tumour, this is a very acceptable degree 
of variation using this demanding form of analysis. Contiguous sections could be 
expected to be very similar in the nature of the contained cell population, and so 
tumour heterogeneity should contribute little of the observed variability. This is one of 
the advantages of using sections for study, rather than unembedded tumour samples.
b) Results from Tumour Segments
In 19 cases, a second sample was analysed from a previously studied tumour, but 
using nuclei obtained by disaggregation of an unembedded tumour sample rather than a 
repeat 50p section. This work was performed on breast cancers from the current 
series, and raw data are shown in table 35, below which are the Bland-Altmann 
summary statistics.
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Labelling Index (%) Length of S Phase (hrs)
Patient Segment Section Segment Section
4 0.4 t-1 16.2 17.0
13 2.9 3.2 10.8 9.8
16 9.5 8.9 20.4 14.2
17 0.6 0.5 13.1 13.7
30 5.0 3.2 16.4 13.6
36 1.3 1.2 6.4 14.0
37 2.2 1.6 9.5 12.0
46 1.9 1.2 24.3 16.2
56 1.8 0.8 22.7 11.8
60 0.6 4.1 6.2 4.8
61 7.1 5.1 14.1 13.6
62 2.2 1.9 13.3 10.5
63 8.2 7.9 14.7 9.4
65 8.3 4.8 4.0 11.1
67 8.3 5.1 24.6 12.0
68 9.9 7.9 19.8 14.9
70 3.7 3.6 12.7 8.8
73 8.0 6.4 18.1 8.5
79 1.2 0.8 12.9 17.1
Mean Ratio SE Mean SD Ratios
LI 1.238 0.108 0.469
Ts 0.991 0.134 0.584
Table 35: Comparison of results obtained from a section and a segment of the same 
tumour, run at separate times. Raw data above, and below the result obtained from 
the section has been divided by that gained from the segment. Columns describe 
the distribution of these ratios.
Neither mean ratio differs significantly from 1, indicating no trend for either type of 
sample to give higher or lower values for either labelling index or length of S phase. In 
this respect, the result is the same as that obtained when the repeat specimen was a 
further section (a, above). The striking difference between the two sets of results is 
that the standard deviation of the distribution of ratios for both LI and Ts is much 
higher here, where the repeat specimen is a separate tumour sample, than in the 
previous experiment when the repeat specimen was a further section from the same 
sample. This increase in variability almost certainly reflects the degree of tumour 
heterogeneity with respect to cell kinetics. Whilst this must cause some disquiet as to 
the validity of any measurement based upon a single tumour sample, it is also 
encouraging technically in the sense that far the smaller component of the overall
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variation, as reflected in the standard deviations in this experiment, is provided by the 
run to run variation as tested in the previous experiment.
c) Inter- and Intra-Observer Variation
We have so far considered the variation from one run to another of the same tumour 
arising in the many steps of sample processing, in the degree of error inherent in any 
measuring system such as a flow cytometer, or due to variation of the measured 
parameters within the tumour itself. We need also to consider the potential for variation 
from the subjectivity of the interpretation of the derived histograms. The values of both 
LI and especially Ts depend upon the precise situation of the boxes defining the 
subgroups of labelled undivided, labelled divided, and unlabelled cells. The criteria 
used for placing these boxes are covered in the Methods chapter. The reproducibility of 
the calculation of kinetic parameters from histograms has been tested by two 
experiments in which the same histograms were analysed by two observers. In the first 
of these, 37 histograms from head and neck cancers were analysed by Ms Forster and 
myself. This experiment looked at labelling index only, the results being shown below:
Mean Ratio SE Mean SD Ratios
U 1.13 0.056 0.160
Table 36: Comparison of results obtained from 37 histograms analysed by two
observers (myself and Ms G Forster). My result has been divided by hers. Columns 
describe the distribution of these ratios.
In the second series, Mr B Bolger and I analysed 23 histograms derived from cervical 
carcinomata. Here the reproducibility was expressed using the difference, My result - 
His result, in respect of labelling index, length of S phase and potential doubling time:
Mean Diff SE Mean SD Diffs
LI 0.177 0.087 0.417
TLI 0.235 0.062 0.298
Ts -0.497 0.126 0.604
Tpot -0.265 0.062 0.298
Table 37: Comparison of results obtained from 23 histograms analysed by two 
observers (myself and Dr B Bolger). His result has been subtracted from mine. 
Columns describe the distribution of these differences.
In both series, there are indeed differences in the answers obtained by the two 
observers, from the same histograms. In the first series, I estimate labelling indices 
13% higher on average than Ms Forster (ie I use a lower cut off between labelled and
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unlabelled cells in terms of amount of green fluorescence). This means that if I 
obtained an estimate of LI of 3.2% (the median value) for a given histogram, then the 
most likely value for Gill's estimate for that histogram would be 2.8%. Given the 
standard deviation of 0.16 for the distribution of ratios, the 95% confidence intervals 
for her estimate of the labelling index are plus or minus 0.32 times the mean of our 
estimates (ie 0.32 x 3%) or 1.8 and 3.8%. Compared to the range of values of LI 
across the 84 tumours of 0.4 to 12.9%, this interobserver error is small in relationship 
to the variability of the parameter being measured, but of considerable size 
nevertheless.
In comparing my results to Mr Bolger's, it needs to be emphasised that these are 
expressed not in terms of ratios, as in the previous experiment, but rather as absolute 
differences between the two sets of data, these showing less tendency to vary with the 
size of the parameters being measured. Whilst this is not directly comparable to the 
results above, it allows us to examine the interobserver variation in terms of magnitude 
rather than proportion. As was the case in the previous comparison, I obtain on 
average higher estimates of labelling indices, and in this case lower estimates of the 
length of S phase, both of which tend to make my estimates of potential doubling time 
shorter. But here the amplitude of these differences is very small in relationship to the 
values of the parameters themselves, with my measurement of LI being on average 
0.18% higher (mean LI for the 23 histograms was 11.1%), and of Ts 0.50hrs shorter 
than his (mean Ts for the 23 histograms 10.9 hrs). The analyses for this experiment 
were performed over a year later than those for the previous one, and this may explain 
the greater concordance of interpretation.
Section xii: Comparison with Kinetics of Squamous Tumours
As the above section makes clear, other workers within the labs at the Royal Infirmary 
have been using the bromodeoxyuridine methodology which we have developed, for 
the study of other tumour types. It would seem to be worthwhile to present at least the 
briefest summary of those data, in order to look at the differences between tumours:
Tumour n % aneup. Ll(%) Ts(hrs) Tpot(days)
Breast 84 57 3.2 12.7 14.6
Cervix 120 71 10.9 13.2 5.3
Head & Neck 105 72 8.0 13.7 6.2
Table 38: Summary of cell kinetic data for three tumour types studied by in vivo 
bromodeoxyuridine labelling in our laboratory. All kinetic values are medians.
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Breast cancers are seen to have cell kinetics quite distinct from those of the two 
squamous tumour types, with a much lower median labelling index and longer median 
potential doubling time. The squamous tumour types are themselves fairly similar in 
their proliferative characteristics. Note that the values of Ts are very much the same for 
all three cancers, as has been the case in all other comparisons of Ts between groups in 
these results.
It is tempting to suggest that this finding is in keeping with the clinical observation that 
breast cancer is a relatively slow growing tumour. Indeed it is, but without information 
as to the relative rates of cell loss from the different tumour types, it is theoretically 
perfectly possible that breast cancers, despite their slower cell production rate, have a 
faster volume growth rate than the squamous tumours.
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Chapter 10: 
Relationship between EGFR Expression and Cell Kinetics
Section i: Introduction
The epidermal growth factor receptor is the oldest known member and exemplar of the 
type I receptor tyrosine kinases, of which c-erbB-2 is also a member. Several ligands 
are now recognised, and monoclonal antibodies to the receptor have been available 
since 1984, so that it has been possible to study the occurrence of this molecule in vivo. 
This has been done by many groups for breast cancer. Two types of method have been 
used. Ligand binding techniques involve the creation of a membrane preparation by 
centrifugation of ground whole tumour. Aliquots of this preparation are then assayed 
for their ability to bind EGF, for which there are no other known specific binding 
proteins. The binding capacity per weight of membrane protein is taken as the measure 
of the number of EGFreceptors present within the tumour. This is generalised to 
represent the tumour cells on the assumptions that these will predominate in the sample, 
and provide most if not all of the binding sites, the other elements of the tumour 
(benign breast epithelium, lymphoid cells, and stromal cells) not contributing 
significant numbers of EGFR to the total pool.
The other technique which has been used is immunohistochemistry, in which tissue 
sections are stained with a primary antibody to the antigen of interest. Binding of the 
antibody is then demonstrated by amplification and chromogen systems, of which there 
are many types. The situation of the detected receptors can be ascertained histologically 
using this type of method, but it is non-quantitative in that it deliberately uses non-linear 
amplification systems in order to visualise antibody binding. Its sensitivity is unknown 
and probably variable from one technique to another, and interpretation is at least 
partially subjective. Having different strengths and weaknesses, ligand binding and 
immunohistochemical methods would seem to complement each other in the study of 
EGFR distribution in breast cancer.
The most influencial study in this field was probably that by Adrian Harris and his 
colleagues using ligand binding, with a cut-off of 20fmol EGFR/mg membrane protein. 
Their latest publication (Fox et al, 1994) gives results for 370 tumours, 175 of which 
(47%) expressed EGFR at or above this level. They found EGFR expression to decline 
with increasing patient age and with increasing oestrogen receptor expression, but to be 
unrelated to tumour size or grade or axillary nodal involvement. In univariate analysis 
EGFR expression did not significantly effect overall survival (OS) in the total patient
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group, although overall and relapse-free survival (RFS) were worse in node negative 
patients expressing EGFR. This persisted, for RFS only, in multivariate analysis. This 
comes down to one of only 4 combinations of OS and RFS against EGFR positive and 
negative, in an analysis with good numbers of patients, and a favourable distribution of 
EGFR (nearly 50/50, the ideal split for statistical power). This suggests that the 
prognostic power of EGFR is limited in comparison to existing factors (especially 
nodal status), a conclusion borne out by the review of published series included in this 
same paper. They identified 16 reports involving 3009 patients (a mean of 188 patients 
per study), only 4 of which showed EGFR expression to be independently prognostic 
in multivariate analysis. None of these series yet have long follow-up (longest 
survivors in the Harris series are still only at about 7 years, and median follow-up for 
the series reported was only 18 months), so that longer term survival may yet turn up a 
greater significance for this factor.
The other series looking at EGFR in breast cancer are broadly in line with Harris in 
respects other than survival as well. A review of 40 studies comprising 5232 cases 
(Klijn et al, 1994) found the overall rate of EGFR positivity to be 45% (although with a 
range from 14-91% positive). The finding that EGFR expression is inversely related to 
ER expression is an almost universal finding where it has been sought (Toi et al, 1994; 
Castellani et al, 1994; Railo et al, 1994; Nicholson et al, 1994; Klijn et al, 1994; 
Charpin et al, 1993; Bellantone et al, 1993; Bolla et al, 1992; Bilous et al, 1992; 
Umekita et al, 1992). Likewise, most authors have agreed with Harris that expression 
of EGFR is not related to tumour size (Toi et al, 1994; Minckwitz et al, 1993; Klijn et 
al, 1994; Charpin et al, 1993; Gasparini et al, 1992), nodal status (Toi et al, 1994; 
Minckwitz et al, 1993; Klijn et al, 1994; Charpin et al, 1993; Bellantone et al, 1993; 
Gasparini et al, 1992; Umekita et al, 1992), or histological grade (Minckwitz et al, 
1993; Charpin et al, 1993; Gasparini et al, 1992; Umekita et al, 1992). A smaller 
number of workers have found such associations, EGFR positive tumours being 
associated with larger tumour size (Bellantone et al, 1993), presence of nodal 
metastases (Castellani et al, 1994), or poor tumour differentiation (Castellani et al, 
1994; Bolla et al, 1992). Three other groups at least have looked at the relationship to 
patient age, and have been unable to confirm Harris's finding in this respect, 
establishing no relationship of EGFR expression to age (Klijn et al, 1994; Charpin et 
al, 1993; Bellantone et al, 1993).
A number of papers have included some measure of cell proliferation, with a consensus 
that EGFR positive tumours show more rapid proliferation. Most commonly, this 
comparison has been performed using Ki-67 staining as the index of proliferation
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(Gasparini et al, 1994; Toi et al, 1994; Nicholson et al, 1994; Charpin et al, 1993; 
Nicholson et al, 1993; Bilous et al, 1992, with Gasparini et al, 1992 and 1991 
dissenting from this view and finding no relationship). Single reports have used PCNA 
staining (Shrestha et al, 1992), confirming this direct relationship, and mitotic index 
(Umekita et al, 1992) in which case no correlation was found.
There is less information in the literature about the expression of EGFR in normal 
breast, with very few of the studies above using this for comparison or as a control 
tissue. What information there is comes predominantly from immunohistochemical 
studies, but at least one report using ligand binding has shown similar binding 
characteristics for EGFR in benign and malignant breast tumours, with significantly 
lower concentrations in malignant tissue (Dittadi et al, 1993). Ozawa et al (1988) found 
the converse, that ligand binding capacity was higher in malignant than benign breast 
tissue, and for completeness Barker et al (1989) found no difference between the two. 
The last study used normal tissue from mastectomy specimens, as opposed to benign 
breasts used by the other two. Immunohistochemical studies cannot perform this 
quantitative comparison, but have consistently noted that EGFR is readily stainable in 
normal breast lobules (particularly in the myo-epithelial cells) and ducts (Damjanov et 
al, 1986; Moller et al, 1989; Tsutsumi et al, 1990), which would suggest that 
expression in the normal is at least higher than that of the 55% of tumours which are 
EGFR negative in the previously discussed ligand binding studies studies. The lower 
rate of detection of EGFR by immunohistochemistry in breast carcinomata compared to 
benign breast tissue was confirmed by a number of groups (Moller et al, 1989; 
Tsutsumi et al, 1990; Tauchi et al, 1989). This is supported by the report of Travers et 
al (1988) that EGFR mRNA can be detected in all non-malignant breast tissues studied, 
but in only 42% of tumour samples examined.
As mentioned earlier in this section, both methods for the study have advantages and 
weaknesses, and are complementary in the the study of EGFR expression. The way in 
which ligand binding is carried out makes the cytogenetic origin of the detected 
receptors uncertain. By this I mean that the membrane preparation created by 
homogenisation of tissue for the assay derives from all cells present within the tumour. 
The heterogeneity of this population has already been discussed in relationship to flow 
cytometry, and consists not only of tumour cells but also potentially elements of insitu 
tumour, normal breast, fibroblasts, myoepithelial cells, endothelium, macrophages and 
lymphocytes. In using ligand binding for EGFR in squamous tumours, which express 
large numbers of receptor per cell, and have a relatively small stromal component, this 
is not necessarily an important problem. It might be so in breast cancers for these very 
reasons.
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Immunohistochemistry (IHC) lacks the ability to quantify receptors as ligand binding 
can do. Additionally, the sensitivity and specificity of IHC depends upon the methods 
used for fixation and detection of antibody binding. A technique which combined the 
quantitation of ligand binding, and the localisation of IHC might be more valid for 
either alone. With this in mind, for this project I have used a quantitative 
immunohistochemical method pioneered in squamous tumours by Fred Hendler in 
Dallas and latterly Louisville. This is done by using a radiation based detection system, 
quantified by emulsion autoradiography, which we have termed radio- 
immunohistochemistry (henceforth REHC). The details of the method as used for the 
breast tumours is given in the following section.
Section ii: Patients and Methods
a) Patients studied, and Material available'
The antibody used for this study was the R1 IgG2 mouse monoclonal originally 
described by Waterfield et al (1984), provided by Dr B Ozanne of the Beatson Institute 
for Cancer Research. The antibody, which recognises an epitope in the extracellular 
domain of the EGFR molecule close to the membrane, is not effective in fixed sections. 
Accordingly, the assay was performed upon frozen sections of tumour. As stated 
earlier, a sample of tumour was kept in liquid nitrogen where possible, but priority was 
given to gaining material for flow cytometry. Frozen tumour was available for 53 of the 
cases who were bromodeoxyuridine labelled. In fact the assay has been performed on a 
total of 105 tumour samples, and the results for all of these are presented where this is 
appropriate, using the 53 overlapping results for the exploration of the relationship 
between EGFR expression and cell proliferation. All 105 patients are listed in Appendix 
V, with pathological prognostic data, identifying separately those who are part of the 
bromodeoxyuridine series.
b) Antibody iodination
The R1 antibody was radio-iodinated for use in the assay by the iodogen method as 
follows. Reaction tubes were prepared by pipetting lOOpl of 0.5mg/ml iodogen 
(l,3,4,6-tetrachloro-3a,6a-diphenylglycoluril, Sigma) into 13x100mm glass test 
tubes, and allowing this to evaporate in a fume hood overnight. Tubes were then stored 
in a dessicator. For each iodination, 50^g of antibody in PBS was pipetted into one of 
these tubes. 250p,Ci of 1-125 (Amersham) in a volume of 2.5pl was mixed with 25pl 
of PBS, added to the tube and incubated for lOmin. The reaction was stopped by the 
addition of 1ml of a 1:1 mixture of PBS and foetal calf serum to the tube. The contents 
of the tube were then added to a NAP-10 column, equilibrated with 10ml of PBS, and
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eluted with 1.5ml of PBS. The eluent was assayed as below, and then divided into 
lOOpl aliquots in micro-Eppendorf tubes for storage at -20°C.
Radioactivity of the iodinated antibody, and absence of unbound iodine, was assayed 
by counting an 5^il aliquot before and after trichloracetic acid (TCA) precipitation. To 
achieve this, a 5pl sample of the antibody solution was counted directly. Another 5pl 
aliquot was diluted to 1ml with PBS and precipitated with lOOpl of TCA. The reaction 
mixture was centrifuged and a lOOpl aliquot counted. This allowed calculation of the 
activity of the iodinated antibody as bound (ie precipitatable) counts per weight of 
antibody. High activity is not necessary or desirable for this assay (shelf life is lower 
due to disruption of antibody molecules by decay, and saturating amounts of antibody 
need to be added to each slide anyway, so that high activity antibody would need to be 
diluted with cold antibody). Levels achieved were of the order of lOOMBq/mg 
(lOOcounts per second per ng of antibody). Antibody was used as soon as possible 
after iodination, to a maximum of one month after iodination, activity at the time of use 
being calculated from a standard decay table for 1-125.
c) Incubation
3 sections were used for each tumour, duplicate test sections and a negative control 
section incubated with the iodinated antibody in the presence of a 100 fold excess of 
unlabelled antibody. 4p.m thick frozen sections on silane coated slides were obtained, 
and a parallel section stained with H&E to confirm the presence of tumour. All sections 
were placed well to one end of the slide. With each batch of tumours a set of standards 
were run, consisting of sections of one particular normal breast from a reduction 
mammoplasty, and sections of pellets of three cell lines (ZR-75-1, EJ, A431).
The sections to be assayed were pre-fixed in acetone for lOmin, washed twice for 5min 
in normal saline, and circled with an oil pen without allowing them to dry. Sections 
were then placed on racks in a closed box with well moistened tissues in the bottom of 
the box to maintain humidity. lOOpl of preincubation solution was added to each 
section. This consisted of a 1:1 mixture of PBS and foetal calf serum (FCS), to which 
was added, for the negative control sections only, cold antibody to lOOx the amount 
calculated to be used as hot (iodinated) antibody for each section (see below). 
Preincubation was carried out for lhr, and at the end of this time, hot antibody was 
added to each section and mixed by pipetting.
The amount of hot antibody per section used was calculated to provide 2xl05 
disintegrations/min. Given the specific activity of the antibody of lOOMBq/mg, this 
amounts to roughly 30ng per slide of hot antibody when it is fresh. The appropriate
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volume of hot antibody solution for all slides was made up to lOpl/slide with 1:1 PBS: 
FCS, and 10p,l added to the pool of preincubation mixture on each slide.
Incubation went on for 3 hours, in the middle of which time the solution on the slide 
was mixed by pipetting with a Gilson. At the end of the time the incubation solution 
was tapped off, the slides washed 3 times for lmin each in PBS, post-fixed with 4% 
formol saline, washed once more, and then dried on a heated plate.
d) Film Autoradiography
Once the sections were thoroughly dry, they were taped into an radiographic cassette, 
and a sheet of Kodak R-PE film laid over them. This was exposed at 4°C for 24hrs. 
This was used to indicate the approximate level of activity on each section, in order to 
indicate how long each trio of sections from a particular tumour should be exposed 
once coated with autoradiographic emulsion. This is basically to ensure an appropriate 
grain density for counting, and is dealt with in more detail in that section. The 
judgement was subjective.
e) Emulsion Autoradiography
Sections were now coated with Kodak NTB-3 autoradiographic emulsion. This 
procedure was carried out in a darkroom with the use of a Kodak No.2 safelight. The 
emulsion was melted into an equal volume of distilled water at a temperature of 43°, 
created by sitting the dipping vessel (a standard 4 slide vertical histochemistry staining 
container) in a water bath. Once this had been done, blank slides were dipped in the 
emulsion until this emerged free o f bubbles. The experimental slides were then dipped 
in the emulsion, stood on end to dry in grooved perspex racks, and placed in standard 
metal slide-staining racks (note that the lighting provided by this type of safelight is 
very dim, in deference to the sensitivity of the emulsion. Racking slides in this light is 
the most difficult part of this procedure). The racks were then stacked in a metal tin 
with freshly dessicated silica gel in the base. The tin was sealed, wrapped in a thick, 
black plastic bag, and placed at 4°C.
It is to economise at this stage that the sections were placed at one end of each slide 
originally, since they can then be dipped that end first into the emulsion. This reduced 
the volume that needed to be made up for each batch, since that was determined by the 
height needed to be covered on each slide in order to coat over the section on it. The 
emulsion is the most expensive consumable item in this procedure.
Once the sections had been exposed to the emulsion for the period of time determined 
by the autoradiographic film to be appropriate, the emulsion was developed. This 
interval varied between 3 hours (the time taken for the emulsion to dry), and 1 week.
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Slides were placed in the staining racks after dipping, as stated above, and those due to 
be developed at the same time were obviously racked together.
Before developing slides the water bath in the darkroom was filled with an ice/water 
slurry, and 4 staining dishes placed in this. These were filled with photographic 
developer (Kodak LX24) diluted 1:1 with distilled water, distilled water (2 dishes), and 
photographic fixer (Champion Super Amfix). The dishes were allowed to equilibrate 
for at least fifteen minutes before use. At the appointed time, the darkroom was re­
entered, safelight conditions resumed, the tin opened, and the appropriate rack 
removed. It was passed through the dishes as follows:
- developer 4 min
- water 1 min
- fixer 5 min
- water 1 min
Slides were then taken out of the darkroom in the last staining dish for counterstaining.
f)  Counterstaining
Sections were stained ’through' the emulsion with 0.12% Safranin O, a red nuclear 
dye, for a period of about 5 min, before being briefly washed in tap water and mounted 
in DPX. The Safranin was made up as a 0.2% solution in distilled water, and mixed 
with 0.1M acetate buffer (9vol 0.1M Na acetate + lvol 0.1M acetic acid) in the ratio 
3vol Safranin to 2vol of buffer. The solution was buffered in this way as it is unstable 
in neutral solution, and precipitates in a matter of days. Shelf life could be prolonged by 
buffering. Fresh stocks were made monthly, but even within this period of time it was 
necessary to use longer staining intervals as the solution aged. This dye also washes 
out very rapidly, and stains the emulsion, so that washing needed to be brief and 
carefully monitored, in order to adequately clear the excess dye, whilst preserving 
adequate staining for tissue identification. This was further complicated by the need to 
obtain a rather light stain so that the counterstain did not produce sufficient opacity to 
appear as grains in the course of image analysis, a problem dealt with in detail below. 
In practice, the sections were barely more than 'dunked' in the water, examined, and 
the immersion repeated as necessary. If eventual microscopic examination revealed the 
end result to be unacceptable, the slides were immersed in xylene until the cover slips 
could be removed, destained with water, and the procedure repeated.
An example of the finished product, at the magnification used for counting, is shown in 
figure 50.
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Figure 50: Photomicrograph of a counterstained radio-immunohistochemistry section with 
moderate grain density over tumour to the right (and over isolated tumour cells centrally in the 
field), and low density background counts over lymphoid elements and stroma to the right and 
centre.
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g) Grain Counting
Measurement of the number of silver grains developed within the emulsion over the 
tumour areas was carried out using a Joyce-Loebl Mini MagiScan system, attached to 
an Olympus BH-2 microscope. Basically, the procedure consisted of the following 
steps:
- establishment of lighting conditions on the microscope, and appropriate
thresholds for detection of grains by the system under these conditions
- examination of the section histologically to identify the tumour elements
- capture of the microscopic image (40x objective) by the image analysis system
- outlining areas of tumour cells on screen by the operator
- automated measurement of the area outlined
- automated count of the number of grains in the indicated area
- storage of these data by the system
- repeat image capture and counting, for at least ten screens per section
The automated counting system works by measuring the optical density o f each screen 
pixel in the captured image (the screen is divided into 512 pixels horizontally and 512 
pixels vertically. Since the overall image area is 6.67xl0'3mm2, each pixel represents 
only 2.54xl0"8mm2 on the section). Grains appear as dense objects on a light 
background. The background is darkened only by the counterstain (thus the need for a 
light stain), an effect enhanced by the use of a red filter, which almost abolished the 
visibility of the counterstain, and so increased the density variation between grains and 
background, and by the fact that the grains are in a different focal plane to the 
counterstain at this high power. Obviously this could only be done once the area to be 
counted on the screen had been identified. Once the screen had been captured, the 
system identified each pixel with a density greater than a certain threshold (this varied 
with each session, depending on the exact microscope setup being used, for example 
the system is extremely sensitive to the lamp voltage which is set with a slide control, 
and so was never quite the same from one session to another).
The positive pixels are then divided into discrete objects, that is all touching pixels are 
regarded as being part of a single object, and the number of these objects is counted. 
This is taken as the number of grains present. Since even the grains are not all exactly 
focussed in the same plane, the number of pixels occupied by one grain varies from one 
to several (an effect enhanced by the fact that even a grain of one pixel size lying at the 
junction of 4 pixels might put all four over the density threshold). This thresholding 
and counting is visible on screen, and so can be monitored by the operator. This 
description hopefully makes it apparent why different sections need to be exposed to 
emulsion for varying lengths of time. This is a compromise between the need for
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enough grains to have developed to create a statistically satisfactory sample, and the 
necessity that the grains remain discrete, so that adjacent grains are not perceived by the 
analysis system as a single object (leading to underestimation of the grain count). There 
is thus an optimum density for counting, and it is to create this that the exposure times 
are judged. Negative controls were exposed for the same time as their test sections, the 
appropriate interval being judged on the basis of the latter, self-evidently.
The counting of the area of the screen occupied by tumour has to b e ; approached 
quirkily using this particular analysis system. The area of interest is drawn around 
using a mouse. Rather than simply measure the area enclosed, it is necessary to 
threshold the enclosed area with a minimum threshold, which means that all pixels 
within it are identified as positive. The area which these cover can then be measured by 
the system. For each section, a file is created in which the system stores the area 
counted, and number of grains counted within that area, for each screen captured. The 
totals for area and grains for all screens for that section is also available, and were 
recorded as the final result.
h) Calculation o f EGFR Expression
Counts were calculated as grains per unit of section area per hour of emulsion 
exposure, averaged over a minimum of 20 fields on the 2 sections of each tumour, and 
less the counts (per area per time) on the negative section, taken to represent non­
specific binding and grain development. They were expressed as a percentage of that in 
one of the standards run with each batch, the A431 cell pellet, and subsequently as a % 
of the counts normal breast based on the average count in the 9 normal breast samples 
(see results, Counts in normal breast). It is also possible to construct a standard curve 
from the counts in the cell lines, and so convert the grain counts to receptors per cell, 
but this involves the assumption that cell density is the same in the tumours and cell 
pellets. For this reason I have not done this, and the standards were only used to check 
the linearity of the assay in each batch. I also felt that the absolute levels of EGFR 
expression were of less clinical importance than their relativity to their tissue of origin.
Appendix V gives the counts per unit area per hour, and count relative to normal breast 
for each of the 105 tumours.
i) Controls
It has already been stated that sections from pellets of three cell lines and normal breast 
were run in all batches. Pellets were created as follows. A large cell culture flask of 
cells in sub-confluent growth was washed three times with normal saline, the cells 
scraped and suspended into a universal container. They were centrifuged at 2000rpm
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for 5 minutes, the universal snap frozen in liquid nitrogen, and the pellet in the conical 
base of the container tapped out. This pellet was then wrapped in foil and returned to 
liquid nitrogen. It was stored at -70°C until required, at which juncture 5pm frozen 
sections were taken from it for use in the assay.
Pellets were made in this fashion from the following lines: ZR-75-1 (a breast cancer cell 
line with 2-3 x 103 receptors/cell), EJ (a bladder cancer cell line with 1.3 x 105 
receptors/cell), and A431 (a vulval cancer cell line with 1.5 x 106 receptors/cell). The 
RIHC method assumes that the amount of antibody bound to each section is in 
proportion to the number of EGFR molecules present, and that in turn the number of 
grains developed in the emulsion is in proportion to the number of antibody molecules 
bound. If saturating amounts of hot antibody are present, then the first assumption is 
reasonable, and likewise the second if the response of the emulsion is linear with time 
(that is, that 1000 disintegations per hour for 3 hours of exposure gives the same grain 
count as 100 disintegrations per hour for 30 hours. The decay of the 1-125 can be 
ignored within the time frame used, up to one week of exposure, given that it has a half 
life of 60 days). If this is the case, then the grain counts for the cell pellets should be in 
proportion to the known receptor density in these cell lines. The ZR-75-1 line lies 
below the sensitivity of this assay, but the ratio EJ:A431 should be 1:10-12. This ratio 
was calculated for each batch to test the underlying assumptions, and the 
appropriateness of the counting procedure.
Samples of normal breast were obtained from 9 specimens from reduction 
mammoplasty procedures. These were dissected to seek areas of breast parenchyme 
(large areas consist macroscopically of fat alone), which were frozen in liquid nitrogen 
and stored at -70°C. In fact 12 specimens were obtained but no macroscopic breast 
parenchyme could be identified in 3 of these. All samples were subsequently checked 
histologically for the presence of breast lobules. Whether this type of sample is truly 
normal breast is open for debate, a point pursued in the discussion.
Section iii: Results
a) Counts in cell pellets
Sample counts are given in the table below for the cell pellet sections used for one of 
the batches. In this example the ratio EJ:A431 is 1:11.6, and this was similar for all 
batches, with ratios consistent with the known ratio of receptors per cell in these lines, 
demonstrated in the lower table, giving the EJ and A431 counts for each batch.
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Cell Line Grains Control Area Exposure Net Grains
(1 O^mm2) Time (hrs) /Area/Time
EJ 3903 30 13.3 23 12.7
A431 7884 42 13.3 4 147
Table 39: Example of Grain Counts in Cell Pellet Sections
A431 Count EJ Count Ratio
135 13.8 9.8
147 12.7 11.6
212 20.0 10.6
140 11.4 12.3
121 11.1 10.9
206 18.7 11.0
170 13.5 12.6
190 18.8 10.1
144 12.2 11.8
148 14.2 10.4
Table 40: Grain counts per lO^mm2 per hour of emulsion expoisure 
for cell pellet standards in each batch with which tumours were run.
b) Counts in normal breast
Results from duplicate sections from one the normal breast samples are given in the 
table below, along with the A431 counts from that batch, as an example of the method 
of calculation of EGFR expression:
Slide Area counted Grains
Hot1 3.40 890
Hot2 2.94 946
Cold 3.22 232
Total area counted = 6.34 x lO^mm2. Total grains = 1836 
Exposure time was 17.5hrs.
/ .  Grains/1 O^mn^/Hr = 1836/6.34/17.5 = 16.55
For cold section (control), grains/10_2mm2/hr = 232/3.22/17.5 = 4.12
Net counts = 16.55 - 4.12 = 12.43 grains/1 O^mn^/hr
For this batch the A431 count was 190 grains/10'2mm2/hr
. \  % normal breast to A431 = 12.43/190 x 100 = 6.54%
Table 41: Grain counts in sample of normal breast, and example of calculation
from this of the net counts and relativity to cell pellet standard.
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Results for all 9 normal breast sam ples are given in the table below. T he  mean value is 
7.2% o f  A431 counts, and this is the figure used in normalising the results in the 
tumours to expression as a % o f  normal breast.
Sample 1 2 3 4 5 6 7 8 9
%A431 6.54 5.21 6.61 9.45 8.79 9.70 5.30 7.70 5.28
Table 42: Grain counts in the 9 samples of normal breast.
c) Counts in breast cancers
Counts in the 105 tum ours are given in A ppendix V. T he  frequency distribution o f  
these counts is show n in the figure below. Note that the x axis for this is the coun t  as a 
percentage o f  that in normal breast lobules, that is 100 on the x axis is 100% o f  normal. 
It is immediately apparent that nearly all o f  the tum our samples lie below this level, with 
only 3 above, that is that virtually all show  downregulation  o f  E G F R  com pared  to 
normal breast. T he  largest num ber o f  tum ours lie in the very lowest group, below  10% 
o f  normal breast.
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Figure 51: Frequency distribution of values for EGFR expression in all 105 tumours 
d) Lower limit o f sensitivity
This was ascertained by using a one sided t test on the counts  per unit area o f  the test 
sections, com pared with those on the corresponding negative section. W hen this was 
not statistically significant the count for that tumour could not be regarded as above 
zero. This depends principally upon the area o f  tum our counted, since how ever  small
Chapter 10 154
the difference between background and specific counts, if enough grains are counted 
this will become significant. It is a problem of sample size. An example is given below. 
For this tumour, the level of expression is 9.2% of normal breast. Comparing the two 
sets of grains per unit area on a one sided t test (experimental slide > control) gives t = 
3.60, df 17, p = 0.0011, that is, the counts on the test slide are statistically higher than 
those on the control, and so this level of activity is above the sensitivity threshold of 
this method. It becomes insignificant at below 5% of normal breast, so this is the 
lowest level of EGFR expression that can be regarded as not zero using the number of 
fields that I have counted for each slide.
1 2 3 4 5 6 7 8 9 10
Grains 51 87 72 83 54 101 54 74 81 89
Area .612 .710 .719 .996 .507 .869 .581 .851 .687 .551
Grains/Area 83 123 100 83 107 116 93 87 118 162
1 2 3 4 5 6 7 8 9 10
Grains 40 82 51 67 71 48 56 64 41 46
Area .612 .865 1.13 1.34 .750 .806 1.09 .781 .428 .607
Grains/Area 65 95 45 50 95 60 51 82 96 76
Table 43: Grain counts on a tumour slide (upper panel) and its negative control (lower panel).
Area is x1 O^mm2. See text for analysis.
e) Relationship to cell proliferation
53 of the 105 cases have cell kinetic data available. It is possible to look at this 
differently to the way in which I analysed theerbB-2 data, because in this case EGFR 
levels are a continuous variable. It is also quite possible to create an arbitrary cut-off, 
and so divide levels into positive and negative, in order to perform the same type of 
comparison as used previously, and this has been done as well. For this purpose, 
tumours with EGFR expression less than 10% of that in normal breast were regarded 
as EGFR negative, and those above this level as positive. This creates a roughly equal 
division of tumours, the distribution not being bimodal so as to suggest a more 
appropriate cut-off. It is worth emphasising again that the great majority of positive 
tumours still have lower EGFR levels than normal breast.
Looking first at EGFR as a continuous variable, each of the kinetic parameters is 
plotted against EGFR expression (the latter on a log scale because of the wide spread of 
values) in figure 52. Since none of the distributions is remotely normal, the appropriate 
statistic here is a rank correlation, and the results of this analysis are given in the 
following table:
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Parameter Spearman coeff Probability
0.019
0.64
0.039
LI
Ts
Tpot
0.321
0.072
-0.308
Table 44: Rank correlation between EGFR expression and kinetic 
parameters using EGFR as a continuous variable
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Figure 52: Relationships between EGFR expression and kinetic parameters. EGFR is 
in each case expressed as % of the mean expression in normal breast, on a log scale 
(because so many-of the values are otherwise crowded at the left side of the plot. 
Values of zero are represented as 0.1%. Tpot also log scale because of the few very 
large outlying values.
It can be seen that labelling index is indeed directly related to EGFR expression, and 
that once again Ts shows no variation, resulting in an inverse relationship between Tp0t 
and EGFR. The raw data plots, however, show that there is marked variation from 
tumour to tumour, with the very highest labelling index being in a case with very low 
EGFR level. The extent of the overall relationship is, however, reinforced by the
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analysis using EGFR classified simply as positive or negative, where the median LI in 
the positive tumours is more than 3 times as high as that in the negatives. The results of 
this analysis are given in the table below:
n
(LI) LI
Median values of 
Ts ^pot
n
(T/Tpot)
Pos 23 5.3 13.3 8.9 17
Neg 30 1.6 11.95 22.3 28
P 0.001 0.206 0.004
Table 45: Relationship between EGFR expression and kinetic parameters, using 
EGFR as a binary variable (below or above 10% of normal breast expression). Medians 
are expressed as % of normal breast, p values based on Kruskall-Wallis tests.
f)  Relationship to pathological variables
The median values of EGFR expression in subgroups defined by nodal status, tumour 
size, histological grade, and oestrogen receptor status are shown in the table below. As 
was the case for cell proliferation, it is tumour grade and ER status which are strongly 
related. In the case of grade, it is apparent that high grade tumours have significantly 
higher levels of EGFR expression, as do ER negative tumours (that is, there is an 
inverse relationship between these two factors).
Factor n Median EGFR
Nodal Status NO 51 5.3
N1 42 7.2
P 0.46
Tumour Size T1 28 5.5
T2 61 5.2
T3 7 4.2
T4 6 7.0
P 0.96
Tumour Grade 1 7 6.3
2 13 3.5
3 24 21.7
P 0.006
CEstrogen ER- 21 11.6
Receptor ER+ 28 2.9
Status P 0.018
Table 46: Relationship between prognostic factors and EGFR expression. 
EGFR is given as % of normal breast, p values- Kruskall-Wallis tests.
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Chapter 11: 
Discussion and Conclusions
Much of the technical discussion of these results has deliberately been included with 
the presentation of the results themselves. In this section, I intend only to complete the 
process by comparing them with previous work, and then seeing to what extent 
bromodeoxyuridine represents an advance over static methods for measuring tumour 
cell kinetics.
Five previous reports of the application of bromodeoxyuridine to the study of tumour 
cell kinetics of human breast cancer were identified in the literature review . The table 
below summarises the results from those studies, alongside the current one:
Author n LI (%) Ts (hrs) V t  (daVs)
Current Series 84 3.2 12.7 14.6
Rew (1992) 69 4.2 8.7 8.2
Lloveras (1991) 148 3.0 na na
Sasaki (1992) 21 10.9 na na
Meyer (1993) 450 3.9 na na
Goodson (1993) 109 10.3 na na
Table 47: Summary of results from previous studies which have used
bromodeoxyuridine in breast cancer. Ail values are means.
The current results are very much in line with three of these previous reports, in terms 
of labelling index. This agreement is backed up by the good correlation with the 
immunohistochemical counts in tumours from this series. Of the other two, Sasaki's is 
a very small and possibly unrepresentative group (see chapter 4). The methodological 
queries about the Goodson series would not be expected to create so large a difference, 
though, and so this must remain partly unexplained.
There is only the one other study which has sought dynamic data among these, which 
makes it difficult to assess the importance of the difference in median values of Ts 
between us and the Mt Vernon group, although it is this which is responsible for most 
of the variation in potential doubling times between the two data sets. Given our 
inability to find any alteration in Ts between subgroups, it seems unlikely that the 
explanation is that the tumours are biologically different. This would imply that there is 
methodological variation- in the histogram interpretation, which could lie either in the 
analysis software or the investigators themselves; or in the sample preparation, and this 
could be an inherent difference between samples created by direct disaggregation as
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opposed to tumours embedded, sectioned and then disaggregated, as we have done. 
When the two methods of sample preparation were directly compared in our lab 
though, no difference in derived parameters was found (Forster et al, 1992). It must 
also be noted that neither series was complete, in the sense that a proportion of 
tumours were completely (no LI or Ts) or partially (no Ts) non-informative in both 
centres. It cannont be assumed that the uninformative tumours have the same kinetic 
behaviour as those from which data were obtained. Therefore the results cannot be 
generalised to the population of all breast cancers. Furthermore, it is possible given the 
different methods of sample preparation used, that a different type of tumour was 
uninformative in the two labs, and this could account for the difference in Ts between 
the series, given that data for Ts is missing in nearly 25% of the total cases.
The present results can also be considered in the context of our own previous work 
using thymidine labelling and flow cytometric S phase fraction, presented earlier in this 
thesis. The results, for S phase estimation only, are summarised in the table:
Method n S Phase (%)
Bromodeoxyuridine 84 3.2
Flow Cytometric SPF 224 7.2
Thymidine Labelling 185 3.2
9
Table 48: Summary of results from studies of the proportion of cells in S 
phase in breast cancers, using different methods, in our laboratory.
The two methods which rely upon functional identification of cells synthesising DNA 
show absolute agreement using this crude measure. The higher median value for SPF 
fits with the finding in the BUDR series that SPF was higher than BUDR labelling 
index in 70/74 cases. These methods seem fairly conclusively not to be measuring the 
same thing. The difference may be the result of technical limitations in either or both 
methods, but it must be understood that the nature of the two measurements is not the 
same. SPF counts all cells with a given DNA content, whether or not they are actively 
synthesizing DNA. A proportion of these cells, of unknown extent, may in fact be 
unable to complete S phase, and have arrested there. By contrast, BUDR and 
thymidine identify only cells actively incorporating pyrimidines into DNA, although it 
has been shown for tritiated thymidine that not all cells doing so are labelled (Allison et 
al, 1985), and this may also apply to BUDR (Wilson et al, 1985). The label may also 
be incorporated by cells undergoing DNA repair rather than synthesis. That this is 
infrequent is suggested by the observation that with short labelling times few labelled 
Gq/G j cells are seen. Both methods will label cells undergoing DNA replication but 
subsequently unable to mitose by virtue of abnormality of the synthetic process, or 
deficiencies of the cellular mitoticinfrastructure. These theoretical considerations are
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not adequate to explain the very large difference between the results for the various 
methods. The more functional techniques, using labelling with DNA precursors, are 
the more soundly based. This puts SPF in a rather poor light, if these are taken as the 
gold standard.
It is also worthwhile at this stage bringing together some of the data gathered on the 
reproducibility of interpretation of the various methods. We have studied breast 
tumours using thymidine labelling, flow cytometric SPF and bromodeoxyuridine. The 
inter-observer variation for each is summarised in the table:
Method n Mean Ratio SE Mean SD Ratios
Bromodeoxyuridine (LI) 37 1.13 0.06 0.16
Flow Cytometric SPF 66 0.84 0.03 0.23
Thymidine Labelling 20 1.01 0.13 0.55
Table 49: Summary of results of reproducibility studies we have carried out on the different 
methods of measuring S phase fraction.
Thymidine labelling emerges as the method where the two observers got the same 
answers on average, but also the one where the variation in individual cases was the 
largest. The other two both show constitutional difference in histogram interpretation 
by the two observers, but greater concordance when this is allowed for (that is, lower 
SD), with bromodeoxyuridine labelling index the least variable by this measure. It is 
worth remembering that this is a very rigorous test of reproducibility, and whilst it 
would certainly be desirable to avoid the constitutional difference between observers, 
the level of variation for individual cases using bromodeoxyuridine is quite low.
The other major potential advantage of using bromodeoxyuridine, though, was the 
ability to gain the additional information as to the length of S phase. This parameter 
could not be measured in as many tumours as the labelling index, but was still 
available for 67/87 tumour samples (77%), and was shown to be independent of the 
labelling index. It showed markedly less variability between tumours, though, and not 
a single subgroup comparison showed a difference in median Ts between groups. 
Theoretically this is compatible with a view that the S phase is a relatively standardised 
process within cells, taking place at a rather fixed rate in all cells. If this is indeed the 
case, then measuring it is not going to provide any useful information, since variation 
in cell production rates will reside almost entirely in variation in the proportion of in­
cycle cells, which can be measured by static methods. It is too early to come to this 
conclusion yet. The fact that length of S phase shows no relationship to known 
prognostic factors does not necessarily mean that it is of no predictive value, as this 
may only indicate that it gives information independent of that available from other
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data. Conversely, the labelling index will almost certainly prove to be prognostic in 
univariate analysis because of its close association with histological grade. Because of 
this very association it may provide little or no additional information, though. Only 
continued observation and subsequent multivariate analysis will answer the question as 
to the prognostic power of tumour cell kinetics as measured with bromodeoxyuridine.
Before considering the results obtained from RIHC for EGFR, since this is a relatively 
novel method, we need to ask whether it is a valid one. In terms of the cell pellets used 
as standards, the answer to this is in the affirmative- the grain counts are in linear 
proportion to the EGFR expression by those lines. However, these preliminary studies 
used only 2 lines (the ZR-75-1 can only really be considered a negative control rather 
than a standard), and more need to be studied to draw up a true standard curve to more 
thoroughly prove this point. In the tumours the matter is not even as simple as this, 
since the cell density cannot be assumed to be the same in all cases. For this reason the 
grain count can only be expressed as grains per unit o f area, not per cell. This is the 
same for ligand binding, where levels can only be expressed per mass of membrane 
protein. In either case, it could be argued that receptor density within the tissue might 
just as easily be the biologically important variable as receptor number per cell. With 
RIHC it would be possible to do separate cell counts in order to correct to bring the 
counts down to numbers per cell, as this would be a useful extension of this work.
In terms of reproducibility the answer to the original question is also yes, the results 
are very consistent for the pellets and normal breast between runs, and for different 
people doing the counting, but this is not proof that the results are accurate. Counts do 
accord with immunohistochemistry, both in the literature and in our hands, but since 
this is a method based on that technique this in not entirely surprising. A comparison 
with ligand binding would be desirable, and will be an area for future study. There 
may well be differences in individual tumours, but it would be hoped that overall the 
results tended to be correlated. In cases of difference it would be helpful to ascertain 
from the histology whether this might be due to presence of distracting elements in the 
tumour which would cause problems for ligand binding- a substantial component of 
normal or in-situ disease, or small areas of positive tumour with a large negative 
stromal component. In fact if there are no such differences, then RIHC has no 
advantage over ligand binding.
In comparison to routine immunohistochemistry, RIHC only has an advantage if the 
quantification which it provides is of any additional value. The advantage applies at top 
and bottom of the expression range though. Immunohistochemistry embraces a wide 
variety of staining systems for visualising primary antibody binding, and these are of 
different sensitivity and specificity. Therefore, at what level of EGFR expression 
staining becomes apparent is inconstant- there is an unknown and variable threshold
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for positivity at the bottom end. There is also a problem in interpretation, given that the 
staining pattern needs to be taken into account if, as is often the case, only some of the 
tumour cells stain positively- what percentage is regarded as making the tumour as a 
whole EGFR positive? At the top end, once the tumour does cross the threshold on 
immunohistochemistry, then further increase in expression will not make it more 
positive. All this said, a simple plus or minus answer, whatever its threshold, may turn 
out to provide all the biological and prognostic information of a more accurate value. 
This can only be assessed by testing this hypothesis in a substantial tumour series, and 
this is another important area for future work with RIHC.
In subjective terms, RIHC is time-consuming, and requires scrupulous attention to the 
emulsion coating and grain counting if reproducible results are to be obtained. The 
need for the use of radioactive materials is also a relative disadvantage, and it is 
difficult to see that this is ever going to be more than a research tool (but then so are 
ligand binding methods for EGFR). Its potential lies in the possibility of using it to 
quantify levels of any antigen for which an antibody with good specificity and high 
affinity is available. An example is erbB-2, for which good antibodies are available in 
quantity, and where quantification is not possible at the protein level in other ways, 
because of the lack of a ligand to use for binding assays. This is in fact the next antigen 
I intend to study, in the same series of tumours, but future efforts need not be directed 
toward this class of compounds, or even to cell surface antigens.
The levels of expression recorded in normal breast samples are quite consistent 
between the 9 specimens analysed. Whilst I have argued against trying to equate grain 
counts with receptor numbers per cell, the level seen is of the order of that in the EJ 
cells, or in normal skin samples that I have also used with this assay. These are EGF 
responsive tissues, and so this is at least potentially a biologically significant level of 
expression. It was noted in the introduction that immunohistochemists have 
intermittently reported in the literature that EGFR is detectable in normal breast, 
particularly in relation to the myoepithelial cells. RIHC does not localise receptors as 
accurately as immunohisto-chemistry, but the examples shown demonstrate that the 
grains are distributed over all of the lobule and not just its basement layer as would be 
expected if all of the receptors were present on the myoepithelial cells.
This raises the issue of how accurate the localisation of receptors is with RIHC, which 
depends upon how far from the molecule of origin any emission travels before 
converting a grain within the emulsion. The 30keV y emission of 1-125 could 
potentially travel a histologically long way in the emulsion before conversion, if its 
angle of exit happened to be low (by which I mean that if its path were at right angles 
to the plane of the section if would not matter, but if it were nearly in the plane of the
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section it would have a long course in the emulsion). Fortunately it is not this y 
emission which converts the silver grains, but rather low energy p particles created by 
internal conversion of the primary emission, which only have a very short course 
(Wilson Angerson, personal communication). Thus the grains will lie within a few pm 
at most of the points of origin of the particle which gave rise to them.
The question must also be raised as to the true normality of tissue taking from 
reduction mammoplasty specimens. It is theoretically possible that very large breasts 
(requiring reduction mammoplasty) are so because of aberration of EGFR expression, 
but to my knowledge there is absolutely no evidence that this is so. These women are 
also younger on average than the breast cancer patients, and it is certainly possible that 
there is variation in EGFR expression with age (and perhaps especially with 
menopausal status). This is explored within the data gained in this study, though, and 
no relationship was found, but few of the specimens are from patients as young as the 
reduction mammoplasty group. It is difficult to obtain fresh (ie surgical) samples of 
unimpeachably normal breast for study. Normal areas are present within breast 
cancers, but breast within which a tumour has developed cannot be considered normal, 
nor areas of fibrocystic disease subject to biopsy. Tissue adjacent to fibroadenomata 
would be accepted by most, but given that these lesions need only be enucleated, it 
would require separate consent to carry out further biopsy at the time of surgery, 
which would be ethically difficult given the increased possibility of complications or 
cosmetic deformity.
Some areas of normal breast seen within the cancer specimens were counted, out of 
interest, and have the same level of expression as seen in the redution mammoplasty 
controls. There is thus no evidence in our material that there is any field change in 
EGFR expression in the cancer containing breast.
The most striking result in terms of the levels of expression seen in breast cancers is 
that virtually all the tumours show lower levels of EGFR than the normal breast from 
which they derived. That is, the great majority of breast cancers show downregulation 
of EGFR. This certainly fits with the observation that amplification is a rare event in 
respect of the EGFR gene, and the incidence of true overexpression in this study (3%), 
fits with the low incidence of amplification observed by others (Rajkumar & Gullick, 
1994). It would be very interesting to look to see whether the overexpressers in the 
current series are in fact those with amplification, but at the moment this is purely 
speculative.
The currency of the idea that significant numbers of breast cancers overexpress EGFR 
arises from the ligand binding studies, which if read carefully never say this. They 
correctly say that 40% of breast cancers detectably express EGFR (eg Fox et al,
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1994), but do not provide comparison with normal breast. This may be because 
normal breast, with its very low content of breast epithelial cells is probably a poor 
tissue for ligand binding studies, and may well give spuriously low estimates of EGFR 
content for this same reason. For whatever reason, and despite the scattering of reports 
from histochemists that EGFR is quite detectable in normal breast, there has been a 
misconception that levels of EGFR in normal breast are low, and that the expression 
detected in tumours is therefore an overexpression. The current results suggest that this 
is wrong. Does this matter? Is this any more than a semantic exercise? I would answer 
that it is, for it is important to way that we think about the biology of EGFR in breast 
cancers. For a start it suggests that there may be selection against expression in 
carcinogenesis, or suppression of expression. This would be consistent with a role for 
EGFR as a differentiation signalling mechanism rather than a mitogenic one in breast 
tissue. This is doubly important if we relate this to the clinical situation, where we 
want to know why tumours grow and how we can stop them. Research is going on in 
targetting EGFR as an anti-tumour therapy for breast cancer (among other tumours, 
like squamous carcinomata, where the rationale is stronger). If EGFR is a 
differentiation signal, then this is biologically an undesirable thing to do. Furthermore, 
if levels of expression in tumours are really low relative to normal tissues, then there is 
a negative therapeutic window, that is, normal tissue toxicity will be produced before 
any therapeutic effects. These are only notes of caution, and it will be interesting to see 
whether this type of approach is of value, but there must be some dubiety in light of 
the results presented here.
The literature on the relationship between EGFR expression and pathological 
prognostic factors is confused. In general, both immunohistochemical and ligand 
binding studies have failed to show associations with nodal status and tumour size, as 
was the case here, and less often this has also been found for tumour grade as well (for 
references, see introductory section of Chapter 10). However, others have found such 
relationships in respect of each of these, and in this series the relationship with tumour 
grade is very strong, in line with Castellani et al (1994) and Bolla et al (1992). The 
former of these was an immunohistochemical study, the latter used ligand binding, so 
the difference in the literature would not seem to be based on technique; nor can the 
failure to establish this relationship be blamed on lack of statistical power since 3 of the 
4 negative studies were larger than the current one. Given the close relationship I have 
found this disparity in other studies is a mystery.
In the light of my findings about the levels of EGFR expression in tumours versus 
normal tissue, and the hypothesis that it may not be a mitogenic, but rather a 
differentiation, signal, it is interesting that the level of expression as determined by 
RIHC is nevertheless very strongly related to cell proliferation as measured by BUDR
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incorporation in vivo. It is striking that mean labelling index in the 40% of tumours 
with greater than 10% of normal levels of EGFR expression is more than 3 times 
higher than that in the low/non expressing tumours, and this is certainly in keeping 
with the consensus in the literature using Ki-67 (references in Chapter 10).
Can we reconcile these findings? It could well be that the association of EGFR and 
labelling index is no more than that, and is not causal. Both are related to tumour 
grade, and may simply be joint markers of poor tumour differentiation, for instance. It 
is also possible that EGFR is playing a different role in the tumours (mitogenesis) than 
it does in the normal breast, by virtue of its reduced numbers or varying in second 
messenger pathways, for example. Ligand availability might also alter the signal 
transduced by a given number of EGFR molecules on the cell surface, and the current 
data provide no information about levels of ligand to which these receptors are 
exposed. It must also be remembered that the receptor is internalised after ligand 
binding, and high levels o f ligand exposure could thus give a falsely low impression of 
EGFR expression on RIHC if the antibody did not recognise these internalised 
receptors. Another useful field for further study would therefore be to analyse the 
levels of EGF, TG Fa and other EGFR ligands in these tumours.
GENERAL
DISCUSSION
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In the second chapter, I identified three reasons for studying tumour cell kinetics:
-for prognostic information;
-as an guide to the use of radio- and chemo-therapy; and 
-as a tool for studying tumour biology.
I also stated a single general aim for the current investigation. So then, just what is "the 
potential use of flow cytometric methods for the determination of tumour cell kinetics", 
in the light of the experimental work reported here, and in terms of the three factors 
above?
One thing that emerges clearly is that for all the increasing sophistication of the 
technology being brought to bear, the current methods for measuring the division of 
cell populations in vivo provide only a very limited description of the process. Flow 
cytometric SPF emerges as markedly subjective, poorly reproducible, and poorly 
correlated with thymidine and bromodeoxyuridine labelling when this is assessed 
critically. This would seem to be more than adequate reason for the finding that it is of 
limited prognostic help- even if cell kinetics were a potent predictor of outcome, this is 
simply not an accurate enough measurement. The bromodeoxyuridine-based kinetic 
method scores better in these areas (with lesser subjectivity as evidenced by inter- 
observer variation, better reproducibility, and greater consistency with parallel 
techniques and previous literature), and might yet prove to be an improvement in terms 
of predicting outcome for this reason. Only more time and more patients would 
determine this- even if the survival advantage was twice that observed for SPF, this 
would require 300-400 patients to be followed for 5 or preferably 10 years.
One of the advantages bromodeoxyuridine was to bring was the addition of the new 
dimension of dynamic measurement, the ability to assess the rate of cell cycle transit. 
Whilst it seems to be capable of doing this, we were forced to the preliminary 
conclusion in the last chapter that this parameter seems to be a relatively fixed 
characteristic, the small degree of variation in which is of little biological significance. 
It is unlikely to add much to the prognostic information given. This raises the 
possibility of using an in vitro method for bromodeoxyuridine labelling (analagous to 
thymidine labelling, but without the radioactivity). This would provide the static but 
not the (probably irrelavant) dynamic data of in vivo labelling. The loss of the in vivo 
element is potentially important though, in that the behaviour of small pieces of tissue 
in culture is not necessarily the same as that of the tumour mass in situ.
Two major issues are still not addressed adequately by these methods. One is that of 
cell loss. This concept was introduced in the very first chapter, and has lain dormant 
since, for the simple reason that none of the techniques for studying cell kinetics has 
anything to tell us about this aspect of tumour growth. It potential importance is easily 
illustrated using the data that I have obtained. If we substitute in equation 8 from the 
first chapter,
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0  = 1 -  Tpot
t 7
using the median value for Td from the literature review, of about 100 days, and the 
median value of Tp0t which we have found in this series, of about 15 days, then we 
obtain 0  = 0.85, that is, 85% of cells produced within the tumours die rather than 
complete a further cycle. This has the very important consequence that the overall rate 
of tumour growth becomes more sensitive to alteration in cell loss than alteration in cell 
production. This is readily apparent if we simply rearrange equation 8 in the form,
Td = Tpot 
(1 - 0)
To bring about a doubling in Td requires a doubling of Tpot> but from a baseline of 
0.85, 0  need only increase to 0.925 to create the same effect. A much smaller
proportional change in cell loss is required to bring about a given alteration in overall 
growth rate. It is this which makes the inability to measure this parameter a critical 
shortcoming in cell kinetic methodology, and is unlikely that better measures of 
prognosis will be forthcoming until they take account of this factor. Put very simply, 
cell loss rate is much more important in determining tumour growth than cell 
proliferation rate. The recent interest in the mechanism of cell loss by programmed cell 
death, or apoptosis (Wyllie, 1992), was discussed in Chapter 1. Methods for 
identifying apoptosis on a cell-by-cell basis have been developed (Ansari et al, 1993; 
Wijsman et al, 1993; Gorczyca et al, 1994), and a very fruitful extension of the current 
work would be to make some measurement of cell loss by these means, in parallel with 
cell proliferation estimates. This could potentially increase the prognostic information, 
but more importantly might give a much more accurate idea of the mechanism of action 
of molecular abnormalities. For instance, overexpression of c-erbB-2 which has 
prognostic implication, yet no demonstrable effect upon cell proliferation in this study, 
might act via an increase in apoptotic rate.
The other Trojan horse in the cell kinetic stockade is heterogeneity. To the extent that 
rates of cell growth vary throughout a tumour, any approach based upon single or few 
samples is limited by the unknown degree to which the samples used reflect the 
situation in the rest of the tumour. It is hard to see that this can ever be overcome, since 
in clinical practice, one does not have access to all of a tumour for study of a single 
factor, nor would one want to do this to the exclusion of all other information about it. 
The critical matter is not what to do about this particular problem, but to be aware of its 
extent. The only information available about this comes from the Mt Vernon group 
report upon the kinetics of colon cancer as determined using BUDR (Rew et al, 1991). 
They analysed multiple biopsies from over half of the 100 tumours which they studied, 
and present detailed data in relation to six of these (their table 3). This shows that very
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large variations exist. In the first tumour in that table, for instance, the range of values 
of labelling index in different areas of the tumour was from 2.4% to 10.7%, and in the 
last the range for Ts was 13.1 hrs to 35.1 hrs. These are important differences by 
anyone's reckoning, and this is an important area for further study. If heterogeneity is 
indeed this large, then it might simply be that a single sample approach for cell 
kinetics, however comprehensive, will never be of help in determining prognosis.
It becomes apparent that prognostication is not where I see cell kinetics as being of 
use. In terms of providing a guide as to who might most benefit from the 
administration of radio- or chemo-therapy, and how these should be individually 
scheduled, the situation is not so glum. This is because the issue of cell loss is not 
necessarily relevant here, for what might be important in determining the response to 
cell cycle related therapies is not so much how fast the cell population is actually 
increasing in size, but rather how fast it is trying to increase. For in this case, it is what 
each individual cell is doing that matters, as that is the level at which the therapy 
operates. The more cells in cycle at any given point in time, the more are susceptible to 
agents which disrupt that process, and what would have happened to them 
subsequently, that is whether they would have lived or died, does not need to be 
known. Furthermore, the rate at which they are dividing, even if it is not biologically 
important to the natural history of the tumour, might well determine tumour survival 
when therapy is given, if it allows repopulation between courses of therapy such that 
the cumulative effect of treatment is lost. So there remains a potential place for this 
information in individualising patient therapy, albeit with the remaining problem of 
heterogeneity. It will be very interesting to see what emerges from the current crop of 
trials looking to use cell kinetic data as a means of selecting patients for accelerated 
radiotherapy (Lochrin et al, 1992; Wilson 1991).
The investigation of tumour biology remains to be considered as a field for the use of 
tumour cell kinetics. This has been explored in a preliminary way here, in looking at 
differences between aneuploid and diploid tumours, and between EGFR, c-erbB-2 
and oestrogen receptor positive and negative tumours. We have shown that although all 
tumours are cytogenetically DNA aneuploid but only become recognisable as such on 
flow cytometry at some arbitrary level of abnormality, this crude distinction does have 
biological significance, since the aneuploid tumours as a group have different cell 
kinetics to their diploid fellows. Similarly, even a small group of patients for whom 
data as to ER expression are available show that this factor clearly identifies groups of 
tumours with quite different characteristics- tumours which have escaped from this 
control mechanism show significantly faster potential growth. In the case of erbB-2, 
although this has been shown to be a prognostic factor in human breast cancer, and 
despite the fact that it is a growth factor receptor, its expression does not correlate with 
the rate of cellular proliferation, suggesting that it does not act as an important 
determinant of cellular growth. As an individual question, this requires closer 
investigation before it can be written off so blithely, based as it is on a binary
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classification of tumours as positive or negative for the oncogene. To assess this 
properly requires a method of quantifying expression which will provide much greater 
power in determining whether there is any relationship between expression and 
growth. This is exactly what has been done for EGFR in this study, and the results of 
this are a very marked difference in kinetics based on level of expression. The 
difference in findings for ER, EGFR and c-erbB-2 illustrate very well the way in 
which this type of experiment may help in working out which factors are functionally 
important in determining the growth of breast cancers.
The question as to which measure of cellular proliferation to use remains open. Flow 
cytometric SPF emerges poorly form our critical examination, bromodeoxyuridine 
rather better. The failure of cell cycle transit to differ between groups does hint that it 
may not be a biologically important parameter. If this is the case, then there is less 
reason to go to the bother of in vivo labelling. It would come back into its own if any 
way of assessing actual tumour growth were developed, as it would then be possible 
to work back to cell loss, and thereby fill in one of the great gaps in our ability to 
describe the process of proliferation. Compared with staining for Ki-67 or PCNA, or 
their eventual successors, the use of bromodeoxyuridine retains the advantage that it is 
a functional, in vivo measure of cell cycle activity. Despite the greater difficulty of 
using it, this alone is a reasonable case for keeping it in parallel with simpler methods 
as a tool for exploring the cell biology of cancer, and as a potential guide to patient 
treatment
The conclusions from all of the foregoing, in stark terms, are then:
- S phase fraction is a subjective measurement, of poor reproducibility and very limited 
prognostic use.
- bromodexoxyuridine labelling index is more valid and more reproducible, but the 
dynamic cell cycle information gained by this method is probably to no benefit.
- cell kinetic measurements of the type used in this work have two major shortcomings:
- they do not account for heterogeneity of kinetics within the tumour; and
- they do not account for cell loss within the tumour cell population.
The methods need to be adapted in order to address these problems.
- proliferation markers do have an important role to play in untangling the many 
abnormalities in the growth control mechanism in tumours, to determine which are 
more likely to be causal. Cell kinetic measurements are a means not an end, in the 
study of tumour biology.
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Appendix I: Raw data from the study of tumour ploidy and S  phase fraction. 
Data are presented from the 281 patients in whom ploidy was calculated. 
Column 1 identifies the case by its accession number in the Liverpool 
Breast Cancer Series, and column 2 the half peak coefficient of variation of 
the diploid G0/G1 peak in the histogram used for analysis. In column 4 
tumour ploidy is coded as D for diploid and A for aneuploid. * in the final 
column indicates that SPF was not obtainable for that tumour.
Series No. CV DNA Index Ploidy SPF(%)
7 5.6 1.0 D 4.6
8 4.1 1.4+2.3 A *
12 5.6 2.1 A 20.8
18 4.5 1.0 D 7.1
19 4.9 1.2+1.5 A *
23 5.0 1.8 A 13.7
24 7.3 1.6 A 6.3
30 9.2 1.6+2.3 A *
31 8.0 1.0 D 7.0
54 7.7 1.8 A *
59 5.8 2.0 A 11.6
60 5.1 1.0 D 5.3
66 6.7 1.0 D 7.4
75 8.5 1.5 A ★
78 7.6 1.0 D *
88 7.8 2.0 A *
90 5.0 2.5 A 17.4
94 8.0 2.0 A 3.4
95 5.8 1.0 D 7.5
jries
98
99
101
110
115
118
125
129
131
132
141
144
145
148
153
155
162
163
164
168
171
172
173
174
175
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CV DNA Index Ploidy SPF(%)
3.5 1.7 A 12.1
8.6 1.6 A *
6.0 1.0 D 1.6
4.7 1.0 D 5.3
4.2 1.7 A 3.7
4.5 1.0 D 3.3
9.2 1.7 A *
4.9 1.0 D 3.1
6.9 1.2 A 5.2
7.1 1.0 D 2.0
5.0 1.0 D *
6.3 1.3 A 2.1
8 1 1.0 D 3.5
8.4 2.0 A 4.5
8.4 1.5 A *
5.9 1.0 D 3.1
8.1 1.9 A 16.8
6.4 1.0 D 3.7
8.6 2.1 A *
6.1 2.0 A 17.7
8.0 1.6 A 14.4
6.8 1.0 D *
7.2 1.0 D 2.4
5.2 1.9 A 10.2
4.5 1.0 D 4.9
6.1 1.0 D 2.8
7.9 1.0 D 4.7
jries
181
203
205
207
220
221
230
231
236
239
245
249
250
256
258
266
272
283
297
301
304
307
310
319
322
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CV DNA Index Ploidy SPF(%)
5.2 1.7 A 21.7
5.2 1.4 A *
7.1 1.0 D 4.0
6.4 1.8 A *
4.5 1.0 D 6.7
7.9 1.1 A *
5.7 1.0 D 3.7
4.3 1.2 A 12.9
6.6 1.5 A 5.9
7.7 1.0 D 7.3
6.6 2.1 A 9.5
8.1 1.0 D 5.5
7.0 1.0 D 8.3
7.6 1.7 A 13.3
4.7 3.3 A *
6.7 1.6 A 12.3
6.5 1.7 A 12.8
7.3 1.4 A 7.9
7.4 1.6 A *
4.5 1.2+1.8 A *
5.2 1.5 A 9.1
9.9 1.3 A *
5.8 2.0 A 9.4
5.1 1.0 D 5.6
7.8 1.4 A 13.5
3.5 1.8 A 6.0
3.8 1.9 A 8.3
jries
325
331
334
338
340
342
346
361
363
370
373
379
384
386
390
391
393
395
396
399
404
408
409
413
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CV DNA Index Ploidy SPF(%)
5.1 1.2 A 16.7
3.0 1.0 D 3.1
6.7 1.5 A 11.9
7.5 1.0 D 5.6
4.7 1.9 A 12.9
6.6 2.2 A 12.2
5.7 1.0 D 5.6
3.7 1.0 D 6.4
4.8 1.3 A 10.9
7.7 1.0 D 3.9
5.6 1.0 D 3.1
7.5 1.2 A 25.9
5.2 1.0 D 4.1
4.7 1.4 A 8.2
4.6 1.8 A 12.3
6.5 1.7 A 9.0
5.0 2.7 A 39.8
8.1 2.0 A 15.0
5.3 1.0 D 1.3
6.3 1.0 D 4.1
6.6 1.7 A 8.4
6.2 2.5 - A 25.8
6.8 2.1 A 2.8
4.4 1.0 D 4.7
7.6 1.0 D 7.8
4.1 1.0 D 4.7
9.8 2.0 A *
Series No. CV DNA Index
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426 3.4 1.5 A 8.4
433 4.6 1.0 D 3.4
436 8.1 1.0 D 4.5
437 4.1 1.8 A 8.3
440 3.8 1.4 A 9.9
441 3.5 2.4 A 8.1
451 7.0 0.8+2.8 A *
452 7.6 1.0 D 5.2
456 6.4 1.6 A 11.3
458 5.4 1.0 D 10.1
459 5.2 1.5 A 5.4
461 6.6 2.0 A *
465 4.4 1.7 A 10.7
470 3.7 0.9 A 9.6
471 4.8 2.0 A 21.1
472 3.9 1.4 A *
474 2.5 0.9 A 6.6
475 7.2 1.0 D 3.8
476 4.3 1.0 D 3.7
477 5.5 1.3 A 4.5
479 6.3 1.7 A 8.7
480 6.0 1.0 A 9.7
483 8.0 1.7 A 6.2
484 5.8 1.0 D 7.7
486 4.3 1.0 D 2.1
488 7.5 2.0 A 6.3
jries
492
495
496
498
500
502
503
504
508
515
518
520
521
529
530
532
536
541
546
547
548
556
558
559
560
565
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CV DNA Index Ploidy SPF(%)
4.6 2.7 A *
7.5 1.0 D 3.6
4.8 1.0 D 4.6
5.8 1.0 D 2.4
7.8 1.6 A *
9.5 1.6 A *
6.7 1.8 A 6.7
5.1 1.6+2.1 A *
4.4 1.0 D 7.9
5.2 1.0 D 6.6
7.2 1.9 A *
7.8 3.2 A 20.4
5.6 1.8 A 2.3
4.4 1.0 D 4.6
5.2 1.8 A 10.8
3.9 2.0 A 16.3
4.6 1.0 D 4.8
4.6 1.0 D 3.1
4.2 1.0 D 4.3
8.8 1.0 D *
2.8 1.8 A 8.0
7.6 1.7 A *
5.1 1.0 D 2.7
3.8 1.0 D 2.5
4.9 1.9 A 5.7
5.0 1.0 D 2.8
4.8 2.0 A 5.2
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Series No. CV DNA Index Ploidy SPF(%)
568 3.7 1.0 D 0.8
569 4.9 1.0 D 1.4
570 4.1 2.0 A 5.1
571 4.1 1.0 D 4.9
575 5.3 2.8 A 13.6
578 5.8 2.7 A 23.7
582 4.1 1.0 D 3.1
591 5.4 1.7 A 10.9
594 6.0 1.7 A 3.3
598 6.9 1.0 D 7.2
602 8.0 1.8 A 2.5
604 6.0 0.7 A 3.1
605 9.4 0.8+1.5+1.9 A *
607 4.0 1.7 A 14.0
611 5.8 1.0 D 2.5
612 7.5 2.1+3.0 A *
622 5.9 1.0 D 6.9
641 6.7 0.6 A 6.2
642 7.1 1.8 A 12.0
648 4.3 1.6 A *
649 6.4 1.7 A 13.3
650 3.8 2.0 A 7.6
651 3.9 2.0 A 14.0
653 7.8 1.0 D 4.1
660 3.6 1.5 A *
661 4.3 2.1 A 27.6
663 4.9 1.0 D 3.3
jries
664
666
667
668
669
670
672
677
678
680
682
683
684
685
686
691
692
693
694
697
698
700
701
702
703
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CV DNA Index Ploidy SPF(%)
5.3 3.0 A *
3.7 1.4+1.7+1.9 A *
5.1 2.0 A 7.0
5.4 1.0 D 3.3
4.7 2.0 A 3.8
4.9 1.7 A 12.8
3.9 1.8 A 7.4
6.6 1.6 A 10.6
5.1 1.6 A 15.8
4.4 2.0 A 10.2
5.4 1.5 A 6.7
4.6 1.8 A 13.4
4.0 1.0 D 2.1
4.1 1.7 A 2.7
5.2 1.0 D 4.2
7.0 1.0 D 7.3
3.9 2.1 A 9.2
4.1 1 5 A 14.3
9.2 2.1 A *
4.2 1.9 A 11.5
4.9 0.9+1.8 A *
8.9 1.0 D *
7.2 2.1 A 6.0
3.3 1.6 A 16.7
4.5 1.7 A 11.3
4.1 2.2 A 6.3
5.4 0.7 A ★
sries
711
712
715
721
723
724
726
727
730
731
732
733
734
735
737
741
743
745
748
752
753
756
758
762
763
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CV DNA Index Ploidy SPF(%)
3.9 1.7+1.9 A *
4.0 1.4 A 17.0
4.4 2.2 A 11.3
6.0 1.8 A 21
4.9 1.0 D 3.6
4.3 1.9 A 7.6
5.8 1.0 D 1.7
8.2 1.8 A 10.5
5.4 0.7+1.7 A *
6.3 1.0 D 2.3
6.2 2.1 A *
5.2 1.0 D 3.9
7.6 1.8 A 5.8
4.5 1.9 A 21.5
4.0 1.0 D 1.9
5.5 1.4+1.7 A *
6.3 1.0 D 1.8
5.6 2.0 A 9.0
8.3 1.0 D 2.3
4.9 1.0 D 6.7
3.7 1.1+2.1 A 3.6
2.8 1.8 A 16.1
5.6 1.5 A 21.0
5.7 2.1 A *
5.8 1.6 A 9.6
3.6 1.7+1.9+3.0 A *
5.9 1.8 A 16.2
Series No. CV DNA Index
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776 6.3 2.0 A 20.5
779 4.9 3.1 A *
783 7.7 1.0 D 4.3
786 3.9 1.8 A 7.1
788 3.0 0.8 A 10.2
797 5.1 1.4 A 9.9
800 3.4 2.0 A 12.1
802 4.2 1.0 D 2.4
803 7.9 1.0 D 3.7
808 6.1 1.0 D 4.4
809 6.7 1.7+2.7 A *
822 7.0 1.5 A *
823 7.8 2.0 A *
824 6.9 1.0 D 4.5
828 9.4 1.5+2.1 A *
829 6.0 1.0 D 3.4
836 8.2 2.2 A *
839 7.0 1.9 A 10.3
841 6.6 2.1 A 2.2
846 6.4 1.0 D 2.7
849 6.5 1.0 D 3.3
853 4.8 1.7 A 21.8
857 4.0 1.0 D 3.2
867 6.3 1.0 D 2.7
882 4.7 1.0 D 4.5
885 7.0 1.0 D 3.3
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Series No. CV DNA Index Ploidy SPF(%)
886 6.8 2.4 A 1.9
896 4.4 1.2+1.9 A *
899 5.5 1.0 D 2.2
905 6.5 1.0 D 5.7
906 5.2 1.7 A 12.3
908 5.5 2.2 A *
917 5.4 1.9 A 6.0
919 8.5 1.9 A *
920 7.1 1.6 A 16.3
924 7.1 1.6 A 16.7
929 6.3 1.0 D 6.0
930 5.7 1.0 D 3.0
932 6.5 2.7 A 23.9
956 6.5 1.9 A 10.5
969 6.0 1.9 A 11.6
973 9.0 1.0 D *
977 6.0 1.9 A 16.0
978 6.1 1.4 A 18.4
981 5.3 1.0 D 5.3
984 6.4 1.0 D 5.0
987 3.3 2.0 A 9.7
Appendix la 202
A p p e n d ix  l a :  P a t h o l o g i c a l  d a t a  f o r  p a t i e n t s  i n  p l o i d y
s e r i e s  f o r  whom SPF i s  a v a i l a b l e .  Columns a r e :  p t  n o ­
a c c e s s i o n  number i n  L i v e r p o o l  P l o i d y  S e r i e s ;  meno-  
m e n o p a u s a l  s t a t u s ,  l = p r e ,  2 = p o s t ;  t , n -  pT,pN b y  TNM 
c l a s s i f i c a t i o n ;  g r a d e -  m o d i f i e d  Bloom and R i c h a r d s o n  
s y s t e m ;  e r -  l = < 5 f m o l / m g ,  2=>5fm ol /m g;  erbB -2 -  ^ p o s ­
i t i v e ,  2 = n e g a t i v e .  *=n ot  a v a i l a b l e
p t  no meno t n g r a d e e r erbB
: 1 7 2 2 2 3 1 2
' 2 12 2 2 1 2 2 2
: 3 18 1 3 1 * 1 2
4 20 2 1 1 1 1 2
5 22 2 1 1 2 1 2
6 23 2 2 2 * 1 1
7 24 1 2 1 * 1 2
8 31 2 2 2 * 1 *
9 33 1 2 2 3 2 2
10 36 2 2 2 * 2 2
11 50 2 2 1 3 2 2
12 56 1 2 2 3 2 2
13 59 2 2 2 3 2 2
14 60 2 2 2 1 1 2
15 66 2 1 1 2 2 1
16 75 2 2 1 3 1 2
17 81 1 2 2 3 2 1
18 84 1 3 2 3 2 2
19 90 2 2 2 3 1 2
20 94 2 3 1 * 2 2
21 98 1 3 1 2 2 2
22 101 2 1 2 3 2 2
23 112 2 2 1 * 2 2
24 113 1 2 2 2 2 2
25 115 2 2 1 * 2 2
26 118 2 3 1 * 1 1
27 125 2 2 1 * 1 2
28 129 1 2 2 1 2 2
29 131 2 2 2 * 1 2
30 132 2 2 2 * 1 2
31 145 2 2 2 2 1 2
32 148 2 2 1 * 1 2
33 153 2 2 1 1 2 1
34 155 2 2 1 1 1 2
35 161 2 3 2 1 1 *
36 162 2 2 2 * 2 1
37 163 2 2 1 * 1 2
38 164 2 2 2 * 1 2
39 168 2 3 1 * 1 2
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
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)t  no meno t
171 1 2
173 2 2
174 1 2
175 2 2
177 2 2
181 * 2
189 2 2
205 1 1
220 2 2
229 2 3
230 2 2
231 1 3
236 2 2
239 2 2
245 2 2
249 2 2
250 2 3
256 2 2
266 2 2
272 2 3
283 1 1
304 2 3
307 2 2
310 1 1
319 1 2
322 2 2
323 2 2
324 2 2
325 2 2
331 2 3
334 1 3
338 1 3
340 1 2
346 1 2
361 2 3
363 1 3
370 1 3
373 2 2
379 2 2
384 1 2
386 2 1
390 1 2
391 2 2
393 2 3
395 2 2
396 2 2
399 * 2
ide e r e rb B
* 2 2
* 2 2
1 1 2
* 1 2
* 1 2
2 1 2
2 1 1
1 1 2
* 2 2
1 1 *
* 1 2
1 2 2
* 2 2
* 1 2
* 1 1
* 1 2
3 1 2
3 1 2
3 1 2
2 2 1
* 1 2
* 2 2
* 2 2
2 1 2
* 1 2
* 2 2
* 1 2
2 1 2
2 1 1
3 2 2
* 2 2
* 1 2
2 1 2
* 2 2
2 1 2
3 1 1
2 2 1
2 1 2
* 2 2
3 1 1
* 1 2
2 2 2
2 1 2
* 1 1
* 2 2
* 1 2
* 1 2
n
1
1
1
2
2
2
1
1
1
2
1
1
1
1
2
2
2
2
1
2
1
1
2
2
2
1
1
1
1
2
1
2
1
2
1
1
1
2
1
2
1
1
1
1
2
2
1
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
1 2 0
121
1 2 2
123
124
125
126
127
128
129
130
131
132
133
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p t  no meno t n g r a d e e r erbB
404 2 3 2 * 1 2
408 2 2 2 * 1 2
409 2 * 1 * 1 2
413 2 1 2 * 1 1
414 2 1 1 2 2 *
419 2 2 2 2 1 2
426 2 3 1 * 1 1
433 2 2 2 1 1 1
436 2 2 2 2 1 2
437 1 2 1 1 2 1
440 2 1 1 * 1 2
441 2 2 2 * 1 2
452 2 3 1 * 1 1
456 2 2 2 3 2 2
458 2 2 1 3 2 2
459 2 2 1 * * *
465 2 2 2 1 2 2
470 2 2 1 1 1 2
471 * 2 1 1 1 2
474 2 3 2 3 2 1
477 2 1 1 * 1 2
479 2 3 1 * 1 1
480 1 2 1 * 1 2
484 2 2 1 * 2 2
486 1 2 1 1 1 2
488 2 2 2 1 1 2
495 2 2 1 2 2 2
498 2 2 2 1 2 2
503 2 2 1 3 1 2
508 2 ★ * * 2 1
515 2 2 1 1 1 2
520 * 2 2 3 2 *
521 2 2 1 1 1 2
522 2 2 1 2 1 *
529 2 2 2 3 1 1
530 * 3 1 1 1 2
532 2 2 1 * 2 1
536 2 2 1 3 1 2
541 2 3 2 1 1 2
543 * 2 1 1 1 2
546 2 2 1 2 1 2
548 1 2 2 * 2 1
559 * 2 1 * * 2
560 * * 1 * 1 2
565 1 2 2 3 2 2
568 2 2 2 1 1 2
569 2 2 2 * 1 2
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
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p t  no me no t n g r a d e e r erbB
570 2 3 2 3 2 1
571 2 2 2 2 1 1
575 2 2 1 * 2 2
578 2 3 2 * 2 2
582 2 2 1 * 1 2
591 2 2 2 1 2 2
594 2 2 1 3 2 2
598 1 1 1 1 2 2
602 2 2 1 * 1 2
604 2 2 2 1 1 2
607 1 2 2 3 2 2
622 2 2 1 * 1 1
637 2 2 2 2 2 2
641 2 1 1 * 1 2
642 2 3 2 1 1 1
649 2 2 1 * 2 1
650 2 2 2 1 1 2
651 2 2 2 2 2 2
653 2 2 2 1 1 2
661 2 3 1 * 2 2
663 * 2 1 * 1 1
667 2 2 1 * * 1
668 2 2 1 * 1 2
669 1 2 1 * 2 2
670 2 3 1 * 2 *
677 2 2 1 1 2 2
678 * 2 2 3 2 2
680 2 3 2 3 2 2
681 1 3 2 2 2 2
682 1 2 2 3 1 2
683 1 2 2 2 2 1
684 2 2 1 3 2 1
685 2 1 1 1 1 2
686 2 2 1 * 2 2
689 1 2 1 * 1 2
691 2 * 1 * 1 2
692 2 2 1 1 1 2
693 1 2 1 2 2 2
694 2 2 1 2 1 2
697 1 2 1 * 2 2
699 * 2 1 2 2 2
701 2 2 1 3 1 2
702 2 1 2 * 2 2
703 2 2 1 ★ 2 1
705 2 2 1 * 1 1
712 2 2 2 3 2 2
713 2 2 2 * 1 2
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
2 0 0
2 01
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
2 2 1
2 2 2
223
224
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p t  no me no t n g r a d e e r erbB
715 2 * 1 * 2 1
721 2 3 2 * 1 2
723 2 3 1 * 1 2
724 2 2 2 1 1 2
726 2 2 1 1 2 2
727 2 2 1 1 1 1
731 2 2 1 * 2 1
733 1 3 1 * 1 2
734 1 3 2 * 1 2
735 * 2 2 3 2 2
737 2 3 1 * 1 2
743 1 2 2 1 2 2
745 2 2 1 * 1 1
748 2 * 1 * 1 2
753 2 2 1 * 1 2
756 1 2 2 3 1 1
763 * 2 1 * 2 2
772 1 3 2 3 1 2
776 2 3 1 * 2 2
783 2 2 1 * 1 2
786 1 3 1 2 2 1
788 1 3 1 * 2 1
797 1 1 1 * 1 2
800 2 3 2 * 1 1
802 * * * * * 2
808 1 2 1 2 1 2
824 * * * * * 2
839 2 2 1 * 1 2
846 2 2 1 2 1 2
849 2 2 1 1 2 2
853 1 2 2 2 1 1
867 2 1 1 2 2 2
882 2 2 1 2 1 *
885 2 2 2 * * 2
886 2 2 2 1 2 2
899 * * 1 * * 1
906 1 2 2 3 2 1
917 2 2 1 * 1 2
919 2 2 ’ 1 * 1 1
930 2 * 1 2 * 1
932 2 2 2 1 1 1
956 2 2 1 1 2 1
984 2 2 1 3 1 1
987 2 1 2 3 1 2
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Appendix III: Characteristics of patients and tumours labelled with bromode- 
oxyuridine, and basic histogram parameters for each tumour. Numbers in 
the first column have simply replaced the patient's names, these being in 
alphabetical order, the three patients with bilateral tumours being identified 
by the suffixes L & R (for left and right). Meno = menopausal status. T & N = 
tumour size and nodal status, using the TNM classification. ER = oestrogen 
receptor status, 0 for negative (<5fmol/mg protein), and 1 for positive, n = 
number of labelled undivided cells available for calculation of Ts . CV = half 
peak coefficient of variation of the diploid G0/G1 peak. Dl = DNA index. * 
means not available, P (in Dl column) means polyploid.
No Age Meno T N ER n CV Dl
1 69 post 2 0 * 484 3.2 1.0
2 49 * 1 1 0 649 4.2 2.0
3 82 post 2 1 * 259 * 1.0
4 59 post 2 1 0 498 7.2 1.0
5 65 post 1 0 * 661 4.0 P
6 61 post * * * 309 3.9 1.6
7 84 post 2 1 * 191 4.4 1.0
8 52 post 1 0 * 411 3.5 1.0
9 51 post 3 1 1 932 5.6 1.7
10 74 post 3 0 * 1107 4.2 1.0
11 77 post 1 * * 183 4.9 1.0
12 77 post 2 0 0 482 13.7 1.0
13 58 post 3 0 0 1095 4.9 1.5
14 70 post 2 * 1 296 4.1 ‘ 1.0
15 66 post * * * 256 5.5 1.3
16 59 post 1 0 0 2523 2.7 1.7
17 62 post 1 0 * 161 4.9 1.0
18 48 pre 2 1 * 2253 8.2 1.5
19 59 post 2 1 * 1672 * 1.4
20 ★ * * * * 1524 5.2 1.4
21 77 post 2 0 1 187 3.3 1.7
22 56 post * * * 1022 3.8 1.7
No
23
24
25
26
27
28L
28R
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44L
44R
45
46
47
48
49
50
51
52
Appendix III
Age Meno T N ER n CV
36 pre 3 0 ★ 203 3.7
46 pre 1 * 0 555 4.4
57 post 2 1 0 1199 13.9
60 post 2 1 * 3605 4.8
55 post 3 0 1 4624 11.4
61 post * * * 1243 *
61 post * * ★ 163 *
64 post 1 1 ★ 257 4.9
40 pre 1 0 * 815 6.5
48 * 2 0 1 179 4.6
69 post 2 1 1 79 9.6
52 post * 1 0 1193 4.9
66 post 2 1 * 956 11.9
63 post 2 0 1 109 4.8
69 post 2 0 * 213 4.1
65 post 2 0 * 720 5.3
55 post 2 1 * 1193 3.3
63 post * * * 1380 *
* pre * * * 762 5.2
64 * * * ★ 233 5.5
* post * * * 210 3.9
68 post 2 0 * 419 3.8
48 * 1 1 1 145 3.8
48 * 1 0 1 274 3.6
68 post 1 * * 225 *
66 post 3 * * 711 *
51 * 1 0 * 871 3.9
70 post * * * 148 4.1
65 post 1 0 0 453 7.2
60 post 2 * * 546 *
39 pre 1 0 * 504 *
62 post 3 0 0 896 5.5
53
54
55
56
56
58
591
591
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
Age Meno T N
* * * *
53 post 3 1
65 post * *
47 pre 1 0
74 post * *
70 post 1 0
71 post 1 0
71 post 1 0
* * * *
71 post * 1
49 * 3 1
68 post 2 0
53 * 2 0
52 post 2 0
55 post * 1
90 post 2 *
75 * * *
59 post * *
73 post 1 1
61 post * *
58 post 1 0
* * * *
* * * *
67 post * *
68 post 2 1
68 post ★ *
54 post 3 *
69 post * *
71 post * *
56 post 1 0
Appendix III
ER n CV
* 633 *
1 426 3.3
* 856 12.8
1 797 4.5
* 2271 7.2
* 1520 9.0
1 991 5.3
1 231 5.8
* 664 3.9
1 348 5.7
1 588 5.7
* 331 3.6
* 2630 5.9
0 1862 4.2
1 687 4.0
* 1271 10.3
* 747 7.7
* 303 7.6
* 1890 8.9
* 421 5.8
0 302 4.7
* 135 4.3
* 181 5.7
* 431 8.1
* 55 7.4
* 148 4.4
* 2272 5.0
* 133 5.7
* 169 5.9
* 226 7.6
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Appendix IV: Kinetic parameters for each of the 84 tumours in which one or 
more could be calculated. The identification number in column 1 is the 
sam e as in the previous appendix. Subsequent columns are: PI- tumour 
ploidy (D diploid, A aneuploid); BLI- bromodeoxyuridine labelling index; 
TLI- total labelling index; ILI- immunohistochemical labelling index; SPF- S 
phase fraction; Ts- length of S  phase in hours; Tpot- potential doubling time 
in days. Missing values are shown as * ■
No. PI. BLI TLI ILI SPF Ts V
1 D 1.4 1.61 * 12.8 11.6 27.6
2 A 8.4 4.32 5.37 16.0 32.0 12.7
3 D 0.5 0.58 * 2.3 11.9 79.2
4 D 1.1 1.29 0.05 1.7 17.0 51.5
5 A 5.3 3.21 5.83 * ★ *
6 A 2.1 1.75 * 25.0 15.5 24.7
7 D 0.9 1.05 ★ 14.8 19.8 73.2
8 D 1.1 1.18 * 2.5 10.3 31.2
9 A 7.6 2.91 7.25 15.8 10.7 4.7
10 D 3.1 3.94 2.58 5.7 16.4 17.7
11 D 1.1 1.22 1.28 5.5 9.5 28.8
12 D 3.3 4.42 4.66 * 14.5 14.6
13 A 3.2 3.40 4.19 7.2 9.8 10.2
14 D 1.2 1.33 1.29 3.1 13.5 37.5
15 A 0.9 1.05 1.45 3.9 * *
16 A 8.9 7.80 12.43 12.7 14.2 5.3
17 D 0.5 0.60 0.90 3.2 13.7 91.1
18 D 5.3 3.35 6.77 23.9 12.7 . 8.0
19 D 8.6 8.35 * 22.6 ★ *
20 A 10.2 8.09 7.53 17.5 11.2 3.7
21 A 0.8 0.68 0.49 5.3 12.2 50.7
22 A 4.3 3.46 * 8.6 16.0 12.4
23 A 2.4 1.19 4.92 14.9 10.5 14.6
24 A 4.4 5.33 0.00 30.8 9.7 7.3
No.
25
26
27
28L
28R
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44L
44R
45
46
47
48-
49
50
51
52
53
54
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PI. BLI TLI ILI SPF Ts V t
D 2.0 2.49 5.91 * 7.5 12.5
A 12.2 7.63 13.76 18.1 21.3 5.8
D 7.2 8.24 2.87 * 10.0 4.6
A 3.9 2.72 * 4.3 6.9 5.9
D 0.5 0.52 * 1.7 9.3 62.2
A 3.2 1.27 1.05 6.5 13.6 14.2
A 10.2 8.22 9.65 39.1 * *
D 0.4 0.48 * 2.4 18.4 153.3
D 0.8 0.95 0.85 3.7 22.3 92.8
A 8.5 5.08 * ★ * *
A 6.4 4.57 * * 16.5 8.6
A 1.2 1.14 0.64 11.4 14.0 38.8
A 1.6 0.78 2.47 6.3 12.0 25.1
D 1.6 1.90 2.76 3.3 10.3 21.5
A 8.2 4.43 7.97 15.7 * *
D 2.7 2.98 * 3.3 8.7 10.8
A 5.2 3.29 * 20.6 17.7 11.4
D 2.3 2.89 * 23.6 24.8 35.9
D 0.9 1.03 * 8.7 12.1 44.8
A 12.9 6.89 * 40.7 * *
A 0.8 0.67 1.78 5.0 19.8 82.5
A 1.2 0.66 * 7.7 * *
A 7.8 2.13 * 10.4 ★ *
A 7.2 2.52 * 7.0 22.7 10.5
A 4.0 1.90 1.76 14.3 * ★
D 0.8 0.88 * 5.2 10.2 42.4
A 2.9 1.20 * 17.0 ★ *
A 6. 7 4.47 * 6.0 8.9 4. 4
D 1.3 1.64 * 5.9 22.7 58.1
A 3.6 2.65 9.48 20.0 14.5 13.4
A 2.8 2.32 * * 17.4 20.7
D 0.8 0.91 2.17 2.7 11.8 49.2
No.
55
56
57
58
59L
59R
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
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PI. BLI TLI ILI SPF Ts Tpot
D 2.5 2.99 * * 9.3 12.5
D 4.5 4.89 11.17 8.8 10.7 7.9
A 9.7 5.93 10.56 11.7 19.8 6.8
D 4.1 4.74 6.83 5.3 4.8 3.9
A 5.1 3.41 * 8.0 13.6 8.9
D 1.9 2.15 2.12 5.8 10.5 18.5
A 7.9 4.26 4.18 16.9 ★ *
D 1.0 1.17 1.37 3.2 10.6 35.5
A 4.8 2.89 3.54 33.0 * *
A 5.4 1.55 * 8.5 13.6 8.4
A 5.1 3.76 7.52 25.6 * ★
A 7.9 5.06 7.30 12.6 14.9 6.3
A 6.7 3.78 * 16.8 13.7 6.8
D 3.6 4.00 3.02 * 8.8 8.1
D 3.3 3.89 * 3.6 11.1 11.2
A 3.5 3.39 4.94 7.3 * *
A 6.4 7.82 * 12.4 8.5 4.4
D 0.8 0.90 1.36 0.8 * *
A 6.9 1.65 11.13 8.5 11.9 5.7
A 2.5 2.65 2.27 19.1 17.3 23.0
D 3.3 2.73 0.30 4.0 12.2 12.3
A 1.6 1.59 2.96 3.6 16.7 34.8
D 0.8 0.91 0.19 9.2 17.1 71.1
D 0.6 0.67 * 7.7 15.9 88.2
A 7.1 6.95 * 15.5 11.7 5.5
D 1.5 1.77 1.65 6.5 16.1 35.9
D 1.0 1.21 4.41 4.7 * *
D 1.7 * * * 9.3 18.2
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Appendix IVa: Results of immunohistochemistry for c-erbB-2 in the BUDR- 
labelled tumours. No. = patient number in the bromodeoxyuridine series (as 
in Appendices III and IV). erbB-2 = O-negative, 1-positive, *-not available.
No erbB
1 0
2 1
3 1
4 0
5 0
6 1
7 0
8 *
9 0
10 0
11 0
12 0
13 0
14 1
15 0
16 1
17 0
18 1
19 0
2 0 0
2 1 1
22 *
2 3 1
24 *
2 5 1
26 1
27 0
2 8 L 0
2 8R 1
29 0
3 0 1
31 0
32 0
33 1
34 0
35 0
36 0
37 1
3 8 1
39 0
40 1
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NO erb B
4 1 0
4 2 0
4 3 0
4 4 L 1
4 4 R 1
4 5 1
4 6 1
4 7 1
4 8 0
4 9 1
5 0 *
5 1 0
5 2 0
5 3 0
5 4 0
5 5 *
5 6 1
5 7 0
5 8 0
5 9 L 0
5 9 R 0
6 0 1
6 1 0
6 2 0
6 3 1
6 4 0
6 5 0
6 6 *
6 7 0
6 8 *
6 9 *
7 0 0
7 1 1
7 2 1
7 3 1
7 4 0
7 5 0
7 6 1
7 7 0
7 8 *
7 9 0
8 0 0
8 1 *
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Appendix V: Data for patients whose tumours were assayed for EGFR by 
radioimmunohistochemistry. Columns: 'BUDR' - patient's number in the cell 
kinetic series, where applicable; 'Grains' - grain count per 10'2mm2 per hour 
of exposure; 'EGFR' - EGFR expression as % of normal breast in that batch; 
T  - TNM system pT; 'N' - TNM system pN; 'Gr.' - histological tumour grade, 
modified Bloom and Riichardson scale; 'ER' - biochemical oestrogen 
receptor expression (0 = <20fmol/mg, 1 = ;>20fmol/mg); 'LI', T s', T pot' - 
kinetic parameters as in Appendix IV . Missing values are shown as *.
No. BUDR Grains EGFR Age T N Gr. ER LI Ts V
1 1 0.75 5.4 69 2 0 2 * 1.4 11.6 27.6
2 2 0.00 0.0 49 1 1 2 0 8.4 32.0 12.7
3 0.54 3.8 * 3 * 3 * * * *
4 3 2.62 25.3 82 2 0 3 * 0.5 11.9 79.2
5 4 0.78 5.2 59 2 1 2 0 1.1 17.0 51.5
6 7.13 48.2 53 1 0 * * 8.1 13.3 5.5
7 5 1.98 22.0 65 2 0 3 * 5.3 * *
8 0.19 2.0 53 2 1 * * * * *
9 0.00 0.0 68 2 0 * * * * *
10 0.00 0.0 63 1 0 * * * 4r *
11 0.34 3.8 61 3 * * * * ★ *
12 4.35 29.4 50 2 0 * * * * *
13 9 3.40 28.6 51 3 1 3 1 7.6 10.7 4.7
14 10 29.20 245.1 74 3 0 2 * 3.1 16.4 17.7
15 0.21 1.7 62 1 1 * 1 * ik *
16 0.75 5.7 76 1 0 3 * * * *
17 0.81 5.7 47 1 * * * * it *
18 11 0.10 0.8 77 2 0 3 * 1.1 9.5 28.8
19 12 89.40 749.3 77 2 0 3 0 3.3 14.5 14.6
20 0.57 4.3 63 2 1 * * ★ * ★
21 1.69 16.9 63 1 0 * * * * *
22 13 0.00 0.0 58 4 0 2 0 3.2 9.8 10.2
23 8.11 76.6 59 2 1 3 * * * *
24 3.29 33.8 92 1 * * 0 * * *
25 0.40 2.7 62 2 0 * * * * -*
26 14 0.23 2.2 70 2 * 1 * 1.2 13.4 37.5
27 0.80 6.7 45 1 0 * * * * ★
28 0.33 3.3 53 1 * ★ ★ * * it
29 18 1.24 12.0 48 2 1 2 ★ 5.3 12.7 8 .0
30 20 7.49 72.3 75 2 1 3 * 10.3 11.2 3.7
31 21 0.25 2.4 77 2 0 2 1 0.8 12.2 50.7
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No. BUDR Grains EGFR A g e T N Gr. ER LI —
I
w Tpo
32 0.83 8.2 46 4 0 * 0 * * *
33 1.20 11.6 58 2 1 * * * * ★
34 6.8 49.9 * 1 0 ★ 0 6.3 20.8 11.0
35 0.18 1.8 67 4 1 * * * * *
36 25 3.16 30.5 57 2 1 3 0 2.0 7.5 12.5
37 6.92 68.8 82 4 * * 0 * * *
38 0.21 2.1 45 2 0 * * * * *
39 0.45 4.6 54 2 1 * 1 * * *
40 0.62 6.1 57 1 1 * * * * *
41 0.00 0.0 74 , 2 * * * * * *
42 26 0.06 0.4 60 2 1 3 * 12.2 21.3 5.8
43 7.33 49.6 61 2 1 * * * * *
44 6.53 75.2 47 2 1 * 1 * * *
45 27 1.89 12.4 55 3 0 3 1 7.2 10.0 4.6
46 0.35 2.4 44 2 0 * 1 * * *
47 0.14 1.7 65 2 1 * * * * *
48 0.27 2.6 65 2 1 * 1 * * *
49 1.55 15.5 57 2 1 * * * * *
50 0.22 2.1 59 1 0 * 0 * * *
51 0.51 5.0 77 2 1 * * 2.5 6.6 8.8
52 0.04 0.4 80 1 0 * * 2.1 13.6 21.6
53 0.00 0.0 78 2 1 * 1 * * *
54 32 0.69 4.6 48 2 0 1 1 0.4 18.4 153.3
55 33 1.98 19.1 69 2 1 2 1 0.8 22.3 92.8
56 0.71 7.2 76 2 1 * 1 * * *
57 34 22.6 189.1 52 4 1 3 * 8.5 * *
58 36 0.70 4.6 63 1 0 2 1 1.2 14.0 38.8
59 38 0.42 3.4 65 2 1 1 0 1.6 10.3 21.5
60 0.17 1.7 67 2 0 * * 1.6 9.6 20.0
61 0.49 5.6 64 ★ 0 * ★ * ★ *
62 0.04 0.3 76 2 1 * 1 * *■ *
63 41 2.60 21.3 47 2 1 3 * 5.2 17.7 11.4
64 0.37 4.2 59 3 * * * * * *
65 4.07 27.6 84 1 1 * * * * *
66 43 1.00 7.2 77 2 1 1 0 0.9 12.1 44.8
67 0.19 2.0 67 2 1 * 1 * * *
68 0.73 8.4 59 2 1 * 1 2.8 12.4 14.8
69 45 0.00 0.0 48 2 0 * 1 0.8 19.8 82.5
70 0.68 5.0 62 1 0 * * 1.1 12.7 38.5
71 0.24 2.4 61 1 1 * 0 3.2 17.5 18.2
72 6.34 42.9 50 2 0 * 0 ★ * it
73 4.95 52.8 58 * 1 * * * ★ ★
74 50 0.85 6.3 80 2 0 1 * 0.8 10.2 42.4
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N o. BUDR G rains EGFR A ge T N Gr. ER LI T s T po
75 56 0.17 1.1 53 3 1 2 1 0.8 11.8 49.2
76 58 0.70 5.3 47 1 0 3 * 4.5 10.7 7.9
77 0.32 3.2 75 2 0 * 1 ★ * *
78 1.13 11.6 66 2 1 * 0 5.2 31.8 20.4
79 0.62 7.5 72 1 ★ 1 * * * *
80 61 2.93 28.3 71 1 0 3 1 5.1 13.6 8.9
81 0.25 2.8 45 1 0 * 1 * * *
82 18.23 156.8 64 1 1 * * * * *
83 63 2.94 24.8 51 2 0 3 * 7.9 * *
84 64 1.09 9.2 71 * 1 1 1 1.0 10.6 35.5
85 67 2.36 15.5 52 2 0 3 0 5.1 * *
86 68 1.06 10.2 52 2 0 3 0 7.9 14.9 6.3
87 0.25 2.5 56 2 0 * 1 * * *
88 71 0.26 2.6 75 2 1 2 1 3.3 11.1 11.2
89 72 0.25 3.5 59 2 0 2 1 3.5 * *
90 6.49 43.9 68 2 1 * * * * *
91 7.51 50.8 67 2 0 * 0 2.3 * *
92 0.20 1.7 92 2 0 * 0 * * *
93 73 0.28 2.6 73 2 1 3 * 6.4 8.5 4.4
94 74 0.00 0.0 61 2 0 2 * 0.8 * *
95 0.19 1.9 47 1 0 * 1 * * *
96 75 4.48 36.8 58 1 0 3 0 6.9 11.9 5.7
97 76 1.18 9.9 75 2 * 3 * 2.5 17.3 23.0
98 9.07 61.3 40 1 1 * * * * *
99 81 2.07 20.6 54 2 0 * 0 7.1 11.7 5.5
100 0.50 5.7 61 4 0 * * 3.1 10.7 11.5
101 0.29 2.9 46 1 0 * 1 * * *
102 0.28 2.9 * 2 0 * 1 * * *
103 6.84 63.5 63 2 * * * * * *
104 83 10.1 85.1 71 2 0 3 * 1.0 * *
105 84 0.53 4.5 56 1 0 3 * 1.7 9.3 18.2
